

CITATION REPORT

List of articles citing

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

DOI: 10.1126/science.6823562
Science, 1983, 219, 983-5.

Source: <https://exaly.com/paper-pdf/16159792/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2284	Fibrin as a component of the tumor stroma: origins and biological significance. 1983 , 2, 41-73		237
2283	Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancs. 1984 , 3, 181-193		101
2282	Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. 1984 , 54, 2367-74		207
2281	Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis. 1984 , 3, 53-74		42
2280	Pathogenesis of Desmoplasia. I. Immunofluorescence Identification and Localization of Some Structural Proteins of Line 1 and Line 10 Guinea Pig Tumors and of Healing Wounds 1,22. 1984 ,		
2279	Protean manifestations of pylethrombosis. A review of thirty-four patients. 1985 , 202, 191-202		72
2278	Regional glucose utilization and blood flow in experimental brain tumors studied by double tracer autoradiography. 1985 , 3, 271-83		10
2277	Therapeutic trial of plasma exchange in osteosclerotic myeloma associated with the POEMS syndrome. 1985 , 2, 253-7		35
2276	Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line. 1985 , 36, 473-8		32
2275	Inhibition of Macrophage Ia Antigen Expression by Shed Plasma Membrane Vesicles From Metastatic Murine Melanoma Lines2. 1985 ,		1
2274	Regulation of extravascular coagulation by microvascular permeability. <i>Science</i> , 1985 , 227, 1059-61	33.3	216
2273	Microvascular permeability of normal and neoplastic tissues. 1986 , 31, 288-305		477
2272	Characterization of vascular permeability-increasing component isolated from solid tumors and the effect of highly polymerized dextran sulfate on its activity. 1986 , 41, 163-71		3
2271	Differential macromolecular leakage from the vasculature of tumors. 1986 , 57, 461-4		83
2270	Inflammatory infiltrates of experimental mammary cancers. 1986 , 865, 13-26		3
2269	Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. 1986 , 315, 1650-9		3349
2268	Shedding of plasma membrane fragments. Neoplastic and developmental importance. 1986 , 3, 33-57		33

2267	Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. 1987 , 67, 880-4		96
2266	Tissue factor apoprotein: intracellular transport and expression in shed membrane vesicles. 1987 , 48, 487-500		39
2265	Thrombosis and cancer. 1987 , 18, 275-84		124
2264	Angiogenic factors. <i>Science</i> , 1987 , 235, 442-7	33.3	4067
2263	Metabolism of protein anticancer agents. 1987 , 34, 1-49		49
2262	Transport of molecules across tumor vasculature. 1987 , 6, 559-93		703
2261	Differential permeability of lymphatic and blood vessels in determining the route of metastasis as demonstrated by indirect lymphography. 1988 , 6, 291-9		4
2260	Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. 1988 , 79, 1327-34		138
2259	Protein leak from normal vasculature due to human malignant ascites. 1988 , 155, 765-9		7
2258	The effects of steroidal and nonsteroidal anti-inflammatory agents on uptake of Evans blue in experimental metastasis. 1988 , 35, 1-7		1
2257	Human malignant ascites and histamine-induced protein leakage from the normal microcirculation. 1988 , 35, 63-72		17
2256	Tumor invasion: a consequence of destructive and compositional matrix alterations. 1988 , 19, 628-39		134
2255	Protein Binding of Macromolecular Anticancer Agent SMANCS: Characterization of Poly(styrene-co-maleic acid) Derivatives as an Albumin Binding Ligand. 1988 , 3, 319-333		50
2254	Improvement of Pharmacological Properties of Protein-Drugs by Tailoring with Synthetic Polymers. 1988 , 3, 27-43		26
2253	Unusual spinal cord enlargement related to intramedullary hemangioblastoma. 1988 , 68, 550-3		38
2252	The biodistribution and effect on hepatic parenchyme with intraarterial injected I-131 Lipiodol into hepatic artery. 1989 , 25, 548		
2251	Vascular permeability factor, an endothelial cell mitogen related to PDGF. <i>Science</i> , 1989 , 246, 1309-12	33.3	1767
2250	Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. 1989 , 140, 1104-7		113

2249	Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. 1989 , 948, 305-26	111
2248	Histopathological effects of homocysteine thiolactone on epithelial and stromal tissues. 1989 , 51, 159-70	25
2247	Immunofluorescent and histochemical staining confirm the identification of the many diseases called interstitial cystitis. 1990 , 66, 265-73	20
2246	Tumor interactions with the vasculature: angiogenesis and tumor metastasis. 1990 , 1032, 89-118	188
2245	Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC. 1990 , 29, 172-80	17
2244	Hemostasis in malignancy. 1990 , 35, 45-55	65
2243	Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids. 1990 , 72, 245-51	55
2242	Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. <i>Growth Factors</i> , 1990 , 4, 53-9	1.6 87
2241	Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. 1990 , 172, 1535-45	743
2240	Effects of a variety of cytokines and inducing agents on vascular permeability factor mRNA levels in U937 cells. 1991 , 180, 572-8	51
2239	Specific binding of vascular permeability factor to endothelial cells. 1991 , 175, 68-76	67
2238	Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. 1991 , 181, 902-6	527
2237	Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). 1991 , 179, 1568-75	67
2236	Penetration of tumor tissue by antibodies and other immunoproteins. 1991 , 618, 367-82	37
2235	Characterization of kininogens in human malignant ascites. 1991 , 63, 641-50	11
2234	Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. 1991 , 198, 391-405	80
2233	SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. 1991 , 6, 181-202	192
2232	Kinin-generating cascade in advanced cancer patients and in vitro study. 1991 , 82, 732-41	89

2231	Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung. 1991 , 99, 981-8		13
2230	Vascular permeability factor: a unique regulator of blood vessel function. 1991 , 47, 219-23		280
2229	Increased capillary permeability in rat brain induced by factors secreted by cultured C6 glioma cells: role in peritumoral brain edema. 1991 , 10, 13-25		19
2228	Development of subrenal capsule tumours following transplantation of rat RN6 multicell spheroids. 1991 , 10, 219-31		3
2227	Comparative Effects of Dexamethasone and Methylprednisolone on Peritumoral Brain Edema. 1991 , 235-242		
2226	Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. 1991 , 174, 1275-8		421
2225	Aortic smooth muscle cells express and secrete vascular endothelial growth factor. <i>Growth Factors</i> , 1991 , 5, 141-8	1.6	127
2224	Tumour-derived factors which induce endothelial tissue factor and enhance the procoagulant response to TNF. 1991 , 60, 273-7		6
2223	Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. 1992 , 3, 211-20		761
2222	Flavone acetic acid induced changes in human endothelial permeability: potentiation by tumour-conditioned medium. 1992 , 28A, 1628-32		5
2221	The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. <i>Growth Factors</i> , 1992 , 7, 53-64	1.6	260
2220	AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. 1992 , 183, 1167-74		142
2219	Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. 1992 , 667, 101-11		199
2218	Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. 1992 , 187, 1579-86		1259
2217	Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. 1992 , 189, 824-31		718
2216	The effects of growth factors on the day 13 chorioallantoic membrane (CAM): a study of VEGF165 and PDGF-BB. 1992 , 186, 251-7		67
2215	Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. 1992 , 359, 843-5		3844
2214	Vascular permeability factor mRNA and protein expression in human kidney. 1992 , 42, 1457-61		206

2213	The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. <i>Science</i> , 1992 , 255, 989-993,3	1809
2212	Vascular permeability factor (VPF, VEGF) in tumor biology. 1993 , 12, 303-24	713
2211	Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. 1993 , 44, 959-66	109
2210	Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. 1993 , 67, 975-80	87
2209	Block copolymer micelles as vehicles for drug delivery. 1993 , 24, 119-132	754
2208	In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane. 1993 , 274, 163-72	136
2207	Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. 1993 , 109, 195-9	119
2206	Two molecules related to the VEGF receptor are expressed in early endothelial cells during avian embryonic development. 1993 , 42, 33-48	179
2205	The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. 1993 , 178, 2077-88	215
2204	Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. 1993 , 2, 913-9	4
2203	Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. 1994 , 180, 341-6	442
2202	Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity. 1994 , 272, 918	
2201	Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity. 1994 , 272, 917	
2200	VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. <i>Growth Factors</i> , 1994 , 11, 187-95	1.6 82
2199	Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. 1994 , 81, 560-6	108
2198	Molecular mechanisms of developmental and tumor angiogenesis. 1994 , 4, 207-18	200
2197	Normal and abnormal development of the blood-brain barrier. 1994 , 27, 495-506	30
2196	Fisiopatologia. [Membrane vesicles, shed from in vitro cultured human breast carcinomas cells, inhibit lymphocytes proliferation.. 1994 , 5, 203-210	2

2195	Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. 1994 , 1, 333-8		131
2194	Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. 1994 , 85, 331-4		178
2193	Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. 1994 , 331, 1480-7		3141
2192	Enhanced expression of multiple forms of VEGF is associated with spontaneous immortalization of murine fibroblasts. 1994 , 1224, 365-70		16
2191	Mechanism of inhibitory actions of minocycline and doxycycline on ascitic fluid production induced by mouse fibrosarcoma cells. 1994 , 54, 703-9		4
2190	Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. 1994 , 180, 1141-6		583
2189	Vascular endothelial growth factor and its receptors. 1994 , 5, 89-97		168
2188	Purification and Characterization of VEGFNPF Secreted by Human Retinal Pigment Epithelial Cells. 1994 , 2, 73-85		8
2187	Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. 1994 , 173, 355-60		40
2186	Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis?. 1994 , 35, 439-48; discussion 448-9		147
2185	An immunohistochemical study of the vascularization of the human Graafian follicle. 1994 , 9, 1401-5		17
2184	Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 10457-61	11.5	1058
2183	Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 905-9	11.5	857
2182	Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 7657-61	11.5	293
2181	Vascular Endothelial Growth Factor in Angiogenesis. 1995 , vmr-6, 311-322		
2180	Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. 1995 , 63, 268-72		108
2179	Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. 1995 , 83, 682-9		105
2178	Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 768-72	11.5	515

2177	Proliferation pattern of capillary endothelial cells in chorioallantoic membrane development indicates local growth control, which is counteracted by vascular endothelial growth factor application. 1995 , 203, 174-86	50
2176	Serum basic fibroblast growth factor in men with and without prostate carcinoma. 1995 , 76, 2304-11	66
2175	Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. 1995 , 14, 87-93	113
2174	Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. 1995 , 164, 385-94	96
2173	Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. 1995 , 36, 193-204	312
2172	Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. 1995 , 177, 259-67	109
2171	Isolation and properties of tumor-derived endothelial cells from rat KMT-17 fibrosarcoma. 1995 , 86, 193-201	13
2170	Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. 1995 , 2, 683-95	235
2169	Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. 1995 , 1246, 1-9	61
2168	Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen. 1995 , 1, 182-193	281
2167	Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor ¹²¹ (VEGF/VPF ¹²¹). 1995 , 14, 475-80	12
2166	Expression of biologically active human vascular endothelial growth factor in yeast. <i>Growth Factors</i> , 1995 , 12, 17-27	1.6 27
2165	The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. 1995 , 376, 57-70	13
2164	Do mucins promote tumor-cell metastasis. 1995 , 7, 913-26	1
2163	Conspicuous growth of intravenously inoculated <i>Staphylococcus aureus</i> in subcutaneously established Ehrlich ascites tumor tissue of mice. 1995 , 39, 153-5	1
2162	Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. 1995 , 104, 744-9	109
2161	Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. 1995 , 20, 27-38	86
2160	Human keratinocytes express the three major splice forms of vascular endothelial growth factor. 1995 , 104, 7-10	98

2159	Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. 1995 , 105, 44-50	190
2158	Role of VEGF-flt receptor system in normal and tumor angiogenesis. 1995 , 67, 281-316	238
2157	Differential expression of vascular endothelial growth factor and its receptor mRNAs in the mouse uterus around the time of implantation. 1995 , 147, 339-52	138
2156	Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. 1995 , 87, 506-16	414
2155	The shortest isoform of human vascular endothelial growth factor/vascular permeability factor (VEGF/VPF121) produced by <i>Saccharomyces cerevisiae</i> promotes both angiogenesis and vascular permeability. 1995 , 1243, 195-202	34
2154	Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. 1995 , 26, 86-91	549
2153	Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. 1995 , 372, 83-7	394
2152	Vascular endothelial growth factor gene expression in ovine placenta and fetal membranes. 1995 , 173, 753-9	88
2151	Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. 1995 , 28, 141-8	78
2150	Polymer conjugates with anticancer activity. 1995 , 55-123	216
2149	Tumor-conditioned medium increases macromolecular permeability of endothelial cell monolayer. 1995 , 89, 7-14	18
2148	Vascular Permeability Factor (Vascular Endothelial Growth Factor) is Strongly Expressed in the Normal Male Genital Tract and is Present in Substantial Quantities in Semen. 1995 , 154, 576-579	67
2147	Hypercoagulability in cancer. 1996 , 10, 499-530	101
2146	Vascular endothelial growth factor in pulmonary hypertension. 1996 , 796, 186-93	36
2145	Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. 1996 , 78, 454-60	121
2144	Degranulation of mast cells in the chick chorioallantoic membrane does not increase macromolecular extravasation during normal angiogenesis. 1996 , 3, 387-93	1
2143	Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. 1996 , 28, 1523-9	75
2142	Mast cell activation accelerates the normal rate of angiogenesis in the chick chorioallantoic membrane. 1996 , 52, 245-57	27

2141	Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. 1996 , 221, 193-8	96
2140	Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells. 1996 , 221, 697-702	55
2139	Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and KDR/flk-1, in regenerating rat liver. 1996 , 226, 176-9	111
2138	Depletion of [Ca ²⁺] _i inhibits hypoxia-induced vascular permeability factor (vascular endothelial growth factor) gene expression. 1996 , 229, 733-8	25
2137	Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. 1996 , 86, 353-64	5591
2136	Angiogenesis and the skin: a primer. 1996 , 34, 486-97	79
2135	Immunohistochemical localization of vascular endothelial growth factor in the human placenta. 1996 , 17, 111-21	109
2134	Vascular endothelial growth factor. 1996 , 32A, 2413-22	302
2133	Vascular endothelial growth factor and its receptors. 1996 , 7, 259-70	360
2132	Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. 1996 , 103, 1820-8	430
2131	Embryonic angiogenesis: a review. 1996 , 83, 153-64	73
2130	Characterization of the promoter region for flt-1 tyrosine kinase gene, a receptor for vascular endothelial growth factor. <i>Growth Factors</i> , 1996 , 13, 151-62	1.6 20
2129	Therapeutic angiogenesis: a new frontier for vascular therapy. 1996 , 1, 79-87	45
2128	Vascular endothelial growth factor affects permeability of brain microvessel endothelial cells in vitro. 1996 , 271, C1973-80	95
2127	Vascular permeability/vascular endothelial growth factors: a potential role in the pathogenesis and treatment of vascular diseases. 1996 , 1, 251-8	14
2126	The ovarian hyperstimulation syndrome. 1996 , 5, 169-184	7
2125	Effect of tumour cell-conditioned medium on endothelial macromolecular permeability and its correlation with collagen. 1996 , 73, 24-8	26
2124	The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. 1996 , 271, 17629-34	635

2123	The vascular endothelial cell growth factor family and its receptors.. 1996 , 433-464	
2122	Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report**Supported in part by grant 16842 from the National Institutes of Health, Bethesda, Maryland and in part by Beth Israel Hospital Pathology Foundation, Boston, Massachusetts.. 1996 , 65, 552-555	96
2121	A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.. 1996 , 15, 290-298	951
2120	Intratumoural distribution as a determinant of tumour responsiveness to therapy using polymer-based macromolecular prodrugs. 1996 , 39, 35-46	26
2119	Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. 1996 , 196, 199-209	32
2118	Macromolecular systems for chemotherapy and magnetic resonance imaging. 1996 , 18, 219-267	53
2117	Growth factors in the retina and retinal pigmented epithelium. 1996 , 15, 547-567	22
2116	Detection of fibrin in canine neoplasia. 1996 , 152, 83-91	4
2115	Quantitative analysis of vascular endothelial growth factor in primary breast cancer. 1996 , 77, 1101-6	142
2114	Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. 1996 , 77, 1598-604	122
2113	Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. 1996 , 69, 205-11	103
2112	1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. 1996 , 46, 540-50	36
2111	A mathematical model of growth factor induced capillary growth in the retina. 1996 , 24, 33-41	12
2110	Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. 1996 , 15, 165-76	153
2109	Reversion of phenotype of endothelial cells in brain tissue around glioblastomas. 1996 , 27, 127-32	4
2108	Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance. 1996 , 14, 190-6	2
2107	Angiogenesis in Preinvasive Lesions of the Breast. 1996 , 2, 364-369	26
2106	Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome. 1996 , 87, 1143-52	9

2105	Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. 1996 , 74, 1354-8		49
2104	Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. 1996 , 74, 1492-8		24
2103	Molecular regulation of angiogenesis in the skin. 1996 , 106, 207-8		66
2102	Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. 1996 , 183, 1981-6		252
2101	Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. 1996 , 80, 363-6		106
2100	Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. <i>Growth Factors</i> , 1996 , 13, 57-64	1.6	215
2099	A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. 1996 , 271, 30823-8		118
2098	The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. 1996 , 271, 3877-83		233
2097	Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. 1996 , 114, 964-70		279
2096	Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. 1996 , 271, 21793-7		124
2095	Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. 1996 , 137, 5589-96		87
2094	Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. 1996 , 271, 5638-46		374
2093	Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas. 1996 , 85, 1095-101		108
2092	Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. 1996 , 10, 375-82		32
2091	The possible role of the immune system in the aetiopathogenesis of ovarian hyperstimulation syndrome. 1997 , 12, 2629-34		33
2090	Increased concentration of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. 1997 , 82, 1968-73		39
2089	Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. <i>Growth Factors</i> , 1997 , 14, 257-68	1.6	75
2088	Regulation of Angiogenesis. 1997 ,		3

2087	Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. 1997 , 272, 13390-6	161
2086	The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. 1997 , 3, 255-66	153
2085	Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. 1997 , 46, 1619-26	152
2084	The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. 1997 , 272, 27509-12	107
2083	Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. 1997 , 115, 1553-8	41
2082	Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. 1997 , 115, 1161-6	250
2081	Lymphatic diameters and radionuclide clearance in a murine melanoma model. 1997 , 132, 311-5	13
2080	A comparison of the expression of the malignant phenotype in two androgen-independent human prostate cancer cell lines after orthotopic implantation in nude mice. 1997 , 11, 771-6	1
2079	Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology. 1997 , 7, 331-361	6
2078	Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. 1997 , 272, 24203-9	62
2077	Role of vascular permeability factor/vascular endothelial growth factor in eye disease. 1997 , 81, 501-12	64
2076	Meningiomas: Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Angiogenesis and Peritumoral Edema. 1997 ,	
2075	Characterization of a soluble vascular endothelial growth factor receptor-immunoglobulin chimera. <i>Growth Factors</i> , 1997 , 14, 243-56	1.6 28
2074	Antiangiogenic Drug Therapy for Macular Degeneration. 1997 , 12, 10-13	
2073	Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. 1997 , 8, 1015-22	37
2072	Vascular Endothelial Growth Factor: Possible Role in Fetal Development and Placental Function. 1997 , 4, 169-177	32
2071	Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 663-8	11.5 639
2070	Immunohistochemical Distribution of Vascular Endothelial Growth Factor in the Human Placenta Associated with Hydrops Fetalis. 1997 , 17, 65-81	2

2069	The biology of vascular endothelial growth factor. 1997 , 18, 4-25		3402
2068	Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. 1997 , 124, 433-46		135
2067	Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: In Situ and in Vitro Expression of VEGF by Human Prostate Cancer Cells. 1997 , 157, 2329-2333		213
2066	Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. 1997 , 67, 261-5		147
2065	Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. 1997 , 235, 493-8		150
2064	Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. 1997 , 236, 712-5		106
2063	VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. 1997 , 188, 96-109		398
2062	Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. <i>Experimental Cell Research</i> , 1997 , 233, 340-9	4.2	88
2061	Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. 1997 , 64, 505-17		220
2060	Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. 1997 , 23, 526-31		75
2059	Ascites revisited: a novel role for tamoxifen. 1997 , 23, 570		5
2058	Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. 1997 , 27, 854-61		144
2057	Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 861-6	11.5	393
2056	Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. 1997 , 104, 223-8		116
2055	Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. 1997 , 504 (Pt 3), 747-61		95
2054	Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. 1997 , 811, 311-22; 322-4		54
2053	Vascular endothelial growth factor is increased in patients with preeclampsia. 1997 , 38, 302-6		99
2052	Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. 1997 , 108, 263-8		202

2051	Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2. 1997 , 14, 463-71	20
2050	The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. 1997 , 14, 2079-89	264
2049	Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. 1997 , 3, 879-86	297
2048	A new model of renal microvascular endothelial injury. 1997 , 52, 182-94	56
2047	Nachweis des angiogenen Zytokins Vascular Endothelial Growth Factor (VEGF) durch nicht radioaktive In-situ-Hybridisierung. 1997 , 179, 559-562	
2046	Mechanisms of retinal angiogenesis. 1997 , 16, 157-181	51
2045	Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. 1997 , 18, 269-76	129
2044	Heparin-binding angiogenic growth factors in pregnancy. 1997 , 18, 215-258	10
2043	Vascular endothelial growth factor. 1997 , 35, 365-72	53
2042	Distinct capillary density and progression promoted by vascular endothelial growth factor-A homodimers and heterodimers. 1997 , 1, 117-30	10
2041	TGF beta-1 regulation of VEGF production by breast cancer cells. 1997 , 4, 621-7	82
2040	The multiple roles of tumour stroma. 1997 , 430, 433-43	145
2039	Expression of the avian VEGF receptor homologues Quek1 and Quek2 in blood-vascular and lymphatic endothelial and non-endothelial cells during quail embryonic development. 1997 , 288, 207-23	94
2038	Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeability in mouse skin. 1997 , 356, 475-80	29
2037	Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. 1997 , 78, 57-70	101
2036	Vascular endothelial growth factor expression in early stage ovarian carcinoma. 1997 , 80, 98-106	323
2035	Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. 1997 , 80, 1945-53	152
2034	Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. 1997 , 49, 268-80	127

2033	Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. 1998 , 2, 167-82	61
2032	Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. 1998 , 27, 163-73	144
2031	Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. 1998 , 89, 307-14	386
2030	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. 1998 , 77, 1870-4	52
2029	Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. 1998 , 78, 1379-84	269
2028	Clearance properties of liposomes involving conjugated proteins for targeting. 1998 , 32, 99-118	45
2027	Control of tumour vascular permeability. 1998 , 34, 109-119	181
2026	A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor ¹⁶⁵ in human plasma. 1998 , 219, 45-55	33
2025	Functions of the VEGF receptor-1 (FLT-1) in the vasculature. 1998 , 8, 241-5	32
2024	Expression of vascular endothelial growth factor in human hepatocellular carcinoma. 1998 , 28, 68-77	316
2023	Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. 1998 , 83, 2528-33	53
2022	Paracrine and autocrine regulation of vascular endothelial growth factor during tissue differentiation in the quail. 1998 , 212, 1-13	37
2021	Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. 1998 , 186, 186-91	46
2020	Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via inhibiting Flk-1 receptor expression in bovine carotid artery endothelial cells. 1998 , 176, 342-9	53
2019	Zur Regulation der Angiogenese im menschlichen Corpus luteum. 1998 , 14, 282-289	
2018	Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. 1998 , 5, 271-8	165
2017	Oxygen, genes, and development: an analysis of the role of hypoxic gene regulation during murine vascular development. 1998 , 76, 391-401	102
2016	Vascular permeability factor in ascites from patients with spontaneous bacterial peritonitis. 1998 , 10, 185-192	

2015	Neuroendocrine cells of the verumontanum: a comparative immunohistochemical study. 1998 , 82, 738-43	19
2014	Increase in serum vascular endothelial growth factor levels during altitude training. 1998 , 162, 455-9	48
2013	Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. 1998 , 134, 15-22	41
2012	Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. 1998 , 89, 43-50	71
2011	Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression. 1998 , 59, 74-83	48
2010	Barbiturates decrease the expression of vascular endothelial growth factor in hypoxic cultures of porcine brain derived microvascular endothelial cells. 1998 , 60, 89-97	11
2009	Analysis of vascularity of human neurofibromas. 1998 , 38, 950-4	42
2008	Upregulation of vascular endothelial growth factor in severe chronic brain hypoxia of the rat. 1998 , 252, 199-202	26
2007	Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. 1998 , 4, 377-86	93
2006	Other medical management of uterine fibroids. 1998 , 12, 269-88	7
2005	Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. 1998 , 34, 2041-5	156
2004	Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats. 1998 , 63, PL71-4	15
2003	Increased Circulating Levels of Vascular Endothelial Growth Factor in Preeclampsia. 1998 , 17, 283-290	16
2002	Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. 1998 , 273, 26722-8	168
2001	Antagonising the expression of VEGF in pathological angiogenesis. 1998 , 8, 1695-1706	3
2000	Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. 1998 , 9, 823-33	151
1999	Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. 1998 , 141, 1659-73	675
1998	Transient induction of polycystic ovary-like syndrome in immature hypothyroid rats. 1998 , 219, 77-84	8

1997	Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. 1998 , 98, 2108-16	389
1996	Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. 1998 , 273, 31283-8	123
1995	Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. 1998 , 249, 73-7	73
1994	Activated human neutrophils express vascular endothelial growth factor (VEGF). 1998 , 10, 254-7	118
1993	What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?. 1998 , 153, 11-6	126
1992	Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. 1998 , 153, 381-94	285
1991	Host microvasculature influence on tumor vascular morphology and endothelial gene expression. 1998 , 153, 1239-48	91
1990	Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. 1998 , 153, 1249-56	323
1989	Liposome-anchored vascular endothelial growth factor aptamers. 1998 , 9, 573-82	151
1988	Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. 1998 , 51, 161-7	192
1987	Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. 1998 , 70, 560-4	60
1986	An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. 1998 , 17, 185-90	31
1985	Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. 1998 , 97, 99-107	428
1984	A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. 1998 , 273, 6599-602	181
1983	Vascular endothelial growth factor C induces angiogenesis in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 14389-94	11.5 465
1982	Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. 1998 , 4, 203-6	55
1981	Effect of time on the viability of ischemic skin flaps treated with vascular endothelial growth factor (VEGF) cDNA. 1998 , 14, 387-90	33
1980	Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancers. 1998 , 28, 176-81	14

1979	Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. 1998 , 139, 4672-8	84
1978	Vascular endothelial growth factor induces endothelial fenestrations in vitro. 1998 , 140, 947-59	521
1977	Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. 1998 , 273, 26277-80	137
1976	2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. 1998 , 273, 20556-67	541
1975	Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. 1998 , 97, 1114-23	962
1974	Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. 1998 , 90, 447-54	314
1973	Vascular permeability factor/vascular endothelial growth factor and vascular stroma formation in neoplasia. Insights from in situ hybridization studies. 1998 , 46, 569-75	16
1972	Gene Therapy Strategies for Tumor Antiangiogenesis. 1998 , 90, 261-263	2
1971	Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. 1998 , 273, 15099-103	254
1970	Regulation of distinct steps of angiogenesis by different angiogenic molecules. 1998 , 12, 749-57	44
1969	8-(3-oxo-4,5,6-trihydroxy-3h-xanthen-9-yl)-1-naphthoic acid inhibits MAPK phosphorylation in endothelial cells induced by VEGF and bFGF. 1998 , 2, 211-215	1
1968	Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. 1998 , 114, 1668-75	91
1967	The mechanisms of hepatic sinusoidal endothelial cell regeneration: A possible communication system associated with vascular endothelial growth factor in liver cells. 1998 , 13, S1-S5	21
1966	Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. 1998 , 77, 956-64	490
1965	Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. 1998 , 185, 173-84	30
1964	Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 548-53	11.5 970
1963	Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. 1998 , 77, 998-1002	253
1962	Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. 1998 , 188, 1135-45	280

1961	Ras activation in astrocytomas and neurofibromas. 1998 , 25, 267-81	57
1960	Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. 1998 , 94, 395-404	227
1959	Serum vascular endothelial growth factor concentration in rapidly progressive glomerulonephritis. 1998 , 80, 357-8	5
1958	In vitro release of vascular endothelial growth factor during platelet aggregation. 1998 , 275, H1054-61	71
1957	Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer. 1998 , 30, 130-7	10
1956	Effects of coronary artery disease on expression and microvascular response to VEGF. 1998 , 275, H1411-8	14
1955	VEGF induces hyperpermeability by a direct action on endothelial cells. 1998 , 274, L678-84	60
1954	Protein profiling of non-malignant and malignant ascites by SELDI-TOF MS: Proof of principle. 1998 , 23, 3	
1953	Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. 1999 , 44, 732-40; discussion 740-1	87
1952	VEGF stimulates tyrosine phosphorylation of beta-catenin and small-pore endothelial barrier dysfunction. 1999 , 277, H2038-49	35
1951	Vascular endothelial growth factor (VEGF) and its receptors. 1999 , 13, 9-22	2817
1950	Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. 1999 , 276, C812-20	189
1949	Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Kaposi's Sarcoma-Associated Herpesvirus-Infected Primary Effusion Lymphomas. 1999 , 94, 4247-4254	95
1948	Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. 1999 , 14, 353-9	14
1947	Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. 1999 , 14, 401-8	29
1946	Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. 1999 , 13, 537-45	190
1945	Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene. 1999 , 140, 5422-30	65
1944	Expression of vascular permeability factor in craniopharyngioma. 1999 , 91, 831-4	25

1943	Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. 1999 , 318, 853-6	41
1942	The pathogenesis of edema in diabetic maculopathy. 1999 , 14, 223-32	269
1941	A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. 1999 , 274, 34884-92	87
1940	Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. 1999 , 27, 78-86	168
1939	Preeclampsia: The Endothelium, Circulating Factor(s) and Vascular Endothelial Growth Factor. 1999 , 6, 3-10	33
1938	Simultaneous in vivo quantitation of vascular endothelial growth factor mRNA splice variants. 1999 , 36, 133-8	17
1937	Vascular endothelial growth factor induces activation and subcellular translocation of focal adhesion kinase (p125FAK) in cultured rat cardiac myocytes. 1999 , 84, 1194-202	73
1936	Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 5728-33	11.5 171
1935	Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. 1999 , 274, 31047-54	217
1934	Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. 1999 , 115, 176-82	156
1933	Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. 1999 , 116, 360-5	32
1932	Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. 1999 , 117, 171-6	68
1931	Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma. 1999 , 24, 426-30	16
1930	Role of vascular endothelial growth factor in the regulation of angiogenesis. 1999 , 56, 794-814	547
1929	Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome. 1999 , 55, 1063-71	40
1928	UVA and UVB Radiation Differentially Regulate Vascular Endothelial Growth Factor Expression in Keratinocyte-derived Cell Lines and in Human Keratinocytes. 1999 , 70, 674-679	59
1927	Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. 1999 , 106, 1019-22	147
1926	Vascular Endothelial Growth Factor and Microvascular Permeability. 1999 , 6, 83-96	113

1925	Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. 1999 , 90, 93-100	48
1924	Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. 1999 , 90, 874-9	58
1923	Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. 1999 , 18, 1619-27	165
1922	VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. 1999 , 18, 2221-30	472
1921	Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. 1999 , 80, 827-33	44
1920	Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. 1999 , 80, 1697-707	107
1919	Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. 1999 , 81, 1335-43	43
1918	Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. 1999 , 109, 810-4	71
1917	Soluble VEGF receptors. 1999 , 3, 33-9	45
1916	Role of endothelial cell survival and death signals in angiogenesis. 1999 , 3, 101-16	45
1915	Angiogenic switch and vascular stability in human Leydig cell tumours. 1999 , 3, 231-40	8
1914	Vascular permeability factor expression in cerebellar hemangioblastomas: correlation with tumor-associated cysts. 1999 , 41, 3-7	16
1913	Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. 1999 , 18, 473-81	71
1912	Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. 1999 , 17, 831-40	16
1911	VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. 1999 , 18, 3964-72	1611
1910	A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. 1999 , 18, 363-74	357
1909	Expression of vascular endothelial growth factor (VEGF) and its corresponding receptors (flt-1 and flk-1) in the bovine oviduct. 1999 , 53, 376-83	47
1908	Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. 1999 , 7, 171-86	183

1907	Molecular and biological properties of vascular endothelial growth factor. 1999 , 77, 527-43	880
1906	Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. 1999 , 42, 579-88	186
1905	Localization of vascular endothelial growth factor in nontumorous human pituitaries. 1999 , 10, 109-22	19
1904	Alginate oligosaccharides stimulate VEGF-mediated growth and migration of human endothelial cells. 1999 , 291, 542-7	95
1903	Immunohistochemical localization of vascular endothelial growth factor in the globule leukocyte/mucosal mast cell of the rat respiratory and digestive tracts. 1999 , 111, 13-21	26
1902	Embryonic lymphangiogenesis. 1999 , 297, 1-11	52
1901	Vascular endothelial growth factor in ovarian cancer. 1999 , 1, 59-63	30
1900	Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. 1999 , 35, 533-42	80
1899	Vascular endothelial growth factor in acute Kawasaki disease. 1999 , 83, 337-9	72
1898	Scatter factor/hepatocyte growth factor gene transfer increases rat blood-glioma barrier permeability. 1999 , 833, 173-80	15
1897	Vascular endothelial growth factor stimulates Schwann cell invasion and neovascularization of acellular nerve grafts. 1999 , 846, 219-28	165
1896	Expression of vascular endothelial growth factor promotes colonization, vascularization, and growth of transplanted hepatic tissues in the mouse. 1999 , 29, 396-402	41
1895	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. 1999 , 29, 1057-63	59
1894	Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. 1999 , 85, 936-44	128
1893	Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. 1999 , 85, 1323-1330	81
1892	Intratumoral neovascularization and growth pattern in early gastric carcinoma. 1999 , 85, 2340-6	44
1891	Differential immunolocalization of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. 1999 , 254, 61-73	79
1890	Vascular endothelial growth factor-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 human fibrosarcoma cell model. 1999 , 80, 738-43	29

1889	Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. 1999 , 189, 72-8		155
1888	In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. 1999 , 1, 50-62		255
1887	The role of the vascular phase in solid tumor growth: a historical review. 1999 , 1, 293-302		112
1886	Factors promoting tumor angiogenesis. 1999 , 17, 594-623		90
1885	The vascular endothelial growth factor family: signalling for vascular development. <i>Growth Factors</i> , 1999 , 17, 1-11	1.6	51
1884	Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 3071-6	11.5	228
1883	Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. 1999 , 35, 133-7		125
1882	Vascular endothelial growth factor is implicated in early invasion in cervical cancer. 1999 , 35, 485-9		57
1881	Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF. 1999 , 17, 565-77		49
1880	Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. 1999 , 4, 915-24		679
1879	Expression of vascular endothelial growth factor mRNA following transient forebrain ischemia in rats. 1999 , 265, 107-10		73
1878	Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells. 1999 , 141, 63-71		32
1877	Vascular endothelial growth factor upregulation in transient global ischemia induced by cardiac arrest and resuscitation in rat brain. 1999 , 74, 83-90		46
1876	Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. 1999 , 30, 911-5		79
1875	Surgical implications of therapeutic angiogenesis. 1999 , 125, 243-249		8
1874	Decreased expression of receptors for vascular endothelial growth factor and sinusoidal endothelial cell damage in cold-preserved rat livers. 1999 , 31, 2668-72		10
1873	Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor. 1999 , 34, 743-7; discussion 747-8		26
1872	Adaptive hypoxic tolerance in the subterranean mole rat <i>Spalax ehrenbergi</i> : the role of vascular endothelial growth factor. 1999 , 452, 133-40		71

1871	Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. 1999 , 463, 260-4	129
1870	Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. 1999 , 30, 1232-41	44
1869	Development of an ELISA for the quantification of fibrin in canine tumours. 1999 , 96, 11-7	1
1868	Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma. 1999 , 51, 292-9	36
1867	Gene Therapy for Peripheral Arterial Disease: Where Do We Stand Now?. 1999 , 10, 135-139	
1866	The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. 1999 , 71, 482-9	169
1865	Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of <i>Vipera aspis aspis</i> (Aspic viper). 1999 , 38, 11796-803	44
1864	Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. 1999 , 155, 421-8	437
1863	Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. 1999 , 155, 723-9	31
1862	Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 8161-6	11.5 83
1861	VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. 1999 , 256, 192-7	186
1860	Lipocortin V may function as a signaling protein for vascular endothelial growth factor receptor-2/Flk-1. 1999 , 258, 713-21	19
1859	Characterization of the VEGF binding site on the Flt-1 receptor. 1999 , 262, 731-8	14
1858	Inhibitory effect of full-length human endostatin on in vitro angiogenesis. 1999 , 263, 340-5	67
1857	Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. 1999 , 264, 781-8	300
1856	Okadaic acid stimulates the expression of vascular endothelial growth factor gene. 1999 , 265, 584-8	8
1855	Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. 1999 , 212, 307-22	247
1854	Quantification of tumor microvascular permeability in human glioma xenografts using dynamic T1 MRI with Gadomer-17. 1999 ,	2

1853	Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. 1999 , 338, 367-374	58
1852	Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. 1999 , 338, 367	22
1851	Chapter 7 Angiogenesis in prostate cancer. 1999 , 3, 139-154	
1850	Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?. 1999 , 10, 965-71	86
1849	Human albumin enhances expression of vascular endothelial growth factor in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome. 1999 , 14, 1157-9	7
1848	Vascular endothelial growth/permeability factor in spinal cord injury. 1999 , 90, 220-3	19
1847	Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. 2000 , 93, 93-9	34
1846	Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. 2000 , 93, 168-74	59
1845	Periovulatory and Interleukin-1 β Dependent Up-Regulation of Intraovarian Vascular Endothelial Growth Factor (VEGF) in the Rat: Potential Role for VEGF in the Promotion of Periovulatory Angiogenesis and Vascular Permeability. 2000 , 7, 51-60	
1844	Expressions of vascular endothelial growth factor and basic fibroblast growth factor in tumors induced by two different cloned cell lines established from transplantable rat malignant fibrous histiocytoma. 2000 , 62, 699-705	4
1843	Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis. 2000 , 105, 1034-42	54
1842	Immunohistochemical studies on vascular endothelial growth factor and platelet endothelial cell adhesion molecule-1/CD-31 in islet transplantation. 2000 , 21, 165-73	18
1841	Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. 2000 , 34, 386-93	62
1840	Expression of hypoxia-inducible factor 1 β in brain tumors. 2000 , 88, 2606-2618	509
1839	Recurrence of meningiomas. 2000 , 89, 1102-10	130
1838	Progress in antiangiogenic gene therapy of cancer. 2000 , 89, 1181-1194	89
1837	Expression and regulation of neuropilin-1 in human astrocytomas. 2000 , 88, 584-92	65
1836	Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer. 2000 , 15, 283-9	13

1835	Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. 2000 , 16, 393-407	72
1834	Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. 2000 , 2, 279-88	46
1833	Enhanced vascularization of cultured skin substitutes genetically modified to overexpress vascular endothelial growth factor. 2000 , 114, 5-13	95
1832	Role of vascular endothelial growth factor in diabetic vascular complications. 2000 , 77, S113-9	190
1831	Tumor angiogenesis. 2000 , 5, 20-3	53
1830	Angiogenesis in head and neck squamous cell carcinoma. 2000 , 25, 169-80	19
1829	Involvement of vascular endothelial growth factor in nasal obstruction in patients with nasal allergy. 2000 , 49, 183-188	5
1828	Expression of angiogenic growth factors in paragangliomas. 2000 , 110, 161-7	48
1827	Keeping in touch with angiogenesis. 2000 , 6, 379-81	15
1826	Varicella-zoster vaccine: the bad news may be good. 2000 , 6, 381-2	4
1825	Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. 2000 , 6, 405-13	216
1824	Angiopoietin-1 protects the adult vasculature against plasma leakage. 2000 , 6, 460-3	1074
1823	Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. 2000 , 7, 1027-33	55
1822	An in vitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokines. 2000 , 80, 501-11	46
1821	VEGF: an update on biological and therapeutic aspects. 2000 , 11, 617-24	315
1820	Angiogenesis in ovarian cancer. 2000 , 14, 901-18	40
1819	Angiogenesis and placental growth in normal and compromised pregnancies. 2000 , 14, 969-80	49
1818	Angiogenesis and intrauterine growth restriction. 2000 , 14, 981-98	84

1817	A phase II trial of triamcinolone hexacetonide for symptomatic recurrent malignant ascites. 2000 , 19, 193-9	26
1816	Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. 2000 , 28, 700-6	83
1815	Investigation of vascular endothelial growth factor effects on pulmonary endothelial monolayer permeability and neutrophil transmigration. 2000 , 35, 149-57	18
1814	The discovery of angiogenic factors: a historical review. 2000 , 35, 227-31	83
1813	Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown. 2000 , 35, 233-9	13
1812	Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells. 2000 , 36, 81-8	18
1811	Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. 2000 , 21 Suppl A, S16-24	246
1810	Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. 2000 , 79, 850-7	100
1809	Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. 2000 , 65, 271-84	5122
1808	Recombinant production of PIGF-1 and its activity in animal models. 2000 , 55, 165-7	6
1807	Expression of vascular endothelial growth factor by reactive astrocytes and associated neoangiogenesis. 2000 , 883, 87-97	56
1806	VEGF in brain tumors. 2000 , 50, 109-20	185
1805	Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. 2000 , 50, 121-37	169
1804	Expression of vascular permeability factor in glioblastoma specimens: correlation with tumor vascular endothelial surface and peritumoral edema. 2000 , 49, 49-55	18
1803	Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. 2000 , 50, 1-15	267
1802	Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. 2000 , 18, 155-61	78
1801	Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. 2000 , 83, 196-203	169
1800	Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. 2000 , 83, 620-5	130

1799	Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. 2000 , 83, 775-81	113
1798	[Angiogenesis and vasculogenesis. Therapeutic strategies for stimulation of postnatal neovascularization]. 2000 , 25, 611-22	26
1797	Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. 2000 , 15, 105-11	30
1796	Focal therapeutic efficacy of transcatheter arterial infusion of styrene maleic acid neocarzinostatin for hepatocellular carcinoma. 2000 , 35, 28-33	8
1795	Immunohistochemical study of tight junction-related protein in neovasculature in astrocytic tumor. 2000 , 17, 1-6	23
1794	Retinal blood flow changes in diabetic retinopathy measured with the Heidelberg scanning laser Doppler flowmeter. 2000 , 238, 935-41	60
1793	Active interaction of human A375 melanoma cells with the lymphatics in vivo. 2000 , 114, 373-85	66
1792	Expression of vascular endothelial growth factor by granulated metrial gland cells in pregnant murine uteri. 2000 , 300, 285-93	44
1791	Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. 2000 , 100, 101-5	62
1790	Angiogenesis in malignant primary and metastatic brain tumors. 2000 , 247, 597-608	52
1789	In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. 2000 , 96, 3181-3187	151
1788	Effect of captopril on skeletal muscle angiogenic growth factor responses to exercise. 2000 , 88, 1690-7	24
1787	Nitric oxide synthase inhibition attenuates the skeletal muscle VEGF mRNA response to exercise. 2000 , 88, 1192-8	73
1786	Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. 2000 , 18, 1423-31	224
1785	The role of vascular endothelial growth factor in human dental pulp cells: induction of chemotaxis, proliferation, and differentiation and activation of the AP-1-dependent signaling pathway. 2000 , 79, 1596-603	85
1784	Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases. 2000 , 275, 41243-50	59
1783	Apoptosis in Cardiac Biology. 2000 ,	1
1782	Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. 2000 , 74, 5320-8	46

1781	CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. 2000 , 164, 5055-61	97
1780	Angiogenesis monitored by perfusion with a space-filling microbead suspension. 2000 , 1, 82-7	38
1779	Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. 2000 , 54, 1670-6	105
1778	Signaling pathways induced by vascular endothelial growth factor (review). 2000 , 5, 447-56	81
1777	Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. 2000 , 16, 445-54	55
1776	Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line. 2000 , 17, 495-9	3
1775	Molecular biology of the VEGF and the VEGF receptor family. 2000 , 26, 561-9	133
1774	Oxygen-independent upregulation of vascular endothelial growth factor and vascular barrier dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. 2000 , 22, 272-9	47
1773	Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. 2000 , 141, 1667-74	448
1772	Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. 2000 , 22, 657-64	239
1771	VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. 2000 , 20, 511-7	27
1770	A novel means of drug delivery: myoblast-mediated gene therapy and regulatable retroviral vectors. 2000 , 40, 295-317	34
1769	VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. 2000 , 21, 637-645	79
1768	Evidence for co-ordinated changes between vascular endothelial growth factor and nitric oxide synthase III immunoreactivity, the functional status of the thyroid follicles, and the microvascular bed during chronic stimulation by low iodine and propylthiouracyl in old mice. 2000 , 142, 651-60	25
1767	Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. 2000 , 20, 7282-91	211
1766	Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle. 2000 , 62, 439-47	98
1765	VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. 2000 , 14, 2087-96	272
1764	Cytokines accumulated in acquired renal cysts in long-term hemodialysis patients. 2000 , 65, 21-7	6

1763	Role of vascular endothelial growth factor in portal hypertensive gastropathy. 2000 , 61, 98-106		14
1762	Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 80-8	9.4	53
1761	Expression of vascular endothelial growth factor mRNA in GI-101A and HL-60 cell lines. 2000 , 270, 709-13		9
1760	Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties. 2000 , 59, 265-77		108
1759	Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. 2000 , 60, 112-20		33
1758	Vascular endothelial growth factor fails to acutely modulate endothelial permeability during early angiogenesis in the chick chorioallantoic membrane. 2000 , 60, 212-21		13
1757	In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. 2000 , 157, 103-10		70
1756	Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. 2000 , 156, 159-67		74
1755	Role of endothelin-1 in neovascularization of ovarian carcinoma. 2000 , 157, 1537-47		161
1754	Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. 2000 , 157, 1893-903		130
1753	Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. 2000 , 156, 1469-76		104
1752	Gene expression of vascular endothelial growth factor in giant cell tumors of bone. 2000 , 31, 804-12		34
1751	Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials. 2000 , 3, 223-235		18
1750	Altered basic fibroblast growth factor expression in common epidermal neoplasms: Examination with in situ hybridization and immunohistochemistry. 2000 , 42, 973-977		21
1749	Angiogenèse: de la physiologie à la thérapeutique. 2000 , 9, 534-544		2
1748	Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer. 2000 , 36, 68-73		34
1747	Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. 2000 , 36, 748-53		248
1746	Clinicopathological and biological assessment of lung cancers with pleural dissemination. 2000 , 69, 1025-9		19

1745	Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. 2000 , 2, 84-91	261
1744	Vascularization is a general requirement for growth of plant and animal tumours. 2000 , 51, 1951-60	56
1743	EXPRESSION OF THE VEGF-RECEPTOR Flt-1 IN BENIGN, PREMALIGNANT AND MALIGNANT PROSTATE TISSUES. 2000 , 164, 506-510	41
1742	A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. 2000 , 37, 443-8	452
1741	Microenvironment-induced cancer metastasis. 2000 , 76, 589-605	303
1740	Villous sprouting: fundamental mechanisms of human placental development. 2000 , 6, 485-94	115
1739	Applications of magnetic resonance in model systems: tumor biology and physiology. 2000 , 2, 139-51	100
1738	Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. 2000 , 2, 53-61	85
1737	The role of VEGF and thrombospondins in skin angiogenesis. 2000 , 24 Suppl 1, S78-84	130
1736	Role of vascular endothelial growth factor in ovarian physiology and pathology. 2000 , 74, 429-38	259
1735	Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells. 2001 , 15, 1318-20	16
1734	The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. 2001 , 41, 189-207	1871
1733	Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. 2001 , 34, 683-9	125
1732	Vascular endothelial growth factor and liver regeneration. 2001 , 34, 759-61	24
1731	The hemostatic system and angiogenesis in malignancy. 2001 , 3, 371-84	91
1730	Hypoxia and VEGF mRNA expression in human tumors. 2001 , 3, 500-8	47
1729	VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells. 2001 , 280, 481-5	52
1728	Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. 2001 , 286, 505-12	64

1727	Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. 2001 , 96, 173-82	146
1726	Bacterial wall products induce downregulation of vascular endothelial growth factor receptors on endothelial cells via a CD14-dependent mechanism: implications for surgical wound healing. 2001 , 101, 138-45	22
1725	Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. 2001 , 158, 789-96	109
1724	Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. 2001 , 158, 1161-72	186
1723	Molecular determinants of ovarian cancer plasticity. 2001 , 158, 1279-88	226
1722	Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma. 2001 , 6, 59-65	8
1721	Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. 2001 , 32, 10-7	49
1720	Aerogenous spread of primary lung adenocarcinoma induces ultrastructural remodeling of the alveolar capillary endothelium. 2001 , 32, 1050-8	14
1719	Vascular endothelial growth factor in chronic subdural haematomas. 2001 , 8, 411-5	57
1718	Prostaglandin E(2) modulation of vascular endothelial growth factor production in murine macrophages. 2001 , 65, 123-31	19
1717	Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome. 2001 , 98, 129-30	28
1716	Elevated interleukin-10 and sex steroid levels in peritoneal fluid of patients with ovarian hyperstimulation syndrome. 2001 , 99, 226-31	14
1715	FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. 2001 , 22, 201-7	754
1714	Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. 2001 , 61, 187-98	21
1713	Vascular endothelial growth factor-A activates Ca ²⁺ -activated K ⁺ channels in human endothelial cells in culture. 2001 , 33, 337-46	35
1712	Angiogenesis in dermatology. 2001 , 13, 183-192	
1711	Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. 2001 , 509, 95-100	55
1710	Role of vascular endothelial growth factor in regulation of physiological angiogenesis. 2001 , 280, C1358-66	773

1709	rhVEGF and Experimental Rat Skin Flaps: Systemic or Local Administration and Morphological Characteristics. 2001 , 24, 743-751	7
1708	Effects of VEGF(165) and VEGF(121) on vasculogenesis and angiogenesis in cultured embryonic quail hearts. 2001 , 280, H2240-7	40
1707	Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. 2001 , 26, 25-35	395
1706	The Contribution of Proangiogenic Factors to the Progression of Malignant Disease: Role of Vascular Endothelial Growth Factor and Its Receptors. 2001 , 10, 339-356	20
1705	Compartmentalization of Vascular Endothelial Growth Factor to the Epithelial Surface of the Human Lung. 2001 , 7, 240-246	100
1704	Bacterial induction of pleural mesothelial monolayer barrier dysfunction. 2001 , 281, L119-25	49
1703	Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells. 2001 , 281, L1500-11	80
1702	Vascular endothelial growth factor: molecular underpinning from development of vasculature to development of disease. 2001 , 280, C1357	1
1701	Shear stress regulates occludin content and phosphorylation. 2001 , 281, H105-13	92
1700	An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. 2001 , 276, 33428-34	87
1699	New strategies in the prevention of restenosis. 2001 , 24, 62-8	11
1698	Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography. 2001 , 36, 487-92	20
1697	Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. 2001 , 21, 469-77	76
1696	Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. 2001 , 12, 1353-7	54
1695	Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. 2001 , 195, 101-13	40
1694	A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. 2001 , 97, 1321-9	90
1693	Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. 2001 , 195, 43-54	24
1692	Pathophysiology of Ovarian Hyperstimulation Syndrome. 2001 , 43-78	

1691	Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. 2001 , 80, 115-46	60
1690	Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats. 2001 , 44, 1043-50	57
1689	Angiozyme: a novel angiogenesis inhibitor. 2001 , 3, 141-6	93
1688	Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. 2001 , 143, 159-66	55
1687	Effects of high-altitude exposure on vascular endothelial growth factor levels in man. 2001 , 85, 113-7	48
1686	Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165). 2001 , 50, 213-20	37
1685	Therapeutic angiogenesis for cardiovascular disease. 2001 , 2, 278-285	30
1684	Angiogenesis in autosomal-dominant polycystic kidney disease. 2001 , 60, 37-45	108
1683	Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. 2001 , 25, 558-65	176
1682	Role of signal transduction pathway of mitogen-activated protein kinase on metastasis of hepatocellular carcinoma induced by VEGF. 2001 , 2, 38-41	
1681	Identification and cloning of an 85-kDa protein homologous to RING3 that is upregulated in proliferating endothelial cells. 2001 , 268, 4398-407	7
1680	Permeability of rat IgE across rat aortic endothelial cell is enhanced by histamine. 2001 , 50, 223-230	1
1679	Immunohistochemical localization of vascular endothelial growth factor in the rat portal hypertensive gastropathy. 2001 , 16, 429-37	19
1678	Influence of host microvascular environment on tumour vascular endothelium. 1999 , 80, 1-10	2
1677	Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. 2001 , 20, 97-113	28
1676	Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. 2001 , 37, 97-114	94
1675	Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. 2001 , 195, 367-74	380
1674	Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. 2001 , 92, 556-68	196

1673	The role of FGF and VEGF in angioblast induction and migration during vascular development. 2001 , 220, 1-17	192
1672	Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. 2001 , 41, 229-37	41
1671	Control of hair growth and follicle size by VEGF-mediated angiogenesis. 2001 , 107, 409-17	411
1670	Complete genome analysis of the mandarin fish infectious spleen and kidney necrosis iridovirus. 2001 , 291, 126-39	211
1669	Angiogenesis in prostate cancer: biology and therapeutic opportunities. 2001 , 20, 297-319	36
1668	Ectodomain shedding of VEGF183, a novel isoform of vascular endothelial growth factor, promotes its mitogenic activity in vitro. 2001 , 4, 103-12	9
1667	The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. 2001 , 33, 841-7	44
1666	Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. 2001 , 34, 487-93	28
1665	Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. 2001 , 85, 273-8	162
1664	Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. 2001 , 85, 313-6	27
1663	Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. 2001 , 85, 576-83	67
1662	Cancer and thrombosis revisited. 2001 , 15, 61-7	32
1661	A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. 2001 , 20, 2768-78	542
1660	A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome. 2001 , 18, 114-9	14
1659	Vascular endothelial growth factor in edematous mouse embryos induced by retinoic acid in utero. 2001 , 41, 95-105	
1658	Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. 2001 , 7, 222-7	300
1657	The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. 2001 , 7, 569-74	298
1656	Angiogenesis after stroke is correlated with increased numbers of macrophages: the clean-up hypothesis. 2001 , 21, 1223-31	141

1655	Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch. 2001 , 132, 1342-8	11
1654	Regulation of VEGF-induced endothelial cell PAF synthesis: role of p42/44 MAPK, p38 MAPK and PI3K pathways. 2001 , 134, 1253-62	38
1653	Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. 2001 , 20, 3751-6	186
1652	Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. 2001 , 20, 4188-97	482
1651	Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. 2001 , 533, 263-72	47
1650	Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. 2001 , 92, 439-51	122
1649	Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. 2001 , 92, 516-23	23
1648	Blood-retinal barrier breakdown in experimental coronavirus retinopathy: association with viral antigen, inflammation, and VEGF in sensitive and resistant strains. 2001 , 119, 175-82	30
1647	Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. 2001 , 74, 47-61	791
1646	SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. 2001 , 46, 169-85	439
1645	In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. 2001 , 411, 231-43	95
1644	Stimulation and inhibition of angiogenesis in diabetic retinopathy. 2001 , 45, 577-84	34
1643	Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells. 2001 , 13, 585-91	17
1642	Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. 2001 , 50, 1166-70	84
1641	The role of vascular endothelial growth factor in angiogenesis. 2001 , 106, 148-56	332
1640	Biological characteristics of carcinomatosa pleuritis in orthotopic model systems using immune-deficient rats. 2001 , 18, 499	
1639	Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. 2001 , 58, 761-8	107
1638	General aspects of anti-angiogenesis and cancer therapy. 2001 , 1, 253-75	39

1637	The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. 2001 , 49, 419-32	207
1636	Cellular interactions in vascular growth and differentiation. 2001 , 204, 1-48	63
1635	Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. 2001 , 276, 32714-9	127
1634	Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. 2001 , 276, 3222-30	473
1633	Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. 2001 , 104, 115-9	209
1632	Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. 2001 , 276, 44307-14	54
1631	Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from gene therapy. 2001 , 8, 191-213	31
1630	Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. 2001 , 276, 39562-8	155
1629	Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma. 2001 , 276, 38781-6	26
1628	Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 12180-5	11.5 96
1627	Assessment of risks associated with cardiovascular gene therapy in human subjects. 2001 , 89, 389-400	119
1626	Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice. 2001 , 80, 1880-3	65
1625	Role of protein kinase C ζ in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. 2001 , 276, 2395-403	60
1624	VEGFR3 gene structure, regulatory region, and sequence polymorphisms. 2001 , 15, 1028-36	59
1623	Building better vasculature. 2001 , 15, 2497-502	65
1622	Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. 2001 , 276, 26969-79	240
1621	Growth Factors and their Receptors in Cancer Metastasis. 2001 ,	
1620	Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. 2001 , 12, 1713-29	33

1619	Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 6390-5	11.5	347
1618	Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the <i>Bothrops insularis</i> pit viper. A new member of the VEGF family of proteins. 2001 , 276, 39836-42		69
1617	Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. 2001 , 10, 81-93		24
1616	Thyroid stimulating hormone downregulates vascular endothelial growth factor expression in FRTL-5 cells. 2001 , 11, 539-43		11
1615	Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. 2001 , 12, 1299-310		93
1614	The molecular control of angiogenesis. 2002 , 21, 33-49		48
1613	Angiogenic and lymphangiogenic molecules in hematological malignancies. 2002 , 43, 219-24		21
1612	Lung Cancer. 2002 ,		
1611	Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. 2002 , 168, 3595-600		127
1610	Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. 2002 , 50, 767-77		122
1609	Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. 2002 , 277, 33564-70		101
1608	Mechanisms of normal and tumor-derived angiogenesis. 2002 , 282, C947-70		551
1607	Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. 2002 , 277, 44385-98		94
1606	Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. 2002 , 87, 231-7		86
1605	Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. 2002 , 20, 1449-56		71
1604	Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. 2002 , 10, 423		1
1603	Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. 2002 , 10, 169		2
1602	Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. 2002 , 166, 382-5		111

1601	Vascular endothelial growth factor causes pulmonary vasodilation through activation of the phosphatidylinositol-3-kinase-nitric oxide pathway in the late-gestation ovine fetus. 2002 , 52, 907-12		24
1600	Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. 2002 , 120, 1075-80		65
1599	Pancreatic Cancer. 2002 ,		1
1598	Von der Pathophysiologie und Prävention des ovariellen Überstimulationssyndroms (OHSS) bis zur stadiengerechten Therapie. 2002 , 62, 1155-1161		4
1597	Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia. 2002 , 87, 835-40		42
1596	Therapies directed at vascular endothelial growth factor. 2002 , 11, 1715-36		80
1595	Stimulation of vascular endothelial growth factor gene transcription by all trans retinoic acid through Sp1 and Sp3 sites in human bronchioloalveolar carcinoma cells. 2002 , 26, 246-53		46
1594	The Embryonic-Like Properties of Aggressive Human Tumor Cells. 2002 , 9, 2-9		17
1593	The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. 2002 , 8, 409-18		45
1592	Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 901-6	9.4	56
1591	Vascular growth factors and lymphangiogenesis. 2002 , 82, 673-700		322
1590	TUMOR VASCULATURE AS A TARGET. 2002 , 123-cp2		1
1589	Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. 2002 , 157, 149-60		296
1588	The role of tumor lymphangiogenesis in metastatic spread. 2002 , 16, 922-34		238
1587	New Directions in the Treatment of Cancer: Inhibition of Signal Transduction. 2002 , 15, 5-16		1
1586	In vitro and in vivo studies of a VEGF121/rGelolin chimeric fusion toxin targeting the neovasculature of solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 7866-71	11.5	126
1585	Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. 2002 , 138, 791-6		61
1584	Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. 2002 , 22, 143-52		351

1583	Gene therapy by adenovirus-mediated vascular endothelial growth factor and angiopoietin-1 promotes perfusion of muscle flaps. 2002 , 110, 149-59	41
1582	Expression of Vascular Endothelial Growth Factor (VEGF) and Specific Receptors (Flt-1 and Flk-1) in Rat Tongue Carcinogenesis Induced by 4-Nitroquinoline 1-Oxide.. 2002 , 35, 331-341	3
1581	Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. 2002 , 15, 69-79	29
1580	Perindopril: possible use in cancer therapy. 2002 , 13, 221-8	27
1579	Effect of transfection time on the survival of epigastric skin flaps pretreated with adenovirus encoding the VEGF gene. 2002 , 49, 161-9	27
1578	Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. 2002 , 102, 187-194	125
1577	BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. 2002 , 100, 3767-75	249
1576	Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. 2002 , 102, 187	57
1575	A novel dihydroxanthene, AGI-B4 with inhibition of VEGF-induced endothelial cell growth. 2002 , 55, 669-72	22
1574	Effect of vascular endothelial growth factor on maturation, fertilization and developmental competence of bovine oocytes. 2002 , 64, 803-6	35
1573	Serum hepatocyte growth factor predicts ventricular remodeling following myocardial infarction. 2002 , 66, 1003-7	22
1572	Extended Abstracts. 2002 , 82, 274-302	
1571	Angiopoietin-1 and VEGF in vascular development and angiogenesis in hypoplastic lungs. 2002 , 283, L60-6	42
1570	Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. 2002 , 283, L585-95	113
1569	Angiogenesis, metastasis, and lung cancer. An overview. 2003 , 74, 329-48	3
1568	Thromboembolic disease and cancer: possible new treatments. 2002 , 25, 67-73	4
1567	VEGF-RII influences the prognosis of pancreatic cancer. 2002 , 236, 738-49; discussion 749	69
1566	Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. 2002 , 61, 914-25	134

1565	Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. 2002 , 20, 4368-80	1287
1564	Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. 2002 , 7 Suppl 3, 4-11	49
1563	Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. 2002 , 125, 2549-57	312
1562	Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. 2002 , 51, 3090-4	259
1561	Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. 2002 , 133, 70-7	285
1560	Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. 2002 , 133, 537-43	140
1559	Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration. 2002 , 160, 1393-403	155
1558	The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. 2002 , 160, 195-204	280
1557	Neuropilin-1 participates in wound angiogenesis. 2002 , 160, 289-96	44
1556	Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. 2002 , 13, 39-53	202
1555	Vascular Endothelial Growth Factors. 2002 , 883-XXXV	
1554	Ovarian Cancer. 2002 ,	1
1553	Hantavirus immunology. 2002 , 15, 609-25	62
1552	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. 2002 , 4, R11	192
1551	Angiogenesis in non-small cell lung cancer. A new target for therapy. 2002 , 1, 325-38	4
1550	CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. 2002 , 54, 132-6	19
1549	Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid. 2002 , 293, 192-200	22
1548	Loss of placental growth factor protects mice against vascular permeability in pathological conditions. 2002 , 295, 428-34	71

1547	Akt signaling mediates VEGF/VPF vascular permeability in vivo. 2002 , 532, 67-9	51
1546	Vascular endothelial growth factor (VEGF) expression in healthy and inflamed human dental pulps. 2002 , 28, 20-3	90
1545	The seed and soil hypothesis: vascularisation and brain metastases. 2002 , 3, 53-7	344
1544	Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. 2002 , 1, 99-108	162
1543	VEGF mRNA expressed in microvessels of neonatal and adult rat cerebral cortex. 2002 , 101, 103-8	15
1542	Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. 2002 , 109, 1745-51	110
1541	Vascular Endothelial Growth Factor Concentrations in Body Cavity Effusions in Dogs. 2002 , 16, 164-168	19
1540	Immunology of the ovary. 2002 , 22, 435-454	
1539	Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. 2002 , 90, 95-102	24
1538	Fibroblast Growth Factor (FGF) and FGF Receptor Families in Bone. 2002 , 825-XXXII	7
1537	Edema cerebral em meningiomas: aspectos radiológicos e histopatológicos. 2002 , 60, 807-817	4
1536	Antiangiogenic Strategies in Pancreatic Cancer. 2002 , 357-367	2
1535	VEGF-Induced Cytoskeletal Alterations Relating to Vascular Permeability in Endothelial Cells. 2002 , 8, 1046-1047	1
1534	Regulation of vascular permeability by vascular endothelial growth factors. 2002 , 39, 225-37	264
1533	Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. 2002 , 39, 257-72	119
1532	Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. 2002 , 52, 331-9	41
1531	VEGF therapy in heart disease: for better or for worse?. 2002 , 7, 209-11	2
1530	Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. 2002 , 57, 289-326	90

1529	Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. 2002 , 46, 1202-9	62
1528	MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factor. 2002 , 15, 120-31	85
1527	VEGF isoforms and mutations in human colorectal cancer. 2002 , 101, 32-6	36
1526	Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. 2002 , 101, 217-23	35
1525	Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. 2002 , 101, 415-22	225
1524	Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. 2002 , 102, 109-16	53
1523	Immunomodulation der Endometriose. 2002 , 35, 238-242	3
1522	Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. 2002 , 309, 387-92	75
1521	Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration. 2002 , 147, 1913-31	77
1520	Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck. 2002 , 29, 585-9	39
1519	Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. 2002 , 31, 28-34	48
1518	The vascular endothelial growth factor family; proteins which guide the development of the vasculature. 1998 , 79, 255-65	92
1517	Enhanced bacterial virulence through exploitation of host glycosaminoglycans. 2002 , 43, 1379-86	70
1516	Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. 2002 , 62, 901-13	152
1515	"Bronchial artery delivery of viral vectors for gene delivery in cystic fibrosis; superior to airway delivery?". 2002 , 2, 2	1
1514	Establishment and characterization of a Kaposi's sarcoma-associated herpesvirus- and Epstein-Barr virus-negative malignant lymphoma cell line (OHK) with primary effusion lymphoma immunophenotype. 2002 , 116, 128-34	8
1513	Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. 2002 , 3, 32	80
1512	Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. 2002 , 7, 93-8	29

1511	Regulation of microvascular permeability by vascular endothelial growth factors. 2002 , 200, 581-97	209
1510	VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. 2002 , 196, 220-7	43
1509	Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. 2002 , 197, 677-83	89
1508	Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model. 2002 , 93, 644-51	19
1507	Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. 2002 , 21, 2504-12	143
1506	Analysis of intrapulmonary vessels and epithelial-endothelial interactions in the human developing lung. 2002 , 82, 293-301	48
1505	VEGF and the quest for tumour angiogenesis factors. 2002 , 2, 795-803	1204
1504	Ascites as a predictor of ovarian malignancy. 2002 , 87, 77-83	77
1503	[Tumor angiogenesis--value and significance in squamous epithelial carcinoma of the mouth cavity]. 2002 , 6, 217-30	
1502	Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. 2002 , 73, 237-43	150
1501	Spatial expression of VEGF-A in human glioma. 2002 , 59, 1-6	26
1500	Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. 2002 , 5, 107-10	68
1499	Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. 2002 , 36, 1172-9	29
1498	Smad4 transcriptional pathways and angiogenesis. 2002 , 31, 47-59	35
1497	Drug delivery and transport to solid tumors. 2003 , 20, 1337-50	360
1496	VEGF165 therapy exacerbates secondary damage following spinal cord injury. 2003 , 28, 1693-703	63
1495	An engineered heparin-binding form of VEGF-E (hbVEGF-E). Biological effects in vitro and mobilization of precursor cells. 2003 , 6, 201-11	14
1494	Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. 2003 , 6, 283-7	359

1493	Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. 2003 , 10, 722-33	49
1492	Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. 2003 , 37, 1105-13	136
1491	The diagnostic and prognostic value of tumor angiogenesis. 1998 , 99-103	4
1490	Pseudocowpox virus encodes a homolog of vascular endothelial growth factor. 2003 , 305, 298-309	39
1489	Specific keynote: molecular determinants of angiogenesis in ovarian cancer. 2003 , 88, S29-36; discussion S37-42	3
1488	VEGF expression is developmentally regulated during human brain angiogenesis. 2003 , 119, 227-32	56
1487	Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. 2003 , 10, 120-8	37
1486	Functions of VEGF in female reproductive system. 2003 , 48, 217-222	2
1485	Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. 2003 , 51, 321-7	54
1484	Angiogenesis factors in gliomas: a new key to tumour therapy?. 2003 , 90, 385-94	40
1483	Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis. 2003 , 90, 433-48	15
1482	Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. 2003 , 18, 142-9	36
1481	The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed during the remodeling of free tendon grafts in sheep. 2003 , 123, 168-74	57
1480	Hypoxia and PDGF have a synergistic effect that increases the expression of the angiogenetic peptide vascular endothelial growth factor in Achilles tendon fibroblasts. 2003 , 123, 485-8	34
1479	Localization of vascular endothelial growth factor in the zona pellucida of developing ovarian follicles in the rat: a possible role in destiny of follicles. 2003 , 120, 383-90	41
1478	VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. 2003 , 314, 5-14	118
1477	Role of VEGF-A in vascularization of pancreatic islets. 2003 , 13, 1070-4	320
1476	Liquor-VEGF (Vascular Endothelial Growth Factor):ein neuer Tumormarker der Meningeosis carcinomatosa. 2003 , 27, 329-338	

1475	Vascular endothelial growth factors and angiogenesis in eye disease. 2003 , 22, 1-29	711
1474	Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. 2003 , 34, 969-86	89
1473	Pulmonary vascular endothelial growth factor and nitric oxide interaction during total cardiopulmonary bypass in neonatal pigs. 2003 , 125, 1050-7	13
1472	Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells. 2003 , 74, 276-81	15
1471	High flow drives vascular endothelial cell proliferation during flow-induced arterial remodeling associated with the expression of vascular endothelial growth factor. 2003 , 75, 1-11	59
1470	Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis. 2003 , 107, 30-7	9
1469	Sphingosine 1-phosphate effect on endothelial cell PAF synthesis: role in cellular migration. 2003 , 90, 719-31	18
1468	Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. 2003 , 19, 442-55	194
1467	Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor. 2003 , 60, 181-5	18
1466	Role of adrenocorticotrophic hormone in the development and maintenance of the adrenal cortical vasculature. 2003 , 61, 247-51	24
1465	Vascular endothelial growth factor: a regulator of vascular morphogenesis in the Japanese quail embryo. 2003 , 272, 403-14	10
1464	From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. 2003 , 69, 363-74	48
1463	Growing and shaping the vascular tree: multiple roles for VEGF. 2003 , 25, 1052-60	134
1462	Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. <i>International Journal of Pharmaceutics</i> , 2003 , 267, 1-12	6.5 41
1461	Reversing the angiogenic switch with photodynamic therapy. 2003 , 121, xi-xii	
1460	Gene therapy of lung cancer. 2003 , 21, 196-204	6
1459	Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells. 2003 , 23, 467-75	70
1458	VEGF expression and its regulation by p53 gene transfection in endometrial carcinoma cells. 2003 , 16, 47-54	13

1457	Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. 2003 , 94, 43-9	104
1456	Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. 2003 , 22, 319-29	446
1455	Angiogenesis, lymphangiogenesis, and melanoma metastasis. 2003 , 22, 3172-9	183
1454	Immunology: Oxygen and the inflammatory cell. 2003 , 422, 675-6	68
1453	The biology of VEGF and its receptors. 2003 , 9, 669-76	7480
1452	Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. 2003 , 9, 604-13	607
1451	Caveolae: mining little caves for new cancer targets. 2003 , 3, 571-81	220
1450	Translating angiogenesis research into the clinic: the challenges ahead. 2003 , 76 Spec No 1, S3-10	29
1449	Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. 2003 , 42, 1089-105	227
1448	Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. 2003 , 4, 340-7	60
1447	The immunolocalisation of VEGF in the articular cartilage of sheep mandibular condyles. 2003 , 31, 244-51	17
1446	Enhancement of expression of vascular endothelial growth factor after adeno-associated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil. 2003 , 48, 309-17	42
1445	Vascular endothelial growth factor and the pathogenesis of emphysema. 2003 , 114, 413-4	13
1444	Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. 2003 , 163, 57-68	122
1443	Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. 2003 , 162, 171-81	170
1442	Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. 2003 , 162, 1747-57	182
1441	Lymphangiogenic growth factors, receptors and therapies. 2003 , 90, 167-84	107
1440	Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells. 2003 , 109, 16-23	57

1439	Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. 2003 , 115, 113-20	54
1438	Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells. 2003 , 182, 435-45	51
1437	Tissue factor expression and prognosis in patients with metastatic prostate cancer. 2003 , 62, 1078-82	56
1436	VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. 2003 , 301, 371-7	78
1435	Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. 2003 , 302, 46-55	62
1434	Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. 2003 , 48, 257-93	757
1433	Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication. 2003 , 202, 47-52	22
1432	Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. 2003 , 110, 979-86	286
1431	Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. 2003 , 110, 1690-6	267
1430	In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents. 2003 , 92, 247-51	21
1429	The role of vascular endothelial growth factor in wound healing. 2003 , 2, 107-20	89
1428	Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion. 2003 , 22, 967-78	28
1427	Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. 2003 , 3, 319-28	423
1426	Angiogenesis. 2003 , 1279-1295	1
1425	Molecular pathogenesis of vascular anomalies: classification into three categories based upon clinical and biochemical characteristics. 2003 , 1, 267-81	37
1424	Mechanisms in Carcinogenesis and Cancer Prevention. 2003 ,	
1423	Polymer Drugs in the Clinical Stage. 2003 ,	13
1422	Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. 2003 , 10, 839-51	34

1421	Therapeutic angiogenesis: protein-based therapy for coronary artery disease. 2003 , 4, 219-26	6
1420	Angiogenesis: basic pathophysiology and implications for disease. 2003 , 24, 586-603	106
1419	Expression of vascular endothelial growth factor and the effects on bone remodeling during experimental tooth movement. 2003 , 82, 177-82	64
1418	Stage-dependent expression of an angiogenic agent and vascular organization in experimental skin tumor development. 2003 , 31, 539-48	5
1417	Antiangiogenic therapy: more promise and, yet again, more questions. 2003 , 21, 3897-9	18
1416	Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. 2003 , 107, 1308-14	85
1415	Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. 2003 , 56, 107-13	60
1414	Perlecan and tumor angiogenesis. 2003 , 51, 1393-410	110
1413	Brain Edema XII. 2003 ,	1
1412	TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. 2003 , 163, 1303-11	147
1411	Enhanced recombinant adeno-associated virus-mediated vascular endothelial growth factor expression in the adult mouse retina: a potential model for diabetic retinopathy. 2003 , 52, 857-63	27
1410	Distinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A2A adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cells. 2003 , 278, 15421-8	14
1409	Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens. 2003 , 278, 38004-14	61
1408	Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. 2003 , 3, 95-117	148
1407	Prognostic impact of vascular leakage in acute Kawasaki disease. 2003 , 108, 325-30	77
1406	Lipoteichoic acid up-regulates VEGF expression in macrophages and pulp cells. 2003 , 82, 466-70	52
1405	Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling. 2003 , 278, 20738-45	70
1404	Vascular endothelial growth factor in the human oviduct: localization and regulation of messenger RNA expression in vivo. 2003 , 68, 1870-6	41

1403	p38 MAP kinase--a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. 2003 , 17, 262-4	146
1402	Genetic loci that control vascular endothelial growth factor-induced angiogenesis. 2003 , 17, 2112-4	47
1401	Induction of angiogenesis in omentum with vascular endothelial growth factor: influence on the viability of encapsulated rat pancreatic islets during transplantation. 2003 , 40, 359-67	38
1400	Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. 2003 , 107, 1532-8	103
1399	Liquor-VEGF (Vasular Endothelial Growth Factor): ein neuer Tumormarker der Meningeosis carcinomatosa/VEGF (Vasular Endothelial Growth Factor) in Cerebrospinal Fluid: A New Tumour Marker for Carcinomatous Meningitis. 2003 , 27, 329-338	
1398	VEGF blocking therapy in the treatment of cancer. 2003 , 3, 263-76	128
1397	Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice. 2003 , 89, 215-21	9
1396	Tumor Suppressor Genes. 2003 ,	
1395	Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. 2003 , 7, 450-9	112
1394	VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. 2003 , 161, 1163-77	2122
1393	Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review. 2003 , 5, 27-34	17
1392	Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). 2003 , 278, 51985-8	91
1391	VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. 2003 , 17, 752-4	100
1390	ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. 2003 , 278, 23656-65	189
1389	VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. 2003 , 92, 1098-106	335
1388	Expression of vascular endothelial growth factor in external auditory canal cholesteatoma. 2003 , 11, 555	1
1387	Treatment of central retinal vein occlusion with triamcinolone acetate: an optical coherence tomography study. 2003 , 18, 67-73	57
1386	Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma. 2003 , 64, 416-22	36

1385	Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. 2003 , 88, 5392-8	89
1384	Fundamental concepts of the angiogenic process. 2003 , 3, 643-51	544
1383	Nutritional regulation of white adipocyte vascular endothelial growth factor (VEGF). 2003 , 35, 211-6	7
1382	Influence of VEGF on the viability of encapsulated pancreatic rat islets after transplantation in diabetic mice. 2003 , 12, 627-35	79
1381	Soluble vascular endothelial growth factor receptor 1 inhibits edema and epithelial proliferation induced by 17beta-estradiol in the mouse uterus. 2003 , 144, 326-34	43
1380	Therapeutic strategies using inhibitors of angiogenesis. <i>Methods in Molecular Biology</i> , 2003 , 223, 599-634.4	2
1379	Gene therapy with vascular endothelial growth factor reduces angina. 2003 , 18, 38-43	4
1378	Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. 2003 , 23, 322-9	56
1377	Serum levels of mast cell tryptase, vascular endothelial growth factor and basic fibroblast growth factor in patients with acute pancreatitis. 2003 , 27, e29-33	16
1376	Pleural mesothelial cell (PMC) defense mechanisms against malignancy. 2003 , 14, 155-61	11
1375	Vascular endothelial growth factor expression in pig latissimus dorsi myocutaneous flaps after ischemia reperfusion injury. 2003 , 111, 775-80	21
1374	Angiogenic factors in the central nervous system. 2003 , 53, 639-60; discussion 660-1	78
1373	Three-Dimensional (3D) Imaging of Tumor Angiogenesis and its Inhibition: Evaluation of Tumor Vascular-Targeting Agent Efficacy in the DMBA-induced Rat Breast Cancer Model by Confocal Laser Scanning Microscopy (CLSM). 2003 , 36, 27-36	3
1372	Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. 2003 , 9, 406-16	142
1371	Regulation of hypoxia-inducible factor-1alpha by cyclical mechanical stretch in rat vascular smooth muscle cells. 2003 , 105, 447-56	80
1370	Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats. 2003 , 50, 515-25	14
1369	Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation. 2003 , 89, 169-176	63
1368	Influence of Inflammatory Cytokines on Arteriogenesis. 2003 , 10, 371-379	91

1367	Role of VEGF and CD44v6 in differentiating benign from malignant ascites. 2003 , 9, 2596-600	31
1366	Animal models of oxygen-induced retinopathy. 2003 , 8, d1030-43	71
1365	VEGF164 is proinflammatory in the diabetic retina. 2003 , 44, 2155-62	318
1364	Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders. 2003 , 3, 81-96	1
1363	The relationship between serum VEGF concentration and prognosis of lung cancer. 2003 , 18, 207-11	8
1362	Mechanisms of tumor cell invasion and angiogenesis in the central nervous system. 2003 , 8, e289-304	31
1361	Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. 2003 , 8, d100-16	54
1360	Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. 2003 , 284, L508-17	76
1359	Acute and chronic changes of vascular endothelial growth factor (VEGF) in induced sputum of toluene diisocyanate (TDI)-induced asthma patients. 2004 , 19, 359-63	15
1358	Cardiovascular gene therapy: angiogenesis and beyond. 2004 , 327, 139-48	16
1357	Development and pathology of the hyaloid, choroidal and retinal vasculature. 2004 , 48, 1045-58	281
1356	Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. 2004 , 19, 879-86	62
1355	IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. 2004 , 45, 2838-47	83
1354	Resistance to anti-VEGF agents. 2004 , 10, 51-64	20
1353	The Biology of Brain Metastasis. 35-54	1
1352	Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. 2004 , 10, 463-70	51
1351	Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia. 2004 , 52, 117-64	24
1350	Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. 2004 , 30, 21-30	46

1349	Ocular neovascularisation and excessive vascular permeability. 2004 , 4, 1395-402	60
1348	Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. 2004 , 145, 2896-905	124
1347	VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. 2005 , 128, 52-63	175
1346	Methods in Endothelial Cell Biology. 2004 ,	13
1345	Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. 2004 , 279, 14844-52	169
1344	A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. 2004 , 279, 46304-14	76
1343	Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. 2004 , 11, 749-59	53
1342	The axonal attractant Netrin-1 is an angiogenic factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 16210-5	11.5 254
1341	Expression of vascular endothelial growth factor during healing of the meniscus in a rabbit model. 2004 , 86, 1082-7	43
1340	Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 6605-10	11.5 124
1339	Vasculogenesis and angiogenesis. 2004 , 117, 3-32	268
1338	Urinary excretion of vascular endothelial growth factor is increased in children with reflux nephropathy. 2004 , 98, c73-8	10
1337	The role of vascular endothelial growth factor in the kidney in health and disease. 2004 , 98, p73-9	24
1336	Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. 2004 , 10, 3342-53	138
1335	A study of VEGF and its receptors in two rat models of proteinuria. 2004 , 96, P26-36	15
1334	Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. 2004 , 30, 729-35	44
1333	Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. 2004 , 279, 33213-9	47
1332	Inducible NO synthase inhibits the growth of free tumor cells, but enhances the growth of solid tumors. 2004 , 25, 2101-5	3

1331	The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology. 2004 , 26, 846-53	72
1330	Therapeutic angiogenesis: a biologic bypass. 2004 , 101, 131-43	45
1329	Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. 2004 , 53, 2939-49	90
1328	Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. 2004 , 10, 4109-17	171
1327	Intravitreal injection of triamcinolone: an emerging treatment for diabetic macular edema. 2004 , 27, 1794-7	25
1326	Therapeutic angiogenesis using vascular endothelial growth factor. 2004 , 12, 173-81	8
1325	Cellular Drug Delivery. 2004 ,	5
1324	Src family kinase inhibitor PP1 reduces secondary damage after spinal cord compression in rats. 2004 , 21, 923-31	22
1323	Pathogenesis of high altitude pulmonary edema: does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak?. 2004 , 5, 399-409	28
1322	Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. 2004 , 94, 1443-50	45
1321	Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. 2004 , 22, 2184-91	1682
1320	Effects of specific signal transduction inhibitors on increased permeability across rat endothelial monolayers induced by neuropeptide Y or VEGF. 2004 , 287, H100-6	14
1319	Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. 2004 , 287, C746-53	54
1318	Alpha C protein of group B Streptococcus binds host cell surface glycosaminoglycan and enters cells by an actin-dependent mechanism. 2004 , 279, 24714-23	68
1317	Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 2108-14	9-4 77
1316	Expression pattern of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) system members in bovine corpus luteum endothelial cells during treatment with FGF-2, VEGF or oestradiol. 2004 , 39, 321-7	38
1315	Vascular endothelial growth factor and the nervous system. 2004 , 30, 427-46	86
1314	Abstracts for the Otolaryngological Research Society, April 2002 meeting. 2004 , 29, 389-396	

1313	Vascular endothelial growth factor in nasal polyps: a comparison of asthmatic and non-asthmatic patients. 2004 , 29, 677-81	12
1312	The role of allergic rhinitis in upper respiratory tract inflammatory diseases. 2004 , 4, 15-20	
1311	Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes. 2004 , 66, 1471-8	19
1310	Endogenous angiogenesis inhibitors. 2004 , 112, 496-507	282
1309	Lymphangiogenic growth factors as markers of tumor metastasis. 2004 , 112, 539-49	59
1308	Local rh-VEGF administration enhances skin flap survival more than other types of rh-VEGF administration: a clinical, morphological and immunohistochemical study. 2004 , 13, 682-90	32
1307	Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. 2004 , 13, 671-81	39
1306	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. 2004 , 3, 391-400	1872
1305	Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. 2004 , 84, 397-405	244
1304	Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. 2004 , 94, 187-93	148
1303	SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. 2004 , 97, 219-30	155
1302	Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. 2004 , 14, 123-30	83
1301	Intravascular embolization therapy in a patient with an enlarged polycystic liver. 2004 , 43, 733-8	31
1300	Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. 2004 , 40, 13-20	94
1299	Malignant ascites: past, present, and future. 2004 , 198, 999-1011	159
1298	Variations in transfection efficiency of VEGF165 and VEGF121-cDNA: its effects on proliferation and migration of human endothelial cells. 2004 , 26, 7-16	4
1297	Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) expression during induced luteolysis in the bovine corpus luteum. 2004 , 67, 389-95	39
1296	Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. 2004 , 21, 31-7	75

1295	Myocardial angiogenesis. 2004 , 264, 35-44	30
1294	Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. 2004 , 264, 51-61	23
1293	Functional significance of vascular endothelial growth factor receptor expression on human glioma cells. 2004 , 67, 9-18	39
1292	Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. 2004 , 130, 52-6	71
1291	Angiogenesis and organ transplantation. 2004 , 49, 499-505	9
1290	A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth. 2004 , 54, 16-24	11
1289	Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression. 2004 , 122, 369-80	10
1288	VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. 2004 , 26, 943-54	423
1287	Microvascular development: learning from pancreatic islets. 2004 , 26, 1069-75	97
1286	NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. 2004 , 108, 181-8	101
1285	Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus. 2004 , 109, 483-90	20
1284	Angiogenesis and prostate cancer tumor growth. 2004 , 91, 125-50	103
1283	Angiogenesis in hepatocellular nodules: correlation of MR imaging and vascular endothelial growth factor. 2004 , 20, 426-34	15
1282	Quantitative assessment of uptake and distribution of iron oxide particles (NC100150) in human melanoma xenografts by contrast-enhanced MRI. 2004 , 51, 727-35	22
1281	Polymeric prodrugs. <i>International Journal of Pharmaceutics</i> , 2004 , 277, 119-31	6.5 154
1280	Cyclic strain influences the expression of the vascular endothelial growth factor (VEGF) and the hypoxia inducible factor 1 alpha (HIF-1alpha) in tendon fibroblasts. 2004 , 22, 847-53	84
1279	The angiogenic status of B-CLL B cells: role of the VEGF receptors. 2004 , 28, 221-2	16
1278	Role of angiogenic growth factors in transplant coronary artery disease. 2004 , 36, 184-93	11

1277	Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. 2004 , 12, 585-91	136
1276	Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. 2004 , 287, H1554-60	66
1275	Vascular endothelial growth factor as a target for anticancer therapy. 2004 , 9 Suppl 1, 2-10	462
1274	Autologous skeletal myoblasts transduced with a new adenoviral bicistronic vector for treatment of hind limb ischemia. 2004 , 40, 774-85	28
1273	Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. 2004 , 64, 2030-8	210
1272	The vascular endothelial growth factor family and its receptors. 2004 , 18, 951-71, vii	45
1271	Expression and function of the angiopoietin receptor Tie-2 in human eosinophils. 2004 , 114, 1077-84	40
1270	Vascular endothelial growth factor: basic science and clinical progress. 2004 , 25, 581-611	2749
1269	VEGF increases paracellular transport without altering the solvent-drag reflection coefficient. 2004 , 68, 295-302	17
1268	Preclinical data targeting vascular endothelial growth factor in colorectal cancer. 2004 , 4 Suppl 2, S55-61	10
1267	Vascular endothelial growth factor antagonists as anticancer agents. 2004 , 3, 229-245	
1266	Ovarian Angiogenesis. 2004 , 305-317	5
1265	Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer. 2004 , 625-645	
1264	Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. 2003 , 519, 29-49	166
1263	Constitutive and inducible expression and regulation of vascular endothelial growth factor. 2004 , 15, 297-324	136
1262	Vascular endothelial growth factor in diabetes induced early retinal abnormalities. 2004 , 65, 197-208	30
1261	Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. 2004 , 7, 289-300	72
1260	Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. 2004 , 317, 24-9	34

1259	Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. 2004 , 325, 144-50	51
1258	Activation and translocation of PKCdelta is necessary for VEGF-induced ERK activation through KDR in HEK293T cells. 2004 , 325, 843-51	23
1257	Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression. 2004 , 164, 1293-302	39
1256	Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. 2004 , 165, 1071-85	104
1255	Angiogenic synergy of bFGF and VEGF is antagonized by Angiopoietin-2 in a modified in vivo Matrigel assay. 2004 , 68, 161-8	50
1254	Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 [Flt-1] and VEGF-R2 [KDR/Flk-1]) in tumorlets and in neuroendocrine cell hyperplasia of the lung. 2004 , 35, 1210-7	27
1253	Neuroblastoma survival and death: an in vitro model of hypoxia and metabolic stress. 2004 , 116, 288-96	10
1252	Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma. 2004 , 41, 333-5	7
1251	Clinical implications of growth factors in flexor tendon wound healing. 2004 , 29, 551-63	122
1250	Effect of age on ovarian stromal flow measured by three-dimensional ultrasound with power Doppler in Chinese women with proven fertility. 2004 , 19, 2132-7	52
1249	In vivo regulation of mRNA expression of vascular endothelial growth factor receptors (KDR and flt-1) in the human oviduct. 2004 , 81, 416-23	19
1248	Circulating angiogenic factors during periovulation and the luteal phase of normal menstrual cycles. 2004 , 81, 1322-7	24
1247	Increased messenger RNA expression of vascular endothelial growth factor and its receptors in the implantation site of the human oviduct with ectopic gestation. 2004 , 82, 686-90	35
1246	Immunohistochemical identification of vascular endothelial growth factor in pig latissimus dorsi musculocutaneous flaps following ischemia-reperfusion injury. 2004 , 53, 398-403	8
1245	The management of brain edema in brain tumors. 2004 , 16, 593-600	193
1244	Role of Hypoxia/Ischemia/VEGF-A, and Strain Differences. 2004 , 115-129	2
1243	Elevated levels of angiostatin in effusions from patients with malignant disease. 2004 , 11, 523	
1242	Expression of VEGFR-1 and VEGFR-2 in degenerative Achilles tendons. 2004 , 286-91	28

1241	Retinal features predictive of progressive stage 4 retinopathy of prematurity. 2004 , 24, 237-41	27
1240	Surgical and other treatments of diabetic macular edema: an update. 2004 , 44, 139-60	24
1239	Innovative treatments for exudative age-related macular degeneration. 2004 , 44, 41-50	6
1238	Peliosis of the spleen with massive recurrent haemorrhagic ascites, despite splenectomy, and associated with elevated levels of vascular endothelial growth factor. 2004 , 16, 1401-6	14
1237	Diabetic macular edema: a review of past, present, and future therapies. 2004 , 44, 51-67	18
1236	Notch4-induced inhibition of endothelial sprouting requires the ankyrin repeats and involves signaling through RBP-Jkappa. 2004 , 104, 1760-8	40
1235	VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. 2004 , 103, 3789-97	46
1234	Gene therapy for cardiovascular diseases. 2004 , 10, 407-23	27
1233	An Introduction to Dynamic Contrast-Enhanced MRI in Oncology. 2005 , 1-22	6
1232	HVEGF165 increases survival of transplanted hepatocytes within portal radicles: suggested mechanism for early cell engraftment. 2005 , 14, 49-57	16
1231	Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. 2005 , 24, 508-12	108
1230	Anterior Cruciate Ligament (ACL) Healing. 2005 , 13, 156-160	4
1229	Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. 2005 , 115, 653-63	179
1228	Dynamic Magnetic Resonance Imaging in Breast Cancer. 2005 , 145-173	2
1227	Errors of measurement for blood volume parameters: a meta-analysis. 2005 , 99, 1745-58	108
1226	The role of vascular endothelial growth factor in ocular health and disease. 2005 , 25, 111-8	280
1225	Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. 2005 , 105, 1508-14	106
1224	The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. 2005 , 105, 1383-95	277

1223 Erratum for vol. 104, p. 2368. **2005**, 105, 1395-1395

1222 Quantitative analysis of the low molecular weight serum proteome using 18O stable isotope labeling in a lung tumor xenograft mouse model. **2005**, 16, 1221-30 55

1221 Evolving molecular-based targeted therapy for cancer: an exciting field. **2005**, 31, 299-305

1220 Genetic variations in vascular endothelial growth factor and endothelial nitric oxide synthase and their contributions to human disease. **2005**, 12, 129-140 13

1219 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. **2005**, 23, 1011-27 2248

1218 Angiogenesis: update 2005. **2005**, 3, 1835-42 235

1217 Effect of female sex hormones on Campylobacter rectus and human gingival fibroblasts. **2005**, 20, 239-43 32

1216 Vascular endothelial growth factor and its soluble receptor, Flt-1, are not correlated to erythropoietin in diabetics with normal or reduced renal function. **2005**, 10, 84-9 3

1215 The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study. **2005**, 46, 209-16 19

1214 The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. **2005**, 128, 303-9 143

1213 ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. **2005**, 92 Suppl 1, S6-13 133

1212 HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. **2005**, 24, 3110-20 323

1211 Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. **2005**, 24, 7850-8 44

1210 Inhibition of vascular endothelial growth factor by macrolides in cultured fibroblasts from nasal polyps. **2005**, 115, 1953-6 19

1209 VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. **2005**, 85, 608-23 60

1208 Common mechanisms of nerve and blood vessel wiring. **2005**, 436, 193-200 813

1207 Pathophysiological consequences of VEGF-induced vascular permeability. **2005**, 437, 497-504 655

1206 The role of vasculature and angiogenesis for the pathogenesis of degenerative tendons disease. **2005**, 15, 211-22 166

1205	Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. 2005 , 7, 251-61	143
1204	Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). 2005 , 9, 777-94	528
1203	Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. 2005 , 7 Suppl 1, S31-8	20
1202	Targeting multiple signal transduction pathways in lung cancer. 2005 , 7 Suppl 1, S39-44	18
1201	Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. 2005 , 78, 123-30	73
1200	LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). 2005 , 97, 870-8	72
1199	Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). 2005 , 114, 224-9	42
1198	Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: the role of stroma cells in tumor angiogenesis. 2005 , 117, 202-11	40
1197	Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. 2005 , 104, 427-38	173
1196	Malignant ascites. 1996 , 83, 6-14	122
1195	Edema is a precursor to central nervous system peritumoral cyst formation. 2005 , 58, 392-9	88
1194	Molecular mechanisms of hepatic metastasis in colorectal cancer. 2005 , 92, 347-59	59
1193	Vascular endothelial growth factor as a biomarker for the early detection of cancer using a whole cell-based biosensor. 2005 , 382, 1010-6	18
1192	[Overload damage to the Achilles tendon: the importance of vascularization and angiogenesis]. 2005 , 34, 533-42	19
1191	Elevated levels of plasma VEGF in patients with dengue hemorrhagic fever. 2005 , 43, 99-102	77
1190	VEGF significance in peritoneal recurrence from gastric cancer. 2005 , 8, 155-63	40
1189	Hypoxia correlates with angiogenesis in cervical cancers. 2005 , 10, 35-9	7
1188	Essential role of PI-3K, ERKs and calcium signal pathways in nickel-induced VEGF expression. 2005 , 279, 35-43	21

1187	Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. 2004 , 21, 685-97	108
1186	References. 2005 , 85, 319-344	
1185	. 2005 ,	6
1184	Gene therapy in plastic and reconstructive surgery. 2005 , 5, 81-99	10
1183	The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. 2005 , 10, 2131-49	57
1182	The induction of vascular endothelial growth factor by ultrafine carbon black contributes to the increase of alveolar-capillary permeability. 2005 , 113, 454-60	17
1181	Immunohistochemical Evaluation of VEGF Inflamed Cystic Radicular Lesions and in Keratocysts. 2005 , 3, 117-125	
1180	Disorders of the Eye. 2005 , 1539-1555	1
1179	Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. 2005 , 37, 188-90	38
1178	Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease. 2005 , 288, H2042-6	37
1177	Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. 2005 , 1, 183-96	13
1176	rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. 2005 , 289, L315-21	22
1175	Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. 2005 , 3, 267-83	50
1174	Ocular Neovascularization: Genomic Implications. 2005 , 6, 315-318	
1173	Autocrine Motility Factor Possesses a Possibility of Developing a New Target for Anti-Cancer Treatment. 2005 , 1, 187-197	1
1172	Effects of cyclic tensile forces on the expression of vascular endothelial growth factor (VEGF) and macrophage-colony-stimulating factor (M-CSF) in murine osteoblastic MC3T3-E1 cells. 2005 , 84, 422-7	36
1171	Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. 2005 , 65, 9261-8	154
1170	Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. 2005 , 114, 289-95	48

1169	Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. 2005 , 96, 1257-65	102
1168	The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. 2005 , 109, 227-41	628
1167	Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice. 2005 , 31, 307-13	13
1166	Vascular endothelial growth factor-A induces prenatal neovascularization and alters bronchial development in mice. 2005 , 57, 82-8	39
1165	Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. 2005 , 6, 511-24	189
1164	Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver and correlation with MRI findings. 2005 , 184, 832-41	19
1163	Response of a nonmalignant pleural effusion to bevacizumab. 2005 , 353, 740-1	29
1162	[Angiogenesis VEGF165 gene therapy with AdVEGF- a new delay procedure for flaps]. 2005 , 37, 365-74	7
1161	Antiangiogenic agents: studies on fumagillin and curcumin analogs. 2005 , 11, 357-73	35
1160	Angiogenesis in benign and malignant thyroid disease. 2005 , 15, 494-510	20
1159	Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. 2005 , 12, 659-68	105
1158	RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. 2005 , 64, 1653-5	79
1157	Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. 2005 , 12, 716-24	31
1156	Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate. 2005 , 19, 1-10	31
1155	Comparison of ovarian stromal blood flow between fertile women with normal ovaries and infertile women with polycystic ovary syndrome. 2005 , 20, 1881-6	44
1154	Angiopoietin-1 opposes VEGF-induced increase in endothelial permeability by inhibiting TRPC1-dependent Ca ²⁺ influx. 2005 , 96, 1282-90	148
1153	Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. 2005 , 11, 8789-98	40
1152	Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. 2005 , 65, 5063-9	91

1151	Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. 2005 , 280, 28848-51	116
1150	Vascular endothelial growth factor in thyroid cancers. 2005 , 20, 648-61	29
1149	Integration/Interaction of Oncologic Growth. 2005 ,	3
1148	A reassessment of vascular endothelial growth factor in central nervous system pathology. 2005 , 103, 853-68	39
1147	Margatoxin inhibits VEGF-induced hyperpolarization, proliferation and nitric oxide production of human endothelial cells. 2005 , 42, 368-76	34
1146	VEGF as a target of therapy in gastrointestinal oncology. 2005 , 22, 282-93	5
1145	Vascular endothelial growth factor in pleural effusions of different origin. 2005 , 25, 600-4	75
1144	Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. 2005 , 19, 1692-4	66
1143	Neuropilin-1 and VEGF correlate with somatostatin expression and microvessel density in ovarian tumours. 2005 , 27, 1283	
1142	Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. 2005 , 26, 977	2
1141	Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction. 2005 , 36, 1259-63	92
1140	Vascular Endothelial Growth Factor Signaling. 2005 , 91-104	4
1139	The EPR Effect and Polymeric Drugs: A Paradigm Shift for Cancer Chemotherapy in the 21st Century. 2005 , 103-121	115
1138	Vascular endothelial growth factor plays more than an angiogenic role in the female reproductive system. 2005 , 84, 1775-8	22
1137	Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. 2005 , 40, 352-68	190
1136	Mechanisms of Angiogenesis. 2005 ,	5
1135	VEGF and VEGF receptor expression after experimental brain contusion in rat. 2005 , 22, 353-67	111
1134	Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?. 2005 , 37, 365-72	32

1133	Angiogenesis and lung cancer: prognostic and therapeutic implications. 2005 , 23, 3243-56	207
1132	Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling. 2005 , 44, 15064-73	26
1131	Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. 2005 , 16, 230-6	85
1130	Angiogenesis: a curse or cure?. 2005 , 81, 236-42	58
1129	Cancer proteomics: many technologies, one goal. 2005 , 2, 693-703	28
1128	Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study. 2005 , 36, 797-805	23
1127	Study for anti-angiogenic activities of polysaccharides isolated from <i>Antrodia cinnamomea</i> in endothelial cells. 2005 , 76, 3029-42	55
1126	Glyceraldehyde-derived advanced glycation end-products preferentially induce VEGF expression and reduce GDNF expression in human astrocytes. 2005 , 330, 361-6	16
1125	Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. 2005 , 333, 328-35	723
1124	Angiogenesis inhibitors: from laboratory to clinical application. 2005 , 333, 289-91	17
1123	[Angiogenesis and breast neoplasms. The pathologist's point of view]. 2005 , 33, 140-6	4
1122	Effects of antiglaucoma drugs timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist, on endotoxin-induced-uveitis in rats. 2005 , 80, 847-52	3
1121	Specific distribution of VEGF-F in Viperinae snake venoms: isolation and characterization of a VGEF-F from the venom of <i>Daboia russelli siamensis</i> . 2005 , 439, 241-7	20
1120	Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. 2005 , 140, 256-61	243
1119	TNF-alpha and endotoxin increase hypoxia-induced VEGF production by cultured human nasal fibroblasts in synergistic fashion. 2005 , 32, 243-9	27
1118	The role of VEGF in the regulation of physiological and pathological angiogenesis. 2005 , 209-31	145
1117	Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. 2005 , 14, 207-21	209
1116	Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application. 2005 , 129, 2076-91	32

1115	The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. 2005 , 6, 209		362
1114	VASCULAR ENDOTHELIAL GROWTH FACTOR. 2006 , 413-418		0
1113	Applications in the Clinic: The Anti-VEGF Aptamer. 2006 , 443-460		1
1112	Intravenous administration of vascular endothelial growth factor improves cardiac performance and inhibits cardiomyocyte apoptosis. <i>Growth Factors</i> , 2006 , 24, 209-17	1.6	9
1111	Recent developments in colorectal cancer treatment by monoclonal antibodies. 2006 , 6, 1175-92		15
1110	Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). 2006 , 47, 223-30		33
1109	Screw vs cement-implant-retained restorations: an experimental study in the beagle. Part 2. Immunohistochemical evaluation of the peri-implant tissues. 2006 , 32, 1-7		14
1108	Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response. 2006 , 8, 41-5		9
1107	The safety of bevacizumab. 2006 , 5, 289-301		28
1106	Promising new treatments for neovascular age-related macular degeneration. 2006 , 15, 779-93		51
1105	Gene therapy for the treatment of sensory neuropathy. 2006 , 6, 499-507		15
1104	Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. 2006 , 11, 753-64		221
1103	Discovery of vascular permeability factor (VPF). <i>Experimental Cell Research</i> , 2006 , 312, 522-6	4.2	122
1102	Future innovations in treating advanced prostate cancer. 2006 , 33, 247-72, viii		3
1101	Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?. 2006 , 7, 82		36
1100	Disaggregation and invasion of ovarian carcinoma ascites spheroids. 2006 , 4, 6		108
1099	Growth factors and the epididymis. 2006 , 27, 348-57		16
1098	Anti-VEGF Therapies for Diseases of the Retina and Choroid. 2006 , 309-339		

1097	Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. 2006 , 51, 143-58	277
1096	Targeting angiogenesis with integrative cancer therapies. 2006 , 5, 9-29	80
1095	Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). 2006 , 31, 171-80	43
1094	Vascular endothelial growth factor in the lung. 2006 , 290, L209-21	303
1093	Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. 2006 , 4, 61-70	282
1092	Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. 2006 , 142, 660-8	116
1091	Vascular endothelial growth factor modulates contractile response in microvascular lung pericytes. 2006 , 191, 349-52	15
1090	Biology of vascular endothelial growth factors. 2006 , 580, 2879-87	355
1089	Human lactoferrin upregulates expression of KDR/Flk-1 and stimulates VEGF-A-mediated endothelial cell proliferation and migration. 2006 , 580, 4332-6	30
1088	Hypoxia regulates vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 secretion by human oviductal epithelial cells and stromal fibroblasts. 2006 , 85 Suppl 1, 1097-102	18
1087	Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. 2006 , 35, 21-8	90
1086	Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. 2006 , 17, 339-48	45
1085	Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. <i>Science</i> , 2006 , 312, 1171-5	333 403
1084	Hyperbaric oxygen induces vascular endothelial growth factor and reduces liver injury in regenerating rat liver after partial hepatectomy. 2006 , 45, 28-34	36
1083	Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. 2006 , 134, 223-30	29
1082	Muscle-targeted deletion of VEGF and exercise capacity in mice. 2006 , 151, 159-66	28
1081	A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. 2006 , 113, 1706-12	250
1080	Current status of anti-angiogenesis therapy for prostate cancer. 2006 , 24, 260-8	16

1079	Influence of treatment parameters on selectivity of verteporfin therapy. 2006 , 47, 371-6	94
1078	Effect of Thyroxine and Propylthiouracil in Ehrlich Ascitic Tumor Cells. 2006 , 24, 665	2
1077	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006 , 69, 756-65	1
1076	The Role of Microvasculature in Metastasis Formation. 2006 , 31-62	5
1075	Insulin-like Growth Factor-I and Its Binding Proteins: Regulation of Secretion and Mechanism of Action at the Receptor Level. 2006 , 51-65	
1074	. 2006 ,	106
1073	Vascular Development and Angiogenesis. 2006 ,	
1072	Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. 2006 , 47, 2701-8	32
1071	Bloodlines. 2006 , 6, S10-S11	
1070	Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature. 2006 , 210, 269-77	25
1069	Enhanced Permeability and Retention (EPR) Effect and Tumor-Selective Delivery of Anticancer Drugs. 2006 , 37-52	7
1068	The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxx _b , are down-regulated in pre-eclamptic placentae at term. 2006 , 110, 575-85	57
1067	Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. 2006 , 111, 171-83	111
1066	The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. 2006 , 107, 3564-71	147
1065	Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis. 2006 , 29, 357	4
1064	Vascular Endothelial Growth Factor (VEGF) Pathway. 2006 , 1, 768-770	26
1063	Vitreous fluid biomarkers. 2006 , 42, 111-66	9
1062	Vascular Endothelial Growth Factor (VEGF) Pathway. 2006 , 1, 768-770	26

1061	'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. 2006 , 65, 529-39	369
1060	Vascular Endothelial Growth Factor Expression (VEGF) in Salivary Glands of Young and Old Hyperoxic Rats. 2006 , 4, 83-96	1
1059	Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. 2006 , 243, 334-40	86
1058	Ultrastructure of perinidal capillaries in cerebral arteriovenous malformations. 2006 , 58, 961-70; discussion 961-70	44
1057	Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. 2006 , 26, 999-1005	380
1056	Plasma obtained during human endotoxemia increases endothelial albumin permeability in vitro. 2006 , 25, 358-62	16
1055	Targeting vascular endothelial growth factor pathway offers new possibilities to counteract microvascular disturbances during ischemia/reperfusion of the pancreas. 2006 , 82, 543-9	19
1054	Mechanism of Inflammation: Activation of the Endothelium. 2006 , 300-335	
1053	VEGF receptors on PC12 cells mediate transient activation of ERK1/2 and Akt: comparison of nerve growth factor and vascular endothelial growth factor. 2006 , 5, 8	3
1052	Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration. 2006 , 23, 21-34	53
1051	Hypoxic damage to the periventricular white matter in neonatal brain: role of vascular endothelial growth factor, nitric oxide and excitotoxicity. 2006 , 98, 1200-16	95
1050	Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. 2006 , 4, 2461-9	74
1049	Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in ischaemic colitis and ulcerative colitis. 2006 , 2, 182-188	3
1048	New therapeutic option for autosomal dominant polycystic kidney disease patients with enlarged kidney and liver. 2006 , 10, 333-41	27
1047	Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. 2006 , 97, 183-91	38
1046	VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. 2006 , 8, 1223-34	768
1045	Tumor metastasis: mechanistic insights and clinical challenges. 2006 , 12, 895-904	1588
1044	Fibroblasts in cancer. 2006 , 6, 392-401	3396

1043	Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. 2006 , 5, 123-32	1018
1042	VEGF receptor signalling - in control of vascular function. 2006 , 7, 359-71	2342
1041	Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. 2006 , 13, 940-7	8
1040	Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. 2006 , 20, 71-9	34
1039	Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. 2006 , 20, 546-52	81
1038	Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlations. 2006 , 20, 674-80	28
1037	New insights into the molecular control of the lymphatic vascular system and its role in disease. 2006 , 126, 2167-77	182
1036	Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. 2006 , 25, 4300-9	180
1035	Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli. 2006 , 570, 141-56	23
1034	The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo. 2006 , 572, 243-57	39
1033	Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. 2006 , 1082, 151-71	109
1032	Pro-angiogenic cytokines and their role in tumor angiogenesis. 2006 , 25, 373-85	71
1031	Colorectal cancer: genetics of development and metastasis. 2006 , 41, 185-92	165
1030	Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events. 2005 , 8, 315-26	39
1029	Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. 2006 , 244, 309-15	209
1028	Gene expression of vascular endothelial growth factor-A in the pituitary during formation of the vascular system in the hypothalamic-pituitary axis of the rat. 2006 , 324, 87-95	18
1027	Expression of vascular endothelial growth factor and angiogenesis in patellar tendon grafts in the early phase after anterior cruciate ligament reconstruction. 2006 , 14, 804-10	45
1026	The role of VEGF receptors in angiogenesis; complex partnerships. 2006 , 63, 601-15	273

1025	Nano-oncology: drug delivery, imaging, and sensing. 2006 , 384, 620-30	363
1024	Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. 2006 , 39, 267-76	72
1023	Inhibitors of angiogenesis. 2006 , 8, 475-81	2
1022	Relationship between PTEN and VEGF expression and clinicopathological characteristics in HCC. 2006 , 26, 682-5	5
1021	Adhesive resin and the hydrophilic monomer HEMA induce VEGF expression on dental pulp cells and macrophages. 2006 , 22, 434-40	39
1020	Exploiting the enhanced permeability and retention effect for tumor targeting. 2006 , 11, 812-8	1422
1019	Hyperbaric oxygen therapy ameliorates the blood-retinal barrier breakdown in diabetic retinopathy. 2006 , 34, 584-9	22
1018	Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. 2006 , 93, 1456-63	41
1017	Experimental hypoxia and embryonic angiogenesis. 2006 , 235, 723-33	63
1016	Hypoxia-induced astrocytic reaction and increased vascular permeability in the rat cerebellum. 2006 , 54, 826-39	140
1015	Environmental enrichment and voluntary exercise massively increase neurogenesis in the adult hippocampus via dissociable pathways. 2006 , 16, 250-60	431
1014	Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. 2006 , 119, 2795-802	56
1013	Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. 2006 , 34, 391-405	35
1012	Proteomic analysis of hemangioblastoma cyst fluid. 2006 , 5, 549-53	25
1011	Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. 2006 , 147, 5400-11	126
1010	Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. 2006 , 173, 1201-7	115
1009	Diverse effects of vascular endothelial growth factor on human pulmonary endothelial barrier and migration. 2006 , 291, L718-24	24
1008	VEGF inhibitors in cancer therapy. 2006 , 12, 387-94	94

1007	Angiogenesis as a therapeutic target in arthritis: lessons from oncology. 2006 , 12, 2631-44	28
1006	Polymeric Systems for Bioinspired Delivery of Angiogenic Molecules. 191-221	20
1005	Vascular endothelial growth factor biology: clinical implications for ocular treatments. 2006 , 90, 1542-7	117
1004	Neovascularization in human atherosclerosis. 2006 , 113, 2245-52	374
1003	Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. 2006 , 34, 131-47	57
1002	Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. 2006 , 12, 791-9	68
1001	Bevacizumab is active in malignant effusion. 2006 , 17, 1853	31
1000	Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. 2006 , 17, 3093-104	163
999	Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. 2006 , 66, 1434-45	85
998	Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?. 2006 , 61, 621-6	106
997	Proteinuria with and without renal glomerular podocyte effacement. 2006 , 17, 2383-9	62
996	Insulin-like growth factor-I regulates vascular endothelial growth factor secretion by human oviductal epithelial cells and stromal fibroblasts. 2006 , 13, 368-71	7
995	Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. 2006 , 12, 1928-35	77
994	Obesity and Diabetes. 2006 ,	4
993	Ocular Angiogenesis. 2006 ,	3
992	Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. 2006 , 26, 859-70	648
991	VEGF activates receptor-operated cation channels in human microvascular endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 1768-76	9-4 97
990	Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 2800-4	11.5 131

989	Is the Vasculature a Potential Therapeutic Target in Arthritis?. 2006 , 2, 151-158	1
988	Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. 2006 , 203, 1447-58	219
987	Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. 2006 , 223-68	49
986	RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. 2006 , 12, 6386-94	66
985	Interleukin-1beta regulates vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 secretion by human oviductal epithelial cells and stromal fibroblasts. 2006 , 22, 495-500	9
984	Vascular endothelial growth factor signaling to endothelial nitric oxide synthase: more than a FleeTing moment. 2006 , 99, 666-8	30
983	Requirement of protein kinase D tyrosine phosphorylation for VEGF-A165-induced angiogenesis through its interaction and regulation of phospholipase Cgamma phosphorylation. 2006 , 281, 32550-8	49
982	Anti-VEGF therapy: a new approach to colorectal cancer therapy. 2006 , 6, 1385-96	13
981	Ranibizumab: treatment in patients with neovascular age-related macular degeneration. 2006 , 6, 1237-45	27
980	Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. 2006 , 177, 7322-31	92
979	In vivo imaging shows abnormal function of vascular endothelial growth factor-induced vasculature. 2007 , 18, 515-24	59
978	Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression. 2007 , 72, 440-9	120
977	Taming glioblastoma: targeting angiogenesis. 2007 , 25, 4705-6	35
976	Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. 2007 , 56, 2161-8	78
975	VEGF inhibition: latest developments. 2007 , 2, 621-632	
974	The contribution of Harold F. Dvorak to the study of tumor angiogenesis and stroma generation mechanisms. 2007 , 14, 131-5	9
973	Expression of VEGF(XXX)b, the inhibitory isoforms of VEGF, in malignant melanoma. 2007 , 97, 223-30	112
972	Targeted therapies for non-small cell lung cancer. 2007 , 13, 2810-31	13

971	Structural Factors Influencing Potency of Currently Used Acetylcholinesterase Reactivators for Treatment of Cyclosarin Intoxications. 2007 , 13, 3445-3452	10
970	Intramyocardial injection of vascular endothelial growth factor gene improves cardiac performance and inhibits cardiomyocyte apoptosis. 2007 , 9, 343-51	32
969	Molecular design and clinical development of VEGFR kinase inhibitors. 2007 , 7, 1379-93	50
968	Angiogenesefaktoren in der Schwangerschaft: Indikatoren für die Präeklampsie. 2007 , 67, 228-235	2
967	Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule. 2007 , 148, 4734-44	30
966	Editorial: Preventing ovarian hyperstimulation syndrome. 2007 , 92, 2882-4	6
965	Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 2007 , 7, 449-60	86
964	Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. 2007 , 39, 122-148	51
963	Anti-VEGF agents in the treatment of neovascular AMD. 2007 , 2, 459-465	
962	Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. 2007 , 56, 1333-40	65
961	Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. 2007 , 25, 3045-54	280
960	Review: side effects of approved molecular targeted therapies in solid cancers. 2007 , 12, 1443-55	250
959	Mechanisms of tumor-related brain edema. 2007 , 22, E8	74
958	Bovine papular stomatitis virus encodes a functionally distinct VEGF that binds both VEGFR-1 and VEGFR-2. 2007 , 88, 781-791	23
957	Grading of Diabetic Retinopathy. 2007 , 291-391	1
956	Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. 2007 , 13, 3942-50	345
955	Angiogenic growth factors in the treatment of peripheral arterial disease. 2007 , 5, 195-209	18
954	The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. 2007 , 13, 5918-25	60

953	Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. 2007 , 25, 2894-901	65
952	Role of vascular endothelial growth factor A in children with acquired airway stenosis. 2007 , 116, 430-5	5
951	Functional VEGF and VEGF receptors are expressed in human medulloblastomas. 2007 , 9, 384-92	41
950	Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. 2007 , 13, 4209-17	73
949	Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. 2007 , 13, 5544s-5548s	64
948	Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. 2007 , 6, 1962-72	109
947	Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 14448-53	11.5 116
946	Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women. 2007 , 31, 531	
945	A case of subclinical hypothyroidism developing marked pleural effusions and peripheral edema with elevated vascular endothelial growth factor. 2007 , 54, 577-84	12
944	Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. 2007 , 110, 2457-65	86
943	Antiangiogenic therapy in neovascular age-related macular degeneration. 2007 , 47, 117-37	10
942	A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. 2007 , 15, 382-8	5
941	Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. 2007 , 27, 419-25	212
940	Role of edema in peritumoral cyst formation. 2007 , 22, E9	17
939	Protective effects of vascular endothelial growth factor on intestinal epithelial apoptosis and bacterial translocation in experimental severe acute pancreatitis. 2007 , 34, 410-6	16
938	Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. 2007 , 8, 257-68	42
937	The role of apoptosis in respiratory diseases. 2007 , 21, 22-8; quiz 29-30	6
936	Parapoxvirus of red deer in New Zealand encodes a variant of viral vascular endothelial growth factor. 2007 , 124, 50-8	18

935	Regulation of angiogenesis: wound healing as a model. 2007 , 42, 115-70	231
934	Vasculogenesis and angiogenesis in the early human placenta. 2007 , 109, 257-65	168
933	Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. 2007 , 144, 627-37	179
932	Interleukin-13 stimulates the secretion of vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 by human oviductal epithelial cells. 2007 , 133, 208-12	4
931	N-acetylchitooligosaccharide is a potent angiogenic inhibitor both in vivo and in vitro. 2007 , 357, 26-31	73
930	Vascular endothelial growth factor family of ligands and receptors: review. 2007 , 38, 258-68	250
929	Tumor necrosis factor-alpha regulates vascular endothelial growth factor secretion by human oviductal epithelial cells and stromal fibroblasts. 2007 , 87, 220-2	3
928	Autocrine VEGF signaling is required for vascular homeostasis. 2007 , 130, 691-703	812
927	Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. 2007 , 33, 230-83	39
926	Vascular endothelial growth factor: biology and therapeutic applications. 2007 , 39, 1349-57	129
925	Co-expression of cyclooxygenase-2 and vascular endothelial growth factor in inflamed human pulp: an immunohistochemical study. 2007 , 33, 18-20	32
924	Relationships between caries bacteria, host responses, and clinical signs and symptoms of pulpitis. 2007 , 33, 213-9	99
923	Innate immune responses of the dental pulp to caries. 2007 , 33, 643-51	133
922	Vascular endothelial growth factor and its relationship with the dental pulp. 2007 , 33, 524-30	60
921	VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. 2007 , 13, 223-30	111
920	Roles for VEGF in the adult. 2007 , 74, 100-13	142
919	Vascular endothelial growth factor concentrations in the serum and peritoneal fluid of women with endometriosis. 2007 , 99, 33-7	54
918	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. 2007 , 7, 551-66	11

917	VEGF-A and the induction of pathological angiogenesis. 2007 , 2, 251-75	284
916	Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. 2007 , 15, 457-64	492
915	Polymeric micelles for drug targeting. 2007 , 15, 553-84	149
914	Expression of vascular endothelial growth factor in Taiwanese benign and malignant prostate tissues. 2007 , 70, 380-4	7
913	Functional vascular endothelial growth factor -634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. 2007 , 30, 275-9	36
912	Cancer Biology. 2007 , 1-31	1
911	Angiogenesis and Cancer. 2007 , 35-61	2
910	Angiogenesis. 2007 , 1-6	
909	Theories of Carcinogenesis. 2007 , 7-28	
908	Angiogenesis. 2007 , 369-388	
907	A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis. 2007 , 17, 1351-1363	3
906	Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. 2007 , 55, 821-30	29
905	Protective role of vascular endothelial growth factor in endotoxin-induced acute lung injury in mice. 2007 , 8, 60	25
904	Therapeutic angiogenesis in cardiovascular disease. 2007 , 2, 49	40
903	Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis. 2007 , 6, 442-6	25
902	Intravenous infusion of dihydrogeninoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-XL. 2007 , 24, 1037-54	36
901	Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. 2007 , 11, 1207-17	55
900	Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. 2007 , 49, 1015-26	354

899 Gene Delivery into Cells and Tissues. **2007**, 493-515

898 Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. **2007**, 50, 4279-94 39

897 Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. **2007**, Volume 2, 0-0

896 The effects of intravitreal bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. **2007**, 48, 5708-15 69

895 Concave pit-containing scaffold surfaces improve stem cell-derived osteoblast performance and lead to significant bone tissue formation. **2007**, 2, e496 57

894 [Angiogenesis and retinal diseases]. **2007**, 70, 547-53 13

893 Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. **2007**, 54, 146-53 13

892 [VE-cadherin takes a walk on the wild side]. **2007**, 23, 119-21 0

891 The Central Role of Endothelial Cells in Severe Angioproliferative Pulmonary Hypertension. 1193-1198

890 Towards a rational approach to combination therapy for neovascular age-related macular degeneration. **2007**, 91, 130-1 2

889 Vascular Permeability Factor/Vascular Endothelial Growth Factor and Its Receptors: Evolving Paradigms in Vascular Biology and Cell Signaling. 266-284 1

888 Angiogenesis. 1444-1456

887 Pathogenese der Primär- und Rezidivvarikosis an der Magna-Krosse. **2007**, 36, 137-142 10

886 Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways. **2007**, 120, 743-748 9

885 Magnetic resonance imaging and spectroscopy of transgenic models of cancer. **2007**, 20, 186-99 23

884 Vascular permeability induced by VEGF family members in vivo: role of endogenous PAF and NO synthesis. **2007**, 100, 727-37 62

883 VEGF in biological control. **2007**, 102, 1358-67 155

882 Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. **2007**, 212, 236-43 54

881	Cotransplanted hepatic stellate cells enhance vascularization of islet allografts. 2007 , 27, 324-7	8
880	Effect of low level laser treatment after installation of dental titanium implant-immunohistochemical study of vascular endothelial growth factor: an experimental study in rats. 2007 , 4, 681-685	25
879	Vascular damaging agents. 2007 , 19, 443-56	114
878	Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. 2007 , 67, 84-90	67
877	Effect of bevacizumab on radiation necrosis of the brain. 2007 , 67, 323-6	321
876	Blood-retinal barrier disruption and ultrastructural changes in the hypoxic retina in adult rats: the beneficial effect of melatonin administration. 2007 , 212, 429-39	93
875	Dynamical behavior of the vascular endothelial growth factor: biological implications. 2007 , 67, 517-25	8
874	MKK signaling and vascularization. 2007 , 26, 1290-6	23
873	Bevacizumab in the treatment of non-small-cell lung cancer. 2007 , 26, 3691-8	22
872	Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. 2007 , 21, 1095-101	78
871	Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability. 2007 , 27, 1152-60	35
870	Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin. 2007 , 127, 65-74	25
869	Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus. 2007 , 18, 346-53	27
868	Vascular endothelial cells and eosinophil infiltration in allergic rhinitis. 2007 , 7, 5-10	
867	Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in ischaemic colitis and ulcerative colitis. 2007 , 24, 182-188	1
866	Heritability for plasma VEGF concentration in the Stanislas family study. 2007 , 71, 54-63	31
865	Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. 2007 , 101, 1567-82	102
864	Increased vascular permeability and nitric oxide production in response to hypoxia in the pineal gland. 2007 , 42, 338-49	31

863	Circulation in normal and inflamed dental pulp. 2007 , 17, 2-11	12
862	Lymphangiogenesis and angiogenesis in non-phymatous rosacea. 2007 , 34, 748-53	75
861	Ranibizumab for the treatment of neovascular AMD. 2007 , 61, 501-9	19
860	Angiogenic factors in normal endometrium and endometrial adenocarcinoma. 2007 , 57, 140-7	19
859	Novel small-molecule inhibitors of the vascular endothelial growth factor receptor. 2007 , 8 Suppl 2, S74-8	7
858	Vascular endothelial growth factor promotes brain tissue regeneration with a novel biomaterial polydimethylsiloxane-tetraethoxysilane. 2007 , 1132, 29-35	31
857	AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. 2007 , 11, 83-95	1493
856	Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. 2007 , 19, 2003-12	707
855	A novel fluorescence-based cellular permeability assay. 2007 , 70, 329-33	7
854	Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression. 2007 , 47, 313-8	20
853	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. 2007 , 104, 768-78	59
852	Ovarian cancer specific kallikrein profile in effusions. 2007 , 105, 501-7	39
851	Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. 2007 , 11, 621-43	95
850	Erratum. 2007 , 12, 355-360	78
849	Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. 2007 , 26, 1-37	163
848	Expression of vascular endothelial growth factor and its receptors in canine lymphoma. 2007 , 137, 30-40	24
847	Changes in cytokine production and morphology of murine lymphoma NK/Ly cells in course of tumor development. 2007 , 2, 71-86	1
846	Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women. 2007 , 197, 271.e1-4	37

845	Neuroprotection against neurodegenerative diseases. 2007 , 35, 55-84	23
844	Vascular endothelial growth factor (VEGF) in autoimmune diseases. 2007 , 27, 246-56	86
843	Hypoxia-driven selection of the metastatic phenotype. 2007 , 26, 319-31	338
842	The role of autocrine motility factor in tumor and tumor microenvironment. 2007 , 26, 725-35	57
841	Retinopathy of prematurity. 2007 , 10, 133-40	438
840	Progress in defining the molecular biology of age related macular degeneration. 2007 , 122, 219-36	58
839	Distribution of Notch protein members in normal and preeclampsia-complicated placentas. 2007 , 330, 527-34	50
838	Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. 2007 , 113, 607-26	89
837	The effect of locally applied vascular endothelial growth factor on meniscus healing: gross and histological findings. 2007 , 127, 235-40	56
836	Vascular endothelial growth factor (VEGF) levels of gingiva and gingival crevicular fluid in diabetic and systemically healthy periodontitis patients. 2007 , 11, 115-20	31
835	VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. 2007 , 2, 153-164	8
834	Vascular endothelial growth factor (VEGF) signaling in tumor progression. 2007 , 62, 179-213	442
833	On the structure, interactions, and dynamics of bound VEGF. 2008 , 26, 1091-103	7
832	Vascular endothelial growth factor and diabetic nephropathy. 2008 , 8, 470-6	42
831	Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. 2008 , 52, 91-98	28
830	Vascular permeability, vascular hyperpermeability and angiogenesis. 2008 , 11, 109-19	441
829	The neurotransmitter dopamine modulates vascular permeability in the endothelium. 2008 , 3, 14	29
828	[Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology]. 2008 , 37, 404-15	4

827	Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. 2008 , 26, 1520-5	36
826	Nanovehicular intracellular delivery systems. 2008 , 97, 3518-90	252
825	Quantification of viable tumor microvascular characteristics by multispectral analysis. 2008 , 60, 64-72	41
824	Angiogenesis and hypoxic factors in colorectal cancer. 2008 , 204, 501-10	16
823	History of Angiogenesis. 2008 , 1-14	11
822	Expression of the vascular endothelial growth factor-receptor system in the porcine endometrium throughout the estrous cycle and early pregnancy. 2008 , 75, 362-72	37
821	Effect of local neutralization of basic fibroblast growth factor or vascular endothelial growth factor by a specific antibody on the development of the corpus luteum in the cow. 2008 , 75, 1449-56	62
820	Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis. 2008 , 15, 1232-8	7
819	Systems biology of vascular endothelial growth factors. 2008 , 15, 715-38	118
818	Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. 2008 , 190, 238-45	50
817	El factor de crecimiento endotelial vascular induce proteínas de matriz extracelular y osteopontina en la arteria umbilical. 2008 , 22, 296-308	
816	Biological properties of "naked" metal nanoparticles. 2008 , 60, 1289-1306	664
815	Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. 2008 , 60, 1421-34	375
814	Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with a polymyxin B-immobilized fiber column. 2008 , 12, 285-91	10
813	Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression. 2008 , 116, 638-47	17
812	Molecular and prognostic markers in prostate cancer. 2008 , 116, 1-62	
811	Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation. 2008 , 18, 3-15	177
810	Anti-VEGF therapy: comparison of current and future agents. 2008 , 22, 1330-6	77

809	Regulation of scar formation by vascular endothelial growth factor. 2008 , 88, 579-90	219
808	Inhibition of tumor specific angiogenesis by amentoflavone. 2008 , 73, 209-18	32
807	Targeted therapy in the treatment of solid tumors: practice contradicts theory. 2008 , 73, 605-18	30
806	Mechanisms of angiogenesis. 2008 , 73, 751-62	205
805	VEGF-A splicing: the key to anti-angiogenic therapeutics?. 2008 , 8, 880-7	379
804	Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. 2008 , 22, 42-8	204
803	Vascular endothelial growth factor and nitric oxide production in response to hypoxia in the choroid plexus in neonatal brain. 2008 , 18, 71-85	35
802	Melatonin attenuates hypoxia-induced ultrastructural changes and increased vascular permeability in the developing hippocampus. 2008 , 18, 533-47	29
801	Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression. 2008 , 18, 851-3	6
800	Inhibition of tumor-induced edema by antisense VEGF is mediated by suppressive vesiculo-vacuolar organelles (VVO) formation. 2008 , 99, 2540-6	17
799	Concordant over-expression of transcription factor Sp1 and vascular endothelial growth factor in extramammary Paget's disease. 2008 , 47, 562-6	14
798	Fracture vascularity and bone healing: a systematic review of the role of VEGF. 2008 , 39 Suppl 2, S45-57	222
797	Distribution of Lipiodol in hepatocellular carcinoma. 1990 , 10, 72-8	39
796	Vascular endothelial growth factor in eye disease. 2008 , 27, 331-71	481
795	The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. 2008 , 27, 372-90	132
794	Pegaptanib sodium for the treatment of age-related macular degeneration. 2008 , 9, 499-508	40
793	Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature. 2008 , 17-33	10
792	Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor. 2008 , 89-108	

791	From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy. 2008 , 6, 165-72	50
790	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. 2008 ,	2
789	Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies. 2008 , 5, 250-67	28
788	Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. 2008 , 147, 99-107	51
787	VEGF and ALS. 2008 , 62, 71-7	34
786	A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. 2008 , 115, 1447-9, 1449.e1-10	444
785	Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. 2008 , 102, 1708-14	32
784	Intravenously-injected gold nanoparticles (AuNPs) access intracerebral F98 rat gliomas better than AuNPs infused directly into the tumor site by convection enhanced delivery. 2018 , 13, 3937-3948	13
783	Microvascular permeability of skeletal muscle after eccentric contraction-induced muscle injury: in vivo imaging using two-photon laser scanning microscopy. 2018 , 125, 369-380	7
782	Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3 46
781	VEGF Signaling in Neurological Disorders. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3 61
780	VEGF Triggers the Activation of Cofilin and the Arp2/3 Complex within the Growth Cone. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3 11
779	Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay. 2018 ,	10
778	Computational Systems Biology for the VEGF Family in Angiogenesis. 2018 , 659-676	8
777	Bones in human CYP26B1 deficiency and rats with hypervitaminosis A phenocopy overexpression. 2018 , 9, 27-36	4
776	Ultrasensitive enzyme-free fluorescent detection of VEGF based on target-triggered hybridization chain reaction amplification.. 2018 , 8, 25955-25960	8
775	Vascular endothelial growth factor signaling in development and disease. 2018 , 145,	150
774	Growth factors in the pathogenesis of diabetic foot ulcers. 2018 , 23, 310-317	22

773	Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma. 2018 , 102, 6503-6513	15
772	Pharmacological Risk Assessment for Dental Implants. 2018 , 37-65	
771	Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15. 2018 , 3, 21	4
770	Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma. 2018 , 24, 171-179	12
769	Hereditary angioedema: the plasma contact system out of control: comment. 2018 , 16, 2347-2348	2
768	Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer. 2018 , 9, 1287-1300	5
767	Nanosecond Laser Treatment for Age-Related Macular Degeneration Does Not Induce Focal Vision Loss or New Vessel Growth in the Retina. 2018 , 59, 731-745	8
766	A functional siRNA screen identifies RhoGTPase-associated genes involved in thrombin-induced endothelial permeability. 2018 , 13, e0201231	8
765	Age-Related Macular Degeneration. 2018 , 35-70	
764	Prophylactic Bevacizumab May Mitigate Radiation Injury: An Experimental Study. 2018 , 116, e791-e800	8
763	New Treatment Modalities for the Management of Peritoneal Metastases. 2018 , 469-506	3
762	Locoregional and Palliative Therapies for Patients with Unresectable Peritoneal Metastases. 2018 , 527-559	1
761	Pro- and antiangiogenic therapies: current status and clinical implications. 2019 , 33, 34-48	28
760	Bioactive lysolipids in cancer and angiogenesis. 2019 , 193, 91-98	47
759	Gintonin-mediated release of astrocytic vascular endothelial growth factor protects cortical astrocytes from hypoxia-induced cell damages. 2019 , 43, 305-311	10
758	Vascular Endothelial Growth Factor and Cutaneous Scarring. 2019 , 8, 671-678	19
757	Decoding inflammation, its causes, genomic responses, and emerging countermeasures. 2019 , 90, e12812	24
756	VEGF and FGF-2: Promising targets for the treatment of respiratory disorders. 2019 , 156, 33-46	51

755	Developing Therapies for Age-related Macular Degeneration: The Art and Science of Problem-solving: The 2018 Charles L. Schepens, MD, Lecture. 2019 , 3, 900-909		3
754	Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis. 2019 ,		6
753	Identification of critical genes associated with human osteosarcoma metastasis based on integrated gene expression profiling. 2019 , 20, 915-930		20
752	Intravitreal Ziv-Aflibercept: A Comprehensive Review. 2019 , 34, 420-435		6
751	Innovative therapies for neovascular age-related macular degeneration. 2019 , 20, 1879-1891		56
750	Glucocorticoid receptor inhibits Müller glial galectin-1 expression via DUSP1-dependent and -independent deactivation of AP-1 signalling. 2019 , 23, 6785-6796		11
749	Angiogenesis Vessels Recruitment by Tumor Cells. 2019 , 141-157		
748	Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components. 2019 , 59, 175-186		22
747	Tumor Endothelial Heterogeneity in Cancer Progression. <i>Cancers</i> , 2019 , 11,	6.6	34
746	The discovery of the fundamental role of VEGF in the development of the vascular system. 2019 , 160, 103579		6
745	Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	3
744	Development of Lenvatinib Mesylate, an Angiogenesis Inhibitor Targeting VEGF and FGF Receptors. 2019 , 155-168		
743	Endothelial life discontinues without Erk. 2019 , 216, 1730-1732		1
742	Hantavirus entry: Perspectives and recent advances. 2019 , 104, 185-224		32
741	Expression and characterization of recombinant human VEGF165 in the middle silk gland of transgenic silkworms. 2019 , 28, 601-609		2
740	Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. 2019 , 28, 861-869		40
739	Induced Expression of VEGFC, ANGPT, and EFNB2 and Their Receptors Characterizes Neovascularization in Proliferative Diabetic Retinopathy. 2019 , 60, 4084-4096		11
738	Trends and Challenges in Tumor Anti-Angiogenic Therapies. <i>Cells</i> , 2019 , 8,	7.9	78

737	The promising role of monoclonal antibodies for gastric cancer treatment. 2019 , 11, 347-364		7
736	VEGF/Neuropilin Signaling in Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	46
735	Emerging angiogenesis inhibitors for non-small cell lung cancer. 2019 , 24, 71-81		9
734	The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 14174-14180	11.5	19
733	Controversial roles for dexamethasone in glioblastoma - Opportunities for novel vascular targeting therapies. 2019 , 39, 1460-1468		16
732	Molecular and Cell Biology of Cancer. 2019 ,		1
731	Biocompatibility, Antiproliferative, and EGFR/VEGFR2 Studies of Heteroleptic Metal(II) Complexes of Thiosemicarbazones and Naproxen. 2019 , 32, 1554-1571		13
730	Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy. 2019 , 421, 319-359		18
729	Passing the Vascular Barrier: Endothelial Signaling Processes Controlling Extravasation. 2019 , 99, 1467-1525		76
728	Physiological Roles of Mast Cells: Collegium Internationale Allergologicum Update 2019. 2019 , 179, 247-261		42
727	A ketogenic diet improves the prognosis in a mouse model of peritoneal dissemination without tumor regression. 2019 , 64, 201-208		5
726	Nanotechnology Approaches in Tackling Cardiovascular Diseases. 2019 , 24,		18
725	Molecular Mechanisms of Inflammation: Induction, Resolution and Escape by <i>Helicobacter pylori</i> . 2019 ,		2
724	VEGF-A from Granuloma Macrophages Regulates Granulomatous Inflammation by a Non-angiogenic Pathway during Mycobacterial Infection. 2019 , 27, 2119-2131.e6		15
723	Tumors: Wounds That Do Not Heal-A Historical Perspective with a Focus on the Fundamental Roles of Increased Vascular Permeability and Clotting. 2019 , 45, 576-592		22
722	Molecular Technology for Injured Brain Regeneration. 2019 , 71-85		
721	Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	79
720	Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. 2019 , 88, 102956		10

719	VEGF in Signaling and Disease: Beyond Discovery and Development. 2019 , 176, 1248-1264		617
718	Intracellular availability of poorly soluble drugs from lipid nanocapsules. 2019 , 139, 23-32		14
717	Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model. 2019 , 2, 1844-1856		17
716	Increased Expression of Vascular Endothelial Growth Factor-D Following Brain Injury. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
715	Mangiferin alleviates arsenic induced oxidative lung injury via upregulation of the Nrf2-HO1 axis. 2019 , 126, 41-55		33
714	Activation of Notch signaling by soluble Dll4 decreases vascular permeability via a cAMP/PKA-dependent pathway. 2019 , 316, H1065-H1075		12
713	Vessel co-option in cancer. 2019 , 16, 469-493		158
712	Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors. 2019 , 8,		7
711	Transport Phenomenon of Nanoparticles in Animals and Humans. 2019 , 23, 173-186		2
710	The Effect of Vascular Endothelial Growth Factor on Bone Marrow Mesenchymal Stem Cell Engraftment in Rat Fibrotic Liver upon Transplantation. 2019 , 2019, 5310202		4
709	. 2019 ,		
708	Ovarian Cancer Dissemination-A Cell Biologist's Perspective. <i>Cancers</i> , 2019 , 11,	6.6	10
707	The impact of the bone marrow microenvironment on multiple myeloma (Review). 2019 , 42, 1272-1282		14
706	Cancer Drug Delivery Systems Based on the Tumor Microenvironment. 2019 ,		3
705	The haematopoietic stem cell niche: a new player in cardiovascular disease?. 2019 , 115, 277-291		13
704	Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350. 2019 , 29, 1-6		4
703	Low Reynolds number flows in a microscopic and tapered tube with a permeability. 2019 , 51, 025504		2
702	Evaluation of flow-modulation approaches in ventricular assist devices using an in-vitro endothelial cell culture model. 2019 , 38, 456-465		9

701	Presence of trophoblast in the uterine lumen affects VEGF-C expression in porcine endometrium. 2019 , 125, 216-223	3
700	Hybrid Nanostructures in Targeted Drug Delivery. 2019 , 139-158	8
699	Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpkl and Srsf1 by the Wilms' Tumor Suppressor Wt1. <i>Cells</i> , 2019 , 8, 7-9	21
698	Aspirin suppresses tumor cell-induced angiogenesis and their incongruity. 2019 , 13, 491-502	11
697	Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics. 2019 , 14, 142-157	32
696	Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. 2019 , 88, 1-33	9
695	TAZ Expression on Endothelial Cells Is Closely Related to Blood Vascular Density and VEGFR2 Expression in Astrocytomas. 2019 , 78, 172-180	4
694	Optimizing immune cell therapies with artificial intelligence. 2019 , 461, 34-40	7
693	Inducing a Transient Increase in Blood-Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme. 2019 , 13, 97-113	36
692	Microvascular Complications in the Eye: Diabetic Retinopathy. 2019 , 305-321	2
691	Heparan sulfate proteoglycan - A common receptor for diverse cytokines. 2019 , 54, 115-121	33
690	Glycosylation and metastases. 2019 , 40, 140-150	12
689	Ovarian Hyperstimulation Syndrome. 2019 , 345-362	
688	Protective effects of dexamethasone on hypoxia-induced retinal edema in a mouse model. 2019 , 178, 82-90	5
687	Accelerated growth of hemangioblastoma in pregnancy: the role of proangiogenic factors and upregulation of hypoxia-inducible factor (HIF) in a non-oxygen-dependent pathway. 2019 , 42, 209-226	9
686	Inhibition of RM-1 prostate carcinoma and eliciting robust immune responses in the mouse model by using VEGF-M-GnRH-hinge-MVP vaccine. 2019 , 20, 245-254	5
685	Nanoinformatics and biomolecular nanomodeling: a novel move en route for effective cancer treatment. 2020 , 27, 19127-19141	7
684	Prostaglandin F ₂ β stimulates angiogenesis at the embryo-maternal interface during early pregnancy in the pig. 2020 , 142, 169-176	13

683	Multimerin-2 maintains vascular stability and permeability. 2020 , 87, 11-25	13
682	The influence of female sex hormones on lung inflammation after brain death - an experimental study. 2020 , 33, 279-287	4
681	Therapeutic vascularization in regenerative medicine. 2020 , 9, 433-444	37
680	Intravitreal anti-VEGF agents and cardiovascular risk. 2020 , 15, 199-210	19
679	Osteogenesis and bone remodeling: A focus on growth factors and bioactive peptides. 2020 , 46, 326-340	27
678	The novel axis of YAP1, transcription enhancer factor 3 and Down Syndrome Candidate Region 1 isoform 1L is a common signaling pathway downstream of several angiogenic factors. 2020 , 129, 103955	2
677	Animal models of scarring control. 2020 , 34, 263-270	2
676	Hereditary angioedema attack: what happens to vasoactive mediators?. 2020 , 78, 106079	6
675	Expression and functional role of fibroblast growth factors (FGF) in placenta during different stages of pregnancy in water buffalo (<i>Bubalus bubalis</i>). 2020 , 143, 98-112	4
674	Exercise-Induced Myokines can Explain the Importance of Physical Activity in the Elderly: An Overview. 2020 , 8,	14
673	Recurrence of arteriovenous malformation in adulthood five years after complete surgical resection: A case report. 2020 , 66, 405-407	1
672	Cancer stromal targeting therapy to overcome the pitfall of EPR effect. 2020 , 154-155, 142-150	14
671	Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy. 2020 , 163-164, 98-124	32
670	Endothelial Damage in Acute Respiratory Distress Syndrome. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 37
669	Vascular endothelial growth factor-activated basophils in asthmatics. 2020 , 37, 584-589	1
668	Nitric Oxide and Oxidative Stress-Mediated Cardiovascular Functionality: From Molecular Mechanism to Cardiovascular Disease. 2020 ,	2
667	VEGF-A in Cardiomyocytes and Heart Diseases. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 35
666	Recent Advancements in Biomarkers and Early Detection of Gastrointestinal Cancers. 2020 ,	1

665	Systems Biology Will Direct Vascular-Targeted Therapy for Obesity. <i>Frontiers in Physiology</i> , 2020 , 11, 831	4.6	5
664	Tumorigenesis and Progression As A Consequence of Hypoxic TME:A Prospective View upon Breast Cancer Therapeutic Targets. <i>Experimental Cell Research</i> , 2020 , 395, 112192	4.2	0
663	Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 19854-19865	11.5	19
662	Zinc Finger Protein St18 Protects against Septic Death by Inhibiting VEGF-A from Macrophages. 2020 , 32, 107906		2
661	Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors. 2020 , 11, 3704		25
660	Eosinophils in the Tumor Microenvironment. 2020 , 1273, 1-28		5
659	Hemostasis vs. homeostasis: Platelets are essential for preserving vascular barrier function in the absence of injury or inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 24316-24325	11.5	13
658	Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. 2020 , 14, 1203-1214		9
657	Signalling, Metabolic Pathways and Iron Homeostasis in Endothelial Cells in Health, Atherosclerosis and Alzheimer's Disease. <i>Cells</i> , 2020 , 9,	7.9	5
656	Electrospun Nanofibers for Improved Angiogenesis: Promises for Tissue Engineering Applications. 2020 , 10,		44
655	Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
654	miR-129-5p and miR-130a-3p Regulate VEGFR-2 Expression in Sensory and Motor Neurons during Development. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
653	Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. 2020 , 11, 4474-4494		40
652	Simultaneous Sensing of Multiple Cancer Biomarkers by a Single DNA Nanoprobe in a Nanopore. 2020 , 92, 9405-9411		14
651	Uses of dimedone to synthesis pyrazole, isoxazole and thiophene derivatives with antiproliferative, tyrosine kinase and Pim-1 kinase inhibitions. 2020 , 29, 1536-1551		3
650	Abicipar pegol for neovascular age-related macular degeneration. 2020 , 20, 999-1008		13
649	Silver(I) metallodrugs of thiosemicarbazones and naproxen: biocompatibility, anti-proliferative activity and interaction studies with EGFR, VEGFR2 and LOX receptors. 2020 , 9, 28-44		2
648	The Relationship between Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Vascular Endothelial Growth Factor and Matrix Metalloproteinase 3. 2020 , 59, 1021-1022		5

647	Sources and lesion-induced changes of VEGF expression in brainstem motoneurons. 2020 , 225, 1033-1053	3
646	PI3K β as a Novel Therapeutic Target in Pathological Angiogenesis. 2020 , 69, 736-748	11
645	Gastrointestinal vascular permeability changes following spinal cord injury. 2020 , 32, e13834	1
644	Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-L-lactide microparticles as a controlled release delivery system. 2020 , 44, 34-47	3
643	Exploration of Oxygen-Induced Retinopathy Model to Discover New Therapeutic Drug Targets in Retinopathies. 2020 , 11, 873	10
642	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. <i>Cells</i> , 2020 , 9, 7-9	46
641	Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A in Ischemic and Non-Ischemic Heart Failure. 2020 , 9,	7
640	The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer:. <i>Cancers</i> , 2020 , 12,	6.6 6
639	VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment. 2020 , 10, 3635	4
638	Mushroom: A New Resource for Anti-Angiogenic Therapeutics. 2020 , 1-22	5
637	Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors. 2020 , 97, 103667	6
636	Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments. 2020 , 258, 1005-1012	0
635	Current concepts of pharmacotherapy of diabetic macular edema. 2020 , 21, 467-475	12
634	Angiocrine endothelium: from physiology to cancer. 2020 , 18, 52	27
633	The Role of Rho GTPases in VEGF Signaling in Cancer Cells. 2020 , 2020, 2097214	6
632	Novel method to evaluate the risk of tumor adhesions and post-operative hemorrhage of meningiomas using 320 row CT-DSA: A clinical research study. 2020 , 162, 2145-2153	0
631	Vascular permeability in the fibrotic lung. 2020 , 56,	15
630	LPS-mediated neutrophil VEGF-A release is modulated by cannabinoid receptor activation. 2021 , 109, 621-631	8

629	Pregnancies after Childhood Craniopharyngioma: Results of KRANIOPHARYNGEOM 2000/2007 and Review of the Literature. 2021 , 111, 16-26	4
628	Microvasculature in hepatocellular carcinoma: An ultrastructural study. 2021 , 133, 104094	0
627	Spatiotemporal variations of vascular endothelial growth factor in the brain of diabetic cognitive impairment. 2021 , 163, 105234	5
626	Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics. 2021 , 41, 464-506	18
625	Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies. 2021 , 27, 314-331	54
624	A History of Anti-VEGF Inhibitors in the Ophthalmic Literature: A Bibliographic Review. 2021 , 5, 304-312	
623	Dual-acting therapeutic proteins for intraocular use. 2021 , 26, 44-55	1
622	Epsins in vascular development, function and disease. 2021 , 78, 833-842	6
621	An Updated and Comprehensive Meta-Analysis of Association between VEGA -634G > C, -460T > C, +405G > C and +936C > T Polymorphisms and Retinopathy of Prematurity Risk. 2021 , 40, 233-249	1
620	Vascular endothelial growth factor and neurodevelopment. 2021 , 237-246	
619	Growth Promoting Effect of Vacuum Sealing Drainage in the Healing Processes of Diabetic Foot Ulcers. 2021 , 17, 65-71	0
618	Pharmacotherapy of Age-Related Macular Degeneration. 2021 , 1-26	
617	Exploring the Intracrine Functions of VEGF-A. 2021 , 11,	10
616	Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy. 2021 , 11, 2497	4
615	Receptors Structural and Functional Insights of VEGF and Its Receptors. 2021 , 286-293	1
614	Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione. 2021 , 21, 468-486	
613	Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation: Clinical Implications. 2021 , 11,	14
612	Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice. 2021 , 134, 111110	2

611	Disabling VEGF-Response of Purkinje Cells by Downregulation of via miRNA-204-5p. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
610	VEGF and FGF-2 Released In Palatal Suture after Rapid Maxillary Expansion (RME). 2021 , 32, 98-103		
609	New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations. 2021 , 21, 327-342		3
608	Reconciling VEGF With VPF: The Importance of Increased Vascular Permeability for Stroma Formation in Tumors, Healing Wounds, and Chronic Inflammation. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 660609	5.7	4
607	Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. <i>Cancers</i> , 2021 , 13,	6.6	8
606	Kisspeptin regulates the development of caprine primordial follicles in vitro. 2021 , 36, 51-58		
605	Vascular endothelial growth factors and angiopoietins as new players in mastocytosis. 2021 , 21, 415-427		5
604	PRSS2 stimulates tumor growth by remodeling the TME via repression of Tsp1.		1
603	Effect of intravitreal bevacizumab in the uninjected fellow eye of patients treated for retinal disorders. 2021 , 7, 234-239		
602	Overview on the Different Patterns of Tumor Vascularization. <i>Cells</i> , 2021 , 10,	7.9	9
601	Similarities and perspectives on the two C's-Cancer and COVID-19. 2021 , 19, 1161-1167		5
600	The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy. <i>Cancers</i> , 2021 , 13,	6.6	9
599	Fibrin and Transforming Growth Factor Alpha Affect Prostatic Smooth Muscle Cell's Phenotype and Motility. 2021 , 1-8		
598	Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. 2021 , 54, e13009		19
597	Vascular normalisation as the stepping stone into tumour microenvironment transformation. 2021 , 125, 324-336		11
596	Neuropilin 1 Regulation of Vascular Permeability Signaling. 2021 , 11,		6
595	Intermittent Hypoxic Preconditioning: A Potential New Powerful Strategy for COVID-19 Rehabilitation. 2021 , 12, 643619		2
594	Angiogenesis Inhibitors. 1-66		

593	Trade-offs between male fertility reduction and selected growth factors or the klotho response in a lipopolysaccharide-dependent mouse model.. 2022 , 38, 175-186		0
592	Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
591	Secretory Expression of Human Vascular Endothelial Growth Factor (VEGF165) in <i>Kluyveromyces lactis</i> and Characterization of Its Biological Activity. 2021 , 27, 1989-2001		0
590	Identification of as the Key Gene Associated with Antivascular Endothelial Growth Factor Therapy in Glioblastoma Multiforme. 2021 , 25, 334-345		1
589	Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer. 2021 , 10,		7
588	Clinical Application of Cytokines in Cancer Immunotherapy. 2021 , 15, 2269-2287		14
587	Targeted Drug Delivery: Trends and Perspectives. 2021 ,		5
586	Regulation of vascular permeability in cancer metastasis. 2021 , 112, 2966-2974		2
585	Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration. 2021 , 15, 2653-2665		6
584	Current Biological Strategies to Enhance Surgical Treatment for Rotator Cuff Repair. 2021 , 9, 657584		3
583	Numerical evaluation reveals the effect of branching morphology on vessel transport properties during angiogenesis. 2021 , 17, e1008398		2
582	Intra-vessel heterogeneity establishes enhanced sites of macromolecular leakage downstream of laminin B. 2021 , 35, 109268		0
581	Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021 , 13,	6.6	1
580	The effect of different irrigation solutions and activation techniques on the expression of growth factors from dentine of extracted premolar teeth. 2021 , 54, 1915-1924		2
579	Hydrostatic pressure stabilizes HIF-1 α expression in cancer cells to protect against oxidative damage during metastasis. 2021 , 46,		0
578	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. 2021 , 230, 107967		7
577	Evaluation of a new multiple regression model based on biochemical parameters for the distinction of canine exudates and transudates. 2021 , 50, 394-403		
576	Snake venom vascular endothelial growth factors (svVEGFs): Unravelling their molecular structure, functions, and research potential. 2021 , 60, 133-143		5

575	Wound fluid under occlusive dressings from diabetic patients show an increased angiogenic response and fibroblast migration. 2021 , 30, 446-453	0
574	Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. 2021 , 21, 300	2
573	The Relationship Between Peritumoral Brain Edema and the Expression of Vascular Endothelial Growth Factor in Vestibular Schwannoma. 2021 , 12, 691378	
572	Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis. 2021 , 26,	5
571	Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. 2021 , 11, 739191	1
570	Involvement of vascular endothelial growth factor in schizophrenia. 2021 , 760, 136093	3
569	Dissecting VEGF-induced acute versus chronic vascular hyperpermeability: Essential roles of dimethylarginine dimethylaminohydrolase-1. 2021 , 24, 103189	1
568	Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability. 2021 , 14,	7
567	Expression Pattern of T-Type Ca Channels in Cerebellar Purkinje Cells after VEGF Treatment. <i>Cells</i> , 2021 , 10,	7.9
566	VEGFR1 signaling in retinal angiogenesis and microinflammation. 2021 , 84, 100954	21
565	Hypoxia-responsive expression of vascular endothelial growth factor for induction of angiogenesis in artificial three-dimensional tissues. 2021 , 132, 399-407	0
564	A novel transcriptional complex on the VE-cadherin promoter regulated the downregulation of VE-cadherin in the Down Syndrome Candidate Region 1 isoform 1L-mediated angiogenesis. 2021 , 138, 104209	
563	Vascular Endothelial Growth Factor and Inflammatory Airway Diseases: An Update. 2022 , 401-408	
562	Neuroprotective Effect of Vascular Endothelial Growth Factor on Motoneurons of the Oculomotor System. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 2
561	Aflibercept in Diabetic Retinopathy. 2021 , 15, 18	0
560	KSI-301: antibody biopolymer conjugate in retinal disorders. 2021 , 13, 25158414211027708	6
559	Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again. 2021 , 10,	1
558	Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs. 2021 , 49, 19-24	1

557	Molecular Biology of Cancer. 2003 , 1-50	3
556	Vascular Endothelial Growth Factors in Tissue Engineering: Challenges and Prospects for Therapeutic Angiogenesis. 275-293	1
555	The Endothelial Frontier. 75-107	1
554	Lymphangiogenesis: Recapitulation of Angiogenesis in Health and Disease. 2006 , 159-202	4
553	Preclinical models of regional lymph node tumor metastasis. 2007 , 135, 129-56	8
552	VEGF Signal Transduction in Angiogenesis. 2008 , 205-216	2
551	Overview and Clinical Applications of VEGF-A. 2008 , 345-352	2
550	Vascular Permeability/Vascular Endothelial Growth Factor. 2008 , 89-98	4
549	Rodent Models of Oxygen-Induced Retinopathy. 2008 , 57-80	1
548	Functions of Autocrine Motility Factor at the Tumor Microenvironment. 2008 , 11-25	1
547	Therapeutically Used Targeted Antigens in Radioimmunotherapy. 2008 , 13-23	2
546	Antiangiogenic Strategies for the Treatment of Gliomas. 2010 , 243-263	2
545	Role of Pericytes in Resistance to Antiangiogenic Therapy. 2010 , 311-323	1
544	Vascular Endothelial Growth Factor in Malignant Disease of the Central Nervous System. 2004 , 72-82	1
543	Growth Factor Regulators of Placental Angiogenesis. 2000 , 149-162	2
542	Angiogenesis, Vascular Imaging, and Therapeutic Approaches in Ovarian Tumors. 2001 , 187-205	1
541	The Biology of Vascular Endothelial Growth Factor, a Specific Regulator of Angiogenesis. 1997 , 317-332	1
540	Macromolecules as Drug Delivery Systems. 1985 , 189-208	4

539	Is there Clinical Relevance for Therapies which Disrupt the Metastatic Cascade?. 1984 , 1-14	3
538	Fibrin Formation: Implications for Tumor Growth and Metastasis. 1984 , 96-114	6
537	Poly-ADP-ribosylation of vascular endothelial growth factor and its implications on angiogenesis. 2012 , 749, 269-78	4
536	Toll-Like Receptor-Linked Signal Transduction in Angiogenesis. 2013 , 139-157	2
535	Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. 2014 , 772, 83-99	10
534	Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. 2014 , 772, 147-65	30
533	A Time Travel Journey Through Cancer Therapies. 2013 , 3-35	1
532	Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots. 2013 , 207-239	2
531	Vascular endothelial growth factor. 2002 , 513, 375-94	15
530	Physiological Pathways Responsible for the Breakdown of the Blood Brain Barrier during Viral Encephalitis. 2001 , 205-216	1
529	Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in the conjunctiva--a potential link between lymphangiogenesis and leukocyte trafficking on the ocular surface. 2002 , 506, 851-60	8
528	Regulation of Vascular Function by Vascular Permeability Factor. 1991 , 69-76	1
527	Infection, Inflammation, and Cancer Mediated by Oxygen Radicals and Nitric Oxide. 1998 , 277-293	7
526	Angiogenesis and Collateral Formation. 1997 , 307-330	2
525	Angiogenesis and metastasis. 2002 , 107, 353-81	12
524	Possible Relationship between Vascular Permeability Factors, Endothelial Cells, and Peritumoral Brain Edema. 1992 , 477-503	3
523	Modulation of Endothelial Coagulant Properties and Barrier Function by Factors in the Vascular Microenvironment. 1992 , 525-545	1
522	Development of the Blood-Brain Barrier. 1995 , 11-31	13

521	Targeted Drug Delivery to Tumor Cells Using Colloidal Carriers. 2004 , 181-215	4
520	Diabetic Retinopathy. 2006 , 291-318	1
519	Endogenous Angiogenic Inhibitors in Diabetic Retinopathy. 2006 , 23-44	1
518	Role of Pericytes in Angiogenesis. 2008 , 117-132	8
517	VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition. 2009 , 119-149	1
516	VEGF Inhibition for Cancer Therapy. 2008 , 573-584	1
515	Retinal Neovascularization and the Role of VEGF. 2008 , 353-373	1
514	Vaso-occlusive Mechanisms that Initiate Hypoxia and Necrosis in Glioblastoma: The Role of Thrombosis and Tissue Factor. 2009 , 507-528	3
513	Evaluation of VEGF-induced vascular permeability in mice. <i>Methods in Molecular Biology</i> , 2011 , 763, 403-154	6
512	Peritumoral Edema. 2009 , 565-571	1
511	RPE and the Vascular Endothelial Growth Factor. 2020 , 85-99	1
510	Endothelial Cells (ECs) Metabolism: A Valuable Piece to Disentangle Cancer Biology. 2020 , 1219, 143-159	2
509	Involvement of Heparanase in Endothelial Cell-Cardiomyocyte Crosstalk. 2020 , 1221, 721-745	3
508	Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. 1997 , 79, 233-69	290
507	The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. 1997 , 79, 361-90	43
506	Vascular endothelial growth factor: basic biology and clinical implications. 1997 , 79, 209-32	73
505	Retinal Vascular Development. 2016 , 1-19	3
504	Gene and Cell Therapy for Critical Limb Ischemia. 2017 , 491-501	1

503	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. 2019 , 211-226	3
502	Controlling Vascular Permeability: How Does It Work and What Is the Impact on Normal and Pathological Angiogenesis. 2019 , 121-132	1
501	Toll-Like Receptors in Angiogenesis. 2017 , 37-58	1
500	Tumor Angiogenesis: from Bench to Bedside. 2008 , 3-28	10
499	VEGF Signaling. 2010 , 421-437	1
498	Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. 1999 , 237, 97-132	493
497	A new nitric oxide scavenger, imidazolineoxyl N-oxide derivative, and its effects in pathophysiology and microbiology. 1995 , 196, 37-50	13
496	Innate immune responses in viral encephalitis. 2002 , 265, 63-94	10
495	Vasogenic edema and VEGF expression in a rat two-vein occlusion model. 2003 , 86, 213-7	10
494	Src family kinase inhibitor PP1 improves motor function by reducing edema after spinal cord contusion in rats. 2003 , 86, 421-3	11
493	The angiogenic drive in chronic inflammation: Hypoxia and the cytokine milieu. 2008 , 15-28	3
492	Acute and Delayed Effects of Transient Global Cerebral Ischemia on Rat Brain Capillary Endothelial Cells in Vivo. 2001 , 319-325	1
491	Tumor-Cell Interactions with Blood Vessels during Cancer Metastasis. 1989 , 84-97	2
490	Macrophage procoagulants and microvascular permeability: roles in the extravascular coagulation of cellular immunity. 1985 , 713-721	1
489	Structure and Functions of the Dentin-Pulp Complex. 2011 , 452-503	13
488	Pathophysiological Effects of High-Output Production of Nitric Oxide. 2000 , 733-745	15
487	Ultrastructural Features of Human Basophil and Mast Cell Secretory Function. 2000 , 63-88	8
486	Cerebral Edema. 2011 , 162-168	1

485	The Cellular Microenvironment and Metastases. 2014 , 40-51.e4	2
484	Molecular Basis for Normal and Abnormal Lung Development. 2008 , 3-41	3
483	Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II.. 1994 , 269, 25106-25119	130
482	A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. 1994 , 269, 9774-9782	65
481	Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.. 1994 , 269, 4355-4359	416
480	Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin.. 1990 , 265, 18051-18054	95
479	The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. 1991 , 266, 11947-11954	1346
478	A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin.. 1990 , 265, 7078-7083	51
477	Human Vascular Permeability Factor. 1989 , 264, 20017-20024	262
476	Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms.. 1992 , 267, 20239-20247	137
475	Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. 1994 , 269, 32879-32885	66
474	Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science. 2017 , 43, 572-580	11
473	Rapid multilayer microfabrication for modeling organotropic metastasis in breast cancer. 2020 ,	5
472	VEGFR3 gene structure, regulatory region, and sequence polymorphisms. 2001 , 15, 1028-1034	5
471	Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma. 1997 , 21, 941-50	53
470	Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization. 1999 , 14, 515-22	20
469	Supersensitive intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma. 1996 , 21, 221-6	20
468	Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. 1996 , 27, 838-44	206

467	Hemodynamic effects of scatter factor in conscious rats. 1997 , 30, 294-301	14
466	Effects of vascular permeability factor on the permeability of cultured endothelial cells from brain capillaries. 1998 , 32, 1-4	36
465	Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene. 2000 , 36, 498-502	19
464	EXPRESSION OF THE VEGF-RECEPTOR Flt-1 IN BENIGN, PREMALIGNANT AND MALIGNANT PROSTATE TISSUES. 2000 , 506-510	1
463	Detection and Quantification of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Brain Tumor Tissue and Cyst Fluid. 1994 , 35, 439-449	8
462	Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. 1997 , 40, 1016-26	164
461	Molecular mechanisms of growth factor action in diabetic retinopathy. 1999 , 6, 146-156	6
460	Numerical evaluation reveals the effect of branching morphology on vessel transport properties during angiogenesis.	1
459	Involvement of G proteins in vascular permeability factor/vascular endothelial growth factor signaling. 2002 , 67, 275-83	6
458	Increased translocation of bacteria from the gastrointestinal tracts of tumor-bearing mice. 1985 , 47, 793-8	35
457	Anti-vascular therapy: a new approach to cancer treatment. 2000 , 172, 39-42	11
456	Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996 , 16, 1399-405	9-4 34
455	A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA. 1996 , 94, 3062-4	25
454	Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. 1996 , 94, 1074-82	268
453	Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. 1996 , 94, 1647-54	184
452	Regulation of vascular endothelial growth factor in cardiac myocytes. 1995 , 76, 758-66	153
451	Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 and VEGF. 2002 , 109, 805-815	163
450	Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. 2000 , 106, 1311-9	831

449	Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. 1989 , 84, 1470-8	959
448	Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. 1992 , 89, 244-53	339
447	Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. 1993 , 91, 153-9	373
446	Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. 1993 , 91, 160-70	132
445	Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. 1993 , 91, 2235-43	391
444	P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. 1993 , 92, 804-13	141
443	Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. 1995 , 95, 1798-807	443
442	Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. 1996 , 97, 469-76	269
441	Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. 1996 , 98, 1400-8	194
440	Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. 1996 , 98, 1667-75	312
439	In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. 1996 , 98, 2507-11	156
438	Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. 2002 , 109, 805-15	84
437	Blasts from the past. 2004 , 114, 1017-33	2
436	Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. 2006 , 116, 1596-605	68
435	Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. 2007 , 117, 2766-77	224
434	Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. 1998 , 102, 1978-85	127
433	Macrophages regulate corpus luteum development during embryo implantation in mice. 2013 , 123, 3472-87	131
432	Infection With Human Immunodeficiency Virus-1 Increases Expression of Vascular Endothelial Cell Growth Factor in T Cells: Implications for Acquired Immunodeficiency Syndrome-Associated Vasculopathy. 1999 , 93, 4232-4241	43

431	In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. 2000 , 96, 3181-3187	3
430	The role of microenvironment in tumor angiogenesis. 2020 , 39, 204	88
429	Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. 2001 , 70, 478-490	70
428	Drug Targeting with Polymeric Micelle Drug Carriers. 2002 ,	1
427	Mechanisms of proteinuria: vascular permeability factor in congenital nephrotic syndrome of the Finnish type. 1996 , 40, 652-7	17
426	Heparin-binding angiogenic factors (basic fibroblast growth factor and vascular endothelial growth factor) in early neonatal life. 1999 , 45, 877-80	8
425	Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. 1995 , 108, 2369-2379	718
424	Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. 1998 , 111, 1853-1865	503
423	Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. 1999 , 112, 2049-2057	91
422	PECAM-1 (CD31) functions as a reservoir for and a modulator of tyrosine-phosphorylated beta-catenin. 1999 , 112, 3005-3014	103
421	The splice variants of vascular endothelial growth factor (VEGF) and their receptors. 2001 , 114, 853-865	637
420	Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. 2011 , 84 Spec No 2, S127-44	42
419	Progression of Diabetic Capillary Occlusion: A Model. 2016 , 12, e1004932	20
418	Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. 2008 , 3, e2748	110
417	Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. 2010 , 5, e11576	120
416	GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. 2011 , 6, e23359	44
415	Protein signature of lung cancer tissues. 2012 , 7, e35157	71
414	In vivo "MRI phenotyping" reveals changes in extracellular matrix transport and vascularization that mediate VEGF-driven increase in breast cancer metastasis. 2013 , 8, e63146	11

413	Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers. 2014 , 8, e64850	25
412	Evaluating the potential bioactivity of a novel compound ER1626. 2014 , 9, e86509	3
411	Effects of a low level laser on periodontal tissue in hypofunctional teeth. 2014 , 9, e100066	6
410	Quantification of edematous changes by diffusion magnetic resonance imaging in gastrocnemius muscles after spinal nerve ligation. 2018 , 13, e0193306	1
409	Comparison of VEGF-A secretion from tumor cells under cellular stresses in conventional monolayer culture and microfluidic three-dimensional spheroid models. 2020 , 15, e0240833	6
408	Advances in biomaterials for adipose tissue reconstruction in plastic surgery. 2020 , 9, 385-395	11
407	A Single Intraventricular Injection of VEGF Leads to Long-Term Neurotrophic Effects in Axotomized Motoneurons. 2020 , 7,	2
406	Genetic and epigenetic modifications in the pathogenesis of diabetic retinopathy: a molecular link to regulate gene expression. 2016 , 2, 192-204	9
405	Alteration of Angiogenic Gene Expression in Heart, Muscle and Adipose Tissue by Exercise. 2018 , 27, 1-14	2
404	Efeito do miradenolide isolado de <i>Alomia myriadenia</i> (Asteraceae) sobre o tumor de Erlich ascítico no camundongo. 2006 , 58, 788-798	7
403	Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. 1999 , 10, 245-55	111
402	Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. 2001 , 12, 1734-1741	122
401	[Vascular endothelial growth factors (VEGF): role in pathological processes]. 2016 , 132, 98-103	2
400	[The role of vascular endothelial growth factor in the regulation of development and functioning of the brain: new target molecules for pharmacotherapy]. 2016 , 62, 124-33	8
399	Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells. 2016 , 7, 78541-78556	31
398	Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice. 2017 , 8, 9488-9499	14
397	RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer. 2017 , 8, 31581-31591	10
396	Clinical efficacy of endostar combined with chemotherapy in the treatment of peritoneal carcinomatosis in gastric cancer: results from a retrospective study. 2017 , 8, 70788-70797	6

395	Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?. 2017 , 8, 39795-39804	26
394	Ascites as a subject of studies in ovarian cancer. 2019 , 18, 116-123	5
393	Effects of VEGF on Ca(2+)-transient in cultured lymphatic endothelial cells and mechanical activity of isolated lymph vessels. 2000 , 50, 343-55	6
392	Neuroprotective and Neurorestorative Effects of Epo and VEGF: Perspectives for New Therapeutic Approaches to Neurological Diseases. 2020 , 26, 1263-1276	10
391	Anti-angiogenic peptides for cancer therapeutics. 2011 , 12, 1101-16	119
390	"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. 2009 , 9, 341-55	56
389	Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review. 2019 , 19, 765-781	1
388	Achievements in Cancer Research and its Therapeutics in Hundred Years. 2019 , 19, 1545-1562	0
387	The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis. 2019 , 15, 99-109	6
386	Synthesis of Tetrahydrobenzo[<i>b</i>]thiophene-3-carbohydrazide Derivatives as Potential Anti-cancer Agents and Pim-1 Kinase Inhibitors. 2019 , 19, 1737-1753	4
385	[Angiogenesis in the central nervous system: a role of vascular endothelial growth factor]. 2005 , 62, 59-67	2
384	Expression of VEGF receptors VEGFR-1 and VEGFR-2, angiopoietin receptors Tie-1 and Tie-2 in chorionic villi tree during early pregnancy. 2009 , 47, 435-45	11
383	Angiogenesis and developmental expression of vascular endothelial growth factor in rat lingual papillae. 2007 , 54, 9-24	4
382	Change in plasma vascular endothelial growth factor after gamma knife radiosurgery for meningioma: a preliminary study. 2015 , 57, 77-81	4
381	Immunohistochemical Analysis of Vascular Endothelial Growth Factor (VEGF) Expression and Tumor Angiogenesis in Tongue Squamous Cell Carcinomas.. 2003 , 8, 13-19	2
380	The Role of Exosomes in Bronchoalveolar Lavage from Patients with Acute Respiratory Distress Syndrome. 2019 , 8,	2
379	Prokineticin 2/Bv8 is expressed in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma. 2008 , 14, 1182-91	19
378	Hypoxia-inducible factor 1 alpha and vascular endothelial growth factor overexpression in ischemic colitis. 2005 , 11, 1535-9	18

377	Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. 2005 , 11, 5455-9	5
376	Expression of TNF-alpha and VEGF in the esophagus of portal hypertensive rats. 2005 , 11, 1232-6	3
375	Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. 2006 , 12, 3970-6	37
374	Molecular targeting to treat gastric cancer. 2014 , 20, 13741-55	20
373	Significance of vascular endothelial growth factor messenger RNA expression in gastric cancer. 1998 , 4, 10-13	19
372	An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats' disease, best disease, and uveitis with childhood neovascularization. 2013 , 50, 11-9	12
371	Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?. 2011 , 3, 19-29	24
370	Angiogenic factors, bladder neuroplasticity and interstitial cystitis-new pathobiological insights. 2015 , 4, 555-62	14
369	Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. 2013 , 6, 228-36	50
368	The Safety and Efficacy of Bevacizumab for Radiosurgery - Induced Steroid - Resistant Brain Edema; Not the Last Part in the Ship of Theseus. 2019 , 67, 1292-1302	5
367	Impact of Intravitreal Injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina. 2008 , 15, 67-72	4
366	Influence of vascular endothelial growth factor and radiation on gap junctional intercellular communication in glioblastoma multiforme cell lines. 2017 , 12, 1816-1822	4
365	Bioinformatic identification of key candidate genes and pathways in axon regeneration after spinal cord injury in zebrafish. 2020 , 15, 103-111	3
364	Collaboration in the presence of cerebral edema: The complications of steroids. 2016 , 7, S185-9	5
363	Orphan Nuclear Receptor TR3/Nur77 is a Specific Therapeutic Target for Hepatic Cancers. 2017 , 6,	4
362	Expressions of Orphan Nuclear Receptor TR3/Nur77 in Chronic Hepatopathy and Its Clinical Significance. 2017 , 6,	1
361	The impact of high density receptor clusters on VEGF signaling. 125, 37-52	5
360	Endometrial Carcinogenesis and Molecular Signaling Pathways. 2014 , 04, 134-149	14

359	The Expression of VEGF-C and Its Receptor VEGFR-3 Correlates with Lymph Node Metastasis in Gastric Cancer. 2014 , 04, 357-377	2
358	Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy. 2015 , 6, 726-33	34
357	Anti-angiogenic agents in metastatic colorectal cancer. 2015 , 7, 71-86	17
356	1,2-Dichloropropane (1,2-DCP)-Induced Angiogenesis in Dermatitis. 2019 , 35, 361-369	4
355	Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer. 2013 , 2, 48-55	11
354	Role of Mesenchymal Stem Cells Transfected With Vascular Endothelial Growth Factor in Maintaining Renal Structure and Function in Rats with Unilateral Ureteral Obstruction. 2015 , 13, 262-72	4
353	Anti-inflammatory Effect of Angelicae Gigantis Radix Water Extract on LPS-stimulated Mouse Macrophages. 2013 , 28, 113-119	7
352	Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. 2015 , 5, 23-42	153
351	Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. 2000 , 132, 880-4	144
350	The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. 2018 , 7, 212532	65
349	Vessels and Coagulation. 2021 , 45-72	
348	Clinical predictors of severe dengue: a systematic review and meta-analysis. 2021 , 10, 123	4
347	Parallels between the Developing Vascular and Neural Systems: Signaling Pathways and Future Perspectives for Regenerative Medicine. 2021 , 8, e2101837	2
346	Biodiversity of the Adipocyte-Derived Hormone, Leptin.	
345	Inhibition Of Vascular Endothelial Growth Factor (Vegf) And Stem- Cell Factor (Scf) Receptor Kinases As Therapeutic Targets For The Treatment Of Human Diseases. 2000 ,	
344	Tumor Angiogenesis. 2001 , 401-413	0
343	Vascular Endothelial Growth Factor: A Key Regulator of Physiologic Angiogenesis. 2001 , 149-165	
342	Inhibitors of Angiogenesis. 2002 , 261-292	

- 341 Immune responses in glioblastoma: an avenue to effective cancer therapy or a mere epiphenomenon?. **2002**, 265, 259-67 3
- 340 Antiangiogenic Gene Therapy. **2002**, 405-419
- 339 Reproduktionsmedizin. **2002**, 239-305
- 338 Gene Transfer Strategies and Therapeutic Applications for Cardiovascular Ischemic Diseases. **2003**, 453-484
- 337 Angiogenesis: Cellular and Molecular Aspects of Postnatal Vessel Formation. **2003**, 455-462
- 336 Angiogenesis: A Promising Target for Cancer Prevention. **2003**, 169-185
- 335 A New Paradigm for Vascular Endothelial Cell Growth Factor Receptor Signaling in Adult Endothelium. **2003**, 153-166
- 334 Role of Alveolar Type II Epithelial Cells in Pulmonary Fibrosis. **2003**, 573-608
- 333 Tumor Angiogenesis as a Target for Early Intervention and Cancer Prevention. **2004**, 611-633
- 332 The Combination of Angiogenesis Inhibitors and Radiotherapy for the Treatment of Primary Tumors. **2004**, 431-438
- 331 Cellular and Tissue Markers in Solid Tumors. **2004**, 181-213
- 330 Analysis of Vascular Permeability in Vivo. **2004**, 223-232
- 329 Targeting VEGF in Pancreatic Cancer. **2004**, 107-116
- 328 The regulation of the VEGF production in normal human cultured dermal fibroblasts by Lipo-PGE1 (alprostadiol): The possibility of the pharmaceutical angiogenesis therapy. **2004**, 24, 656-660 2
- 327 VEGF and Its Receptors. **2004**, 1-11
- 326 Vascular Endothelial Growth Factor in Breast Cancer. **2004**, 40-47
- 325 Antimalignant Properties of Antithrombotic Agents. **2004**, 207-222
- 324 Modeling Blood Vessel Formation in the Mouse.

323 Tumor Angiogenesis: General Principles and Therapeutic Approaches. **2005**, 41-55

322 Vascular Endothelial Growth Factor Change in Gingival Crevicular Fluid Before and After Scaling and Root Planing in Periodontitis Patients. **2005**, 47, 203-210

321 Vascular Biology of the Placenta. **2005**, 289-313

320 Regenerative cardiology: there are various ways to prosper. **2005**, 94, 695-6

319 Pharmacotherapy of Age-Related Macular Degeneration. **2006**, 1211-1239

1

318 Angiogenesis Inhibitors in Prostate Cancer. **2006**, 127-141

317 Retinal Angiogenesis and Growth Factors. **2007**, 38-77

316 Angiogenesis in Inflammatory Arthritis. **2007**, 403-440

315 Antiangiogenic Therapy for Lung Cancer: Small-Molecule Inhibitors. **2007**, 45-72

314 Gene Therapy. **2007**, 14-1-14-15

313 Induction of Blood-Brain Barrier Properties in Cultured Endothelial Cells. 357-374

1

312 Pathophysiologic Role of VEGF in Hematologic Malignancies. **2007**, 109-148

311 Nanogold in Cancer Therapy and Diagnosis.

310 The Cellular Microenvironment and Metastases. **2008**, 33-47

309 Expression of Vascular Endothelial Growth Factor in Colorectal Cancer. **2008**, 24, 433

308 Angiogenic Factors and Inhibitors. **2008**, 315-336

307 Anti-VEGF and Other Pharmacologic Treatments for Age-Related Macular Degeneration. **2008**, 1963-1976

306 Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease. **2008**, 63-80

- 305 Anti-VEGF Therapy as an Emerging Treatment for Diabetic Retinopathy. **2008**, 401-422
- 304 VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. **2008**, 30, 497-503 17
- 303 Vascular Endothelial Growth Factor: Basic Biology and Clinical Applications. **2009**, 11-21
- 302 ??. **2009**, 35, 285-293
- 301 Diabetic Retinopathy. **2009**, 165-177
- 300 Tumor Microvasculature and Microenvironment: Therapeutic Targets for Inhibition of Tumor Angiogenesis and Metastasis. **2009**, 1-47
- 299 Heme/Lymphvasculogenesis, Hem/Lymphangiogenesis, Hem/Lymphangiotumorigenesis, and Tumor Hem/Lymphangiogenesis: Need for a Terminology Adjustment. **2009**, 77-92
- 298 Onkologie I. **2009**, 33-101
- 297 Prospects for the treatment of diabetic retinopathy: Modulation of endothelial growth factor. **2009**, 12, 33-38 1
- 296 Update on diagnostic practice: tumors of the nervous system. **2009**, 133, 1062-77 15
- 295 Role of Angiogenesis in the Pathogenesis of Arthritis: Potential Therapeutic Applications. **2010**, 361-382
- 294 Vascular Endothelial Growth Factor (VEGF) Expression in Contused Brain Tissue: The Role of Angiogenesis after Traumatic Brain Injury in Rats. **2010**, 69, 298-303
- 293 Safe and Effective Vascular Endothelial Cell Growth Factor (VEGF)-based Therapeutic Angiogenesis for Ischemic Stroke: Insights from Preclinical Trials. **2010**, 169-212 1
- 292 Napoleone Ferrara receives the 2010 Lasker~DeBakey Clinical Award for breakthroughs in angiogenesis research. **2010**, 120, 3409-3412 78
- 291 Therapeutic advances in women's cancers. **2011**, 3, 82-97 3
- 290 Bevacizumab: Current Approach in the Treatment of Hepatocellular Carcinoma. **2011**, 01, 1-5
- 289 Molecular Mechanisms of Hemodialysis Graft Failure. **2011**, 77-91
- 288 D  f  c de la macula et de la r  tine choro  dienne. **2011**, 163-178

287 Growth Factors in Glial Tumors. **2011**, 1124-1132

286 Selected Aspects of Angiogenesis in Haematological Malignancies. **2011**, 3, 17-39

285 Molecular Regulation of Skin Wound Healing. **2012**, 1-23

o

284 Targeting angiogenesis in metastatic breast cancer. **2011**, 101-119

283 Molecular Markers of Lymph Node Disease in Melanoma. **2012**, 209-226

282 Glial Cell Derived Cytokines and Vascular Integrity in Diabetic Retinopathy. **2012**, 325-338

281 From Concept to the Clinics: Development of Cancer Therapeutics.

280 Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema. **2012**, 289-306

279 Hyperthermia and Intracavitary Chemotherapy in Prevention and Treatment of Malignant Effusions. **2012**, 123-150

1

278 Anti-VEGF Monotherapy Treatment Strategies for Neovascular AMD. **2012**, 479-499

277 Pathogenesis of Malignant Effusions. **2012**, 11-21

276 Growth Factors, Stem Cells, Scaffolds and Biomaterials for Tendon Regeneration. **2012**, 327-344

275 Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on the Nature of Tumor Stroma. **2013**, 161-181

274 Hypoxia and the Cardiac Lymphatic System. **2013**, 145-160

273 Counteracting Hypoxia in Radio-Resistant Metastatic Lesions. **2013**, 255-269

272 Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics. 438-469

271 Variations in vascular endothelial growth factor levels during ovarian superovulation and reduction of ovarian hyperstimulation incidence in young women: A prospective study. **2013**, 03, 296-300

270 Angiogenesis in Diseases and Therapy. **2013**, 3-16

269 VEGF Signaling in Normal and Tumor Angiogenesis. **2013**, 1-36

268 Breast milk soluble vascular endothelial growth factor receptor-1 and implications for health. **2013**, 437-446

267 BloodBrain Barrier and CNS Malignancy. **2014**, 519-539

266 Finding New Partnerships: The Function of Individual Extracellular Receptor Domains in Angiogenic Signalling by VEGF Receptors. **2014**, 47-75

265 Stimulation of Therapeutic Angiogenesis Using Amniotic Fluid Stem Cells. **2014**, 125-138

264 VEGF A. **2014**, 1-14

263 Effusions. **1989**, 195-213

262 T. **1990**, 263-321

261 Cellular Models for Angiogenesis Research. **1994**, 125-164

260 Biochemical tumour markers for VPF and their use for detection and diagnosis of cancer. **1994**, 4, 147-148

259 Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. **1995**, 154, 576-9

10

258 Angiogenesis and Lymphangiogenesis: Analogous Mechanisms and Homologous Growth Factors. **1996**, 21-34

257 Development and Differentiation of Blood Vessels in the Central Nervous System. **1997**, 305-312

256 References. **1997**, 215-326

255 Angiogenesis in diabetic retinopathy: a history of accomplishment, discovery and promise. **1998**, 181-196

254 Sinusoidal Endothelial Cells in Liver Regeneration. **1999**, 114-123

253 Regulation of Endothelial Cell Specific Receptor Tyrosine Kinase Gene Expression during Development and Disease. **1999**, 35-48

252 Peritumoral Brain Edema. **1999**, 11, 149-154

- 251 Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Kaposi's Sarcoma-Associated Herpesvirus-Infected Primary Effusion Lymphomas. **1999**, 94, 4247-4254 2
- 250 Molecular Imaging at Nanoscale with Magnetic Resonance Imaging. **2014**, 75-102
- 249 Hypertension and Vascular Endothelial Growth Factors. **2015**, 695-707 1
- 248 Cellular Plasticity, Cancer Stem Cells and Metastasis. **2015**, 13-66
- 247 Study of novel coating strategy for coronary stents: simultaneous coating of VEGF and anti- CD34 antibody. **2015**, 30, 159-63 1
- 246 Inflammatory Mediators and the Blood-Brain Barrier. **2015**, 239-288
- 245 Neuroprotective Activity of Valeriana officinalis against Global Cerebral Ischemia/Reperfusion Induced Oxidative Stress in Rat. **2015**, 6, 421-429
- 244 Cancer-Induced Edema/Lymphedema. **2016**, 85-103 1
- 243 Resistance to Angiokinase Inhibitors. **2016**, 165-178
- 242 VEGF Ligands. **2016**, 1-20
- 241 Antiangiogenic Therapy for Glioblastoma. **2016**, 143-149 1
- 240 Circulating galectin-3 correlates with angiogenetic factors and indicators of systemic inflammation in patients with stage IV esophageal cancer. **2016**, 24, 30-34 1
- 239 VEGF inhibitors in glaucoma surgery. **2016**, 9, 47-55 0
- 238 PLGA Nano- and Microparticles for VEGF Delivery. **2016**, 445-478
- 237 Discoveries Interview: Professor Harold F. Dvorak on the discovery of Vascular Endothelial Growth Factor (VEGF). **2016**, 4, e62
- 236 IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers. **2017**, 25, 67-76 4
- 235 Encyclopedia of Signaling Molecules. **2017**, 1-7
- 234 Neuropilin-1-Expressing Monocytes: Implications for Therapeutic Angiogenesis and Cancer Therapy. **2017**, 213-224

233 Pharmacomodulation in the Treatment of Retinopathy of Prematurity. **2017**, 79-94

232 Peri-operative Shift in Angiogenesis-Related Factors in Breast Cancer Patients. **2017**, 55-81

231 The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. **2017**, 481-506

230 The Role of the Neuropilins in Tumour Angiogenesis and Tumour Progression. **2017**, 163-186

229 Dynamic Contrast Enhanced MRI in Glioma Diagnosis. **2017**, 88-96

228 Characterization of the Experimentally Observed Clustering of VEGF Receptors. **2018**, 75-92

2

227 The Role of VEGF in Controlling Vascular Permeability. **2018**, 1-18

226 OBSOLETE: Angiogenesis. **2018**,

225 Encyclopedia of Signaling Molecules. **2018**, 5915-5920

224 Controlling Vascular Permeability: How Does It Work and What Is the Impact on Normal and Pathological Angiogenesis. **2019**, 1-13

223 Effect of continuous compressive force on the expression of RANKL, OPG, and VEGF in MC3T3-E1 and MLO-Y4 cells.

222 Role of inflammation cytokines in forming and rupture of brain arterio-venous malformations. **2018**, 185-194

1

221 FARMACI ANTI-VEGF INTRAVITREALI E RISCHIO CARDIOVASCOLARE: UN NUOVO CAMPO DI INTERESSE PER IL DIABETOLOGO?. **2018**, 30,

220 Principle of CAST Strategy. **2019**, 255-267

O

219 The Role of VEGF in Controlling Vascular Permeability. **2019**, 33-50

218 The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. **2019**, 1-16

217 Cancer and Blood Coagulation. **2019**, 23-40

O

216 CAST Therapy. **2019**, 269-288

- 215 Angiogenic factors in normal pregnancy and preeclampsia. **2019**, 2, 61
- 214 Brain Metastases Cell Partners and Tumor Microenvironment. **2020**, 59-71 0
- 213 Therapeutic Use of Inorganic Nanomaterials in Malignant Diseases. **2020**, 47-87
- 212 Pathogenesis of Choroidal Neovascularization. **2020**, 7-14
- 211 Vascular Endothelial Growth Factor Expression in the Pathological Angiogenesis in Oral Squamous Cell Carcinoma. 0
- 210 Mapping endothelial functional phenotype in cancer by unveiling the kinase and phosphatase drivers.
- 209 The Canonical Wnt Signaling (Wnt/ECatenin Pathway): A Potential Target for Cancer Prevention and Therapy. **2020**, 24, 269-80 2
- 208 The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients.. **2021**, 1, 20210051 5
- 207 Genetic Susceptibility Markers of Gastrointestinal Cancer. **2020**, 93-115
- 206 Pediatric Application of Dynamic Contrast-Enhanced MR Imaging (DCE-MR) in the Management of Extra-Cranial Tumor: Experience in Routine Clinical Practice. **2020**, 10, 57-68 0
- 205 Blood Plasma Trophic Growth Factors Predict the Outcome in Patients with Acute Ischemic Stroke. **2020**, 27-39 2
- 204 Uses of Cyclohexan-1,3-dione for the Synthesis of Thiazole, Pyrazole, Thiophene, Isoxazole and Pyran Derivatives with Antitumor Activities. **2020**, 17, 597-609
- 203 Wnt Signaling in Inner Blood-Retinal Barrier Maintenance. *International Journal of Molecular Sciences*, **2021**, 22, 6.3 1
- 202 Angiogenesis in Chronic Inflammatory Skin Disorders. *International Journal of Molecular Sciences*, **2021**, 22, 6.3 6
- 201 Vascular Endothelial Growth Factor as an Immediate-Early Activator of UV-induced Skin Injury.
- 200 Recurrent Conjunctival Granuloma Treated with Subconjunctival Bevacizumab. **2020**, 61, 815-818
- 199 Angiogenesis in prostate cancer: Biology and therapeutic opportunities. **2002**, 161-183
- 198 VEGF-C/VEGFRS and Cancer Metastasis. **2001**, 223-239

197 Current and Future Therapeutic Targets of the Tumour-Host Microenvironment. **2005**, 345-367

196 Angiogenesis and Lung Cancer. **2005**, 13-30

195 Retinopathy of Prematurity: Molecular Mechanism of Disease. **2006**, 51-61

194 Apoptosis and cell cycle in endothelial cells. **2000**, 141-156

193 Diabetic Retinopathy. **2008**, 407-418

192 Molecular Basis for Vascular Endothelial Growth Factor Expression in Tumor. **2008**, 79-124

191 Coronary Artery Development. **2005**, 167-183

190 Vascular and Neuronal Effects of VEGF in the Nervous System. **2006**, 245-264

189 Control of Neovascularization and Cell Survival in the Eye by PEDF. **2006**, 215-231

188 Ocular Inflammation and Neovascularization. **2006**, 291-305

187 Vascular Endothelial Growth Factor Family and Its Receptors. **2008**, 3-26

186 VEGF in the Adult. **2008**, 245-259

185 Regulation of Angiogenesis in Cancer and Its Therapeutic Implications. **2008**, 331-349

1

184 Clinical Angioblast Therapy. **2007**, 245-258

183 Cytokines and Tumor Angiogenesis. **2007**, 245-266

182 Retinopathy of Prematurity. **2007**, 392-423

181 Hypoxia in the Pathogenesis of Retinal Disease. **2007**, 121-138

1

180 Anti-VEGF Treatment for Age-Related Macular Degeneration. **2007**, 53-66

179	Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability. 2020 ,	0
178	Pre-determined macromolecular leakage sites with dynamic properties establish endothelial intra-vessel heterogeneity.	
177	Single-cell Multi-omics reveal heterogeneity and metastasis potential in different liver cancer cell lines.	0
176	Angiogenesis: Perspectives from Therapeutic Angiogenesis. 2021 , 129-153	
175	A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. 1996 , 15, 290-98	348
174	Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. 1999 , 338 (Pt 2), 367-74	16
173	Antidepressant effects of exercise: evidence for an adult-neurogenesis hypothesis?. 2006 , 31, 84-92	160
172	Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. 1997 , 151, 679-88	140
171	Vascular endothelial growth factor and ocular neovascularization. 1997 , 151, 13-23	80
170	Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. 1998 , 152, 399-411	164
169	VEGF induces cardiovascular malformation and embryonic lethality. 1997 , 151, 1407-16	44
168	Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. 1997 , 150, 1315-26	34
167	Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. 1997 , 150, 1673-85	134
166	Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. 1997 , 150, 713-25	110
165	Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. 1998 , 152, 1445-52	544
164	Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. 1996 , 148, 1065-74	84
163	Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. 1996 , 148, 1203-17	43
162	Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. 1996 , 149, 293-305	404

161	Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. 1996 , 149, 1-7	100
160	Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. 1996 , 149, 59-71	161
159	Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. 1996 , 149, 1851-69	120
158	Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. 1995 , 146, 1029-39	2062
157	Regulation of fibrin deposition by malignant mesothelioma. 1995 , 147, 1318-29	31
156	Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. 1995 , 146, 157-65	222
155	Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. 1988 , 133, 95-109	452
154	Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. 1988 , 130, 455-65	68
153	Tumor-secreted vascular permeability factor increases cytosolic Ca ²⁺ and von Willebrand factor release in human endothelial cells. 1991 , 138, 213-21	235
152	Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. 1993 , 142, 1409-22	67
151	Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. 1994 , 144, 275-85	517
150	Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. 1993 , 143, 1255-62	371
149	Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. 1994 , 145, 574-84	449
148	Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. 2006 , 13, 14-26	128
147	Experimental neovascularization in vivo: the early changes in a stable adult vasculature responding to angiogenic stimulation by a syngeneic neoplasm. 1987 , 68, 625-35	2
146	Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. 1995 , 1, 182-93	85
145	Microphthalmia, persistent hyperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF-A188 from the alphaA-crystallin promoter. 2007 , 13, 47-56	34
144	The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. 1993 , 66, 277-314	72

- 143 Clinical neurosciences in the decade of the brain: hypotheses in neuro-oncology. VEG/PF acts upon the actin cytoskeleton and is inhibited by dexamethasone: relevance to tumor angiogenesis and vasogenic edema. **1996**, 69, 337-55 6
- 142 Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. **2007**, 1, 185-94 4
- 141 Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients. **2009**, 15, 2663-72 14
- 140 Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. **2007**, 2, 31-49 3
- 139 RNA aptamers and their therapeutic and diagnostic applications. **2013**, 4, 27-40 56
- 138 Angiogenesis in chronic obstructive pulmonary disease: a translational appraisal. **2012**, 3, 49-56 12
- 137 Age-related macular degeneration: beyond anti-angiogenesis. **2014**, 20, 46-55 24
- 136 Adeno-associated virus type 8 vector-mediated expression of siRNA targeting vascular endothelial growth factor efficiently inhibits neovascularization in a murine choroidal neovascularization model. **2014**, 20, 488-96 6
- 135 The impact of high density receptor clusters on VEGF signaling. **2013**, 2013, 37-52 3
- 134 Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). **2014**, 112, 160-98 20
- 133 Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept. **2015**, 21, 185-93 12
- 132 Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis. **2015**, 8, 2289-98 11
- 131 Mechanism and Function of Angiogenin in Hematopoietic Malignancy. **2015**, 31, 1267-1275 2
- 130 Vascular endothelial growth factor from embryonic status to cardiovascular pathology. **2014**, 2, 59-69 18
- 129 Vascular Endothelial Growth Factor Increases Endothelial Nitric Oxide Synthase Transcription In Huvec Cells. **2010**, 1, 1 1
- 128 Expression of Vascular Endothelial Growth Factor in Nasal Polyp and Chronic Rhinosinusitis. **2016**, 11, 231-237 2
- 127 [Advances of VEGF gene polymorphism and its clinical values in lung cancer]. **2013**, 16, 433-7 1
- 126 Why we do what we do. A brief analysis of cancer therapies. **2020**, 19, 1401-1413

125	Inhibition of HMGB1 Might Enhance the Protective Effect of Taxifolin in Cardiomyocytes via PI3K/AKT Signaling Pathway. 2021 , 20, 316-332		1
124	Substrate stiffening promotes VEGF-A functions via the PI3K/Akt/mTOR pathway. 2021 , 586, 27-33		2
123	Treatment of acute pulmonary edema by blocking VEGF-induced vascular leakage. 2021 , 1, 2-5		
122	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. 2021 , 1		5
121	Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. 2021 ,		0
120	[Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina]. 2021 , 141, 1307-1317		1
119	Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both?. 2022 , 82, 15-17		4
118	Down Syndrome Candidate Region 1 Isoform 1L regulated tumor growth by targeting both angiogenesis and tumor cells.. 2021 , 140, 104305		
117	VEGF: A KEY PLAYER NOT ONLY IN MACULAR DEGENERATION. A REVIEW. 2020 , 76, 1-3		
116	Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review.. 2021 , 12, 251-264		1
115	The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	3
114	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment.. 2022 , 12,		1
113	Single-cell multiomics reveals heterogeneous cell states linked to metastatic potential in liver cancer cell lines.. 2022 , 25, 103857		0
112	VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types.. <i>Experimental and Therapeutic Medicine</i> , 2022 , 23, 251	2.1	0
111	Intraperitoneal infusion of recombinant human indentation improves prognosis in gastric cancer ascites.. 2022 , 523-531		2
110	Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin. 2007 , 35, 55-84		8
109	Down-regulation of microRNA-216a confers protection against yttrium aluminium garnet laser-induced retinal injury the GDNF-mediated GDNF/GFR α /RET signalling pathway. 2018 , 43, 985-1000		
108	Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.. 2022 , 34, 28-39		0

107	Claudin5 protects the peripheral endothelial barrier in an organ and vessel type-specific manner.		
106	Phospholipase C α Promotes Vascular Endothelial Growth Factor Induced Vascular Permeability.		0
105	Aflibercept as a treatment for malignant tumors. 2022 , 11, 35-39		
104	The Roles of Tumor Endothelial Cells in Cancer Metastasis.		0
103	Hyperadhesive von Willebrand Factor Promotes Extracellular Vesicle-Induced Angiogenesis: Implication for LVAD-Induced Bleeding.. 2022 , 7, 247-261		0
102	Expression of vascular endothelial growth factor A (VEGFA), placental growth factor (PlGF) and insulin-like growth factor 1 (IGF-1) in serum from women undergoing frozen embryo transfer.. 2022 , 1-11		
101	Editorial: Tumor Vessels as Directors of the Tumor Microenvironment: New Findings, Current Challenges & Perspectives.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 885670	5.7	0
100	Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. 2022 , 38, 60-66		
99	Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination.. 2022 ,		1
98	A review on inflammation and angiogenesis as key mechanisms involved in the pathogenesis of bovine cystic ovarian disease.. 2022 , 186, 70-85		
97	Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhus gastric cancer.. 2022 , 600, 80-86		0
96	Permeability, anti-inflammatory and anti-VEGF profiles of steroidal-loaded cationic nanoemulsions in retinal pigment epithelial cells under oxidative stress.. <i>International Journal of Pharmaceutics</i> , 2022 , 617, 121615	6.5	2
95	Editorial: Molecular Mechanisms and Signaling in Endothelial Cell Biology and Vascular Heterogeneity.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 821100	5.7	0
94	MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential.. 2021 , 11, 705634		1
93	The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non-Small Cell Lung Cancer for Radiotherapy. 2021 , 1, 164-177		1
92	Thymoquinone modulates the expression of sepsis-related microRNAs in a CLP model.. <i>Experimental and Therapeutic Medicine</i> , 2022 , 23, 395	2.1	0
91	Circular RNAs in Pregnancy and the Placenta.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
90	image_1.PDF. 2018 ,		

89	table_1.PDF. 2018 ,		
88	webmedcentral. 2010 , 1,		1
87	Non-coding RNA regulatory networks in post-transcriptional regulation of VEGFA in cancer.. <i>IUBMB Life</i> , 2022 ,	4.7	2
86	Assessing Molecular Regulation of Vascular Permeability Using a VEGF-Inducible Zebrafish Model.. <i>Methods in Molecular Biology</i> , 2022 , 2475, 339-350	1.4	
85	SH2-Domain Protein Isolation Using Synthetic Phosphorylated Peptides to Study VEGFR2 Signaling.. <i>Methods in Molecular Biology</i> , 2022 , 2475, 97-111	1.4	
84	Effects of Pulsatility on Arterial Endothelial and Smooth Muscle cells.. <i>Cells Tissues Organs</i> , 2022 ,	2.1	0
83	Perspectives of SLIT/ROBO signaling in placental angiogenesis. <i>Histology and Histopathology</i> , 2010 , 25, 1181-90	1.4	21
82	Pharmacotherapy of Age-Related Macular Degeneration. 2022 , 3619-3644		
81	The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 886533	5.7	1
80	Development of isatin-based Schiff bases targeting VEGFR2 inhibition: Synthesis, characterization, antiproliferative properties, and QSAR studies.. <i>ChemMedChem</i> , 2022 ,	3.7	3
79	Overexpression of VEGF in the MOPC 315 Plasmacytoma Induces Tumor Immunity in Mice.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
78	Angiogenic Hydrogels to Accelerate Early Wound Healing.. <i>Macromolecular Bioscience</i> , 2022 , e2200067	5.5	
77	Development of a nanocapsule-loaded hydrogel for drug delivery for intraperitoneal administration. <i>International Journal of Pharmaceutics</i> , 2022 , 121828	6.5	2
76	An appraisal of vascular endothelial growth factor (VEGF): the dynamic molecule of wound healing and its current clinical applications.. <i>Growth Factors</i> , 2022 , 1-16	1.6	0
75	Therapeutic potential of traditional Chinese medicine for vascular endothelial growth factor.. <i>Journal of Zhejiang University: Science B</i> , 2022 , 23, 353-364	4.5	
74	Angiogenesis, Lymphangiogenesis, and Inflammation in Chronic Obstructive Pulmonary Disease (COPD): Few Certainties and Many Outstanding Questions. <i>Cells</i> , 2022 , 11, 1720	7.9	1
73	LncRNA HOTTIP facilitates osteogenic differentiation in bone marrow mesenchymal stem cells and induces angiogenesis via interacting with TAF15 to stabilize DLX2. <i>Experimental Cell Research</i> , 2022 , 113226	4.2	0
72	Tumour Angiogenesis in Breast Cancer.		

71	Receptor, Signal, Nucleus, Action: Signals That Pass through Akt on the Road to Head and Neck Cancer Cell Migration. <i>Cancers</i> , 2022 , 14, 2606	6.6	
70	Advances in the Treatment of Pleural Effusion Associated with Lung Cancer by Intrathoracic Perfusion. <i>Advances in Clinical Medicine</i> , 2022 , 12, 5533-5539	0	
69	Lymphangiogenesis: Lymphatic System and Lymph Nodes; Cancer Lymphangiogenesis and Metastasis. 2022 , 209-229		
68	Plasma apelin and vascular endothelial growth factor levels in preterm infants: relationship to neonatal respiratory distress syndrome. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 1-8	2	
67	Neuroprotective Effects of VEGF in the Enteric Nervous System. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 6756	6.3	1
66	MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. <i>Communications Biology</i> , 2022 , 5,	6.7	2
65	VEGF is an essential retrograde trophic factor for motoneurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119,	11.5	2
64	Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 10,	5.7	0
63	Lymphatics in Malignant Tumors. 2022 , 53-62		
62	Tumor-Vascular Interactions in Non-Small Cell Lung Cancer. 2022 , 497-508		
61	VEGFR endocytosis: Implications for angiogenesis. <i>Progress in Molecular Biology and Translational Science</i> , 2022 ,	4	
60	The Role of the Tumor Microenvironment in Regulating Angiogenesis. 2022 , 3-15		
59	The expression and significance of vascular endothelial growth factor A in adenoid cystic carcinoma of palatal salivary gland. <i>European Archives of Oto-Rhino-Laryngology</i> ,	3.5	0
58	Annexin A2 modulates phospholipid membrane composition upstream of Arp2 to control angiogenic sprout initiation.		
57	Signaling Pathways in Neurovascular Development. <i>Annual Review of Neuroscience</i> , 2022 , 45, 87-108	17	0
56	The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview. <i>Medicina (Lithuania)</i> , 2022 , 58, 903	3.1	0
55	Targeting Angiogenesis via Resolution of Inflammation. <i>Cold Spring Harbor Perspectives in Medicine</i> , a041172	17.2	0
54	PLC (Phospholipase C) β Promotes VEGF (Vascular Endothelial Growth Factor)-Induced Vascular Permeability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> ,	9.4	0

53	Prognostic role of elevated VEGF in sepsis: A systematic review and meta-analysis. <i>Frontiers in Physiology</i> , 13,	4.6	o
52	Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study. 2022 , 27, 4898		o
51	Claudin5 protects the peripheral endothelial barrier in an organ and vessel-type-specific manner. 11,	1	
50	Pharmacophore Modeling of Targets Infested with Activity Cliffs via Molecular Dynamics Simulation Coupled with QSAR and Comparison with other Pharmacophore Generation Methods: KDR as Case Study.		o
49	Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.	1	
48	Extraocular Motoneurons and Neurotrophism. 2022 , 281-319		o
47	The Role of Periostin in Angiogenesis and Lymphangiogenesis in Tumors. 2022 , 14, 4225		o
46	Immunosuppressive effects of vascular endothelial growth factor (Review). 2022 , 24,	2	
45	Retinal and Choroidal Neovascularization Antivascular Endothelial Growth Factor Treatments: The Role of Gene Therapy.		o
44	Endothelial cells and their role in the vasculature: Past, present and future. 10,		o
43	VEGF and Neuronal Survival. 107385842211208		o
42	The ambivalent nature of the relationship between lymphatics and cancer. 10,		o
41	Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1. 2022 , 86, 126-135		o
40	PDGF-BB signaling via PDGFR- β regulates the maturation of blood vessels generated upon vasculogenic differentiation of dental pulp stem cells. 10,		o
39	Angiopoietins, vascular endothelial growth factors and secretory phospholipase A2 in heart failure patients with preserved ejection fraction. 2022 ,		o
38	Molecular mechanism of VEGF and its role in pathological angiogenesis.		o
37	Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms. 2022 , 103920		o
36	Tumor Angiogenesis. 1-30		o

- 35 Controlled release of vascular endothelial growth factor (VEGF) in alginate and hyaluronic acid (ALGHA) bead system to promote wound healing in punch-induced wound rat model. 1-20 0
- 34 Intercellular communication analysis of the human retinal pigment epithelial and choroidal cells predicts pathways associated with aging, cellular senescence and age-related macular degeneration. 14, 1
- 33 Single-cell RNA sequencing implicates venous endothelial cells as a source of VEGF-mediated neo-angiogenesis in neuroinflammation. 0
- 32 Neovascular Glaucoma in Chronic Retinal Detachments. 2022, 79-85 0
- 31 Tumour Interstitial Fluid Pressure May Regulate Angiogenic Factors in Osteosarcoma. 2009, 38, 1041-1047 2
- 30 The Tumor Microenvironment in Hepatocellular Carcinoma. 2022, 0
- 29 Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis. 0
- 28 The role of angiogenesis in melanoma: Clinical treatments and future expectations. 13, 0
- 27 WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma. 0
- 26 Annexin A2 modulates phospholipid membrane composition upstream of Arp2 to control angiogenic sprout initiation. 2023, 37, 0
- 25 PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. 2022, 13, 0
- 24 Inadvertent Use of Bevacizumab to Treat Choroidal Neovascularisation During Pregnancy: A Case Report. 2010, 39, 143-145 2
- 23 Effect of Anti-VEGF Therapy on Inner and Outer Retinal Layers on Spectral-Domain Optical Coherence Tomography in Diabetic Macular Edema. 2022, 77-86 0
- 22 Bacterial meningitis in the early postnatal mouse studied at single-cell resolution. 0
- 21 The Role of Inflammation and Therapeutic Concepts in Diabetic RetinopathyA Short Review. 2023, 24, 1024 0
- 20 Vascular endothelial growth factor isoforms are expressed in the uterus during estrous cycle of golden hamsters (Mesocricetus auratus). 2023, 94, 0
- 19 Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials. 2201381 0
- 18 Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic Signatures. 2023, 12, 266 0

- 17 VEGFA may be a potential marker of myopic choroidal thickness and vascular density changes. ○
- 16 The role of PLVAP in endothelial cells. ○
- 15 Endothelial cells LEENE on noncoding RNAs in diabetic vasculopathy. **2023**, 133, ○
- 14 EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis. **2023**, 119, 110001 ○
- 13 Inhibition of VEGFR-2 by SU5416 increases neonatally glutamate-induced neuronal damage in the cerebral motor cortex and hippocampus. ○
- 12 Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia. **2023**, 45, 1536-1567 1
- 11 Impact of exercise on brain neurochemicals: a comprehensive review. ○
- 10 Polymorphic Variants of Genes Encoding Angiogenesis-Related Factors in Infertile Women with Recurrent Implantation Failure. **2023**, 24, 4267 ○
- 9 A review of vascular endothelial growth factor and its potential to improve functional outcomes following spinal cord injury. **2023**, 61, 231-237 ○
- 8 Radiation and Diabetic Retinopathy: A Dark Synergy. **2023**, 3, 120-159 ○
- 7 Catalytic response and molecular simulation studies in the development of synthetic routes in trimeric triaryl pyridinium type ionic liquids. **2023**, 13, ○
- 6 The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice. **2023**, 2023, 1-6 ○
- 5 Key aspects for conception and construction of co-culture models of tumor-stroma interactions. 11, ○
- 4 Extracellular vesicles, hyperadhesive von willebrand factor, and outcomes of gastric cancer: a clinical observational study. **2023**, 40, ○
- 3 Targeting angiogenesis in oncology, ophthalmology and beyond. ○
- 2 VEGF levels in the aqueous humor of patients with primary open angle glaucoma: A systematic review and a meta-analysis. 112067212311681 ○
- 1 Proteomics Analysis of R-Ras Deficiency in Oxygen Induced Retinopathy. **2023**, 24, 7914 ○